<!DOCTYPE drug_guide PUBLIC "-//ES//DTD drug_guide DTD version 3.1//EN//XML" "Y:\WWW1\tools\Drugs\3_1_drug.dtd">
<drug_guide isbn="9780323448260">
	<alpha letter="i">
		<monograph id="1" status="active">
			<mono_name>ibandronate (Rx)</mono_name>
			<info>
				<pronunciation>(eye-ban′dro-nate)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x210">Boniva</tradename>
				</tradenames>
				<class type="func"> Bone-resorption inhibitor, electrolyte modifier</class>
				<class type="chem"> Bisphosphonate</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x31">
				<sec_title>Action:</sec_title>
				<para>Inhibits bone resorption, apparently without inhibiting bone formation and mineralization; absorbs calcium phosphate crystals in bone and may directly block dissolution of hydroxyapatite crystals of bone; more potent than other products</para>
			</section>
			<section type="uses" id="sidelem4x36">
				<sec_title>Uses:</sec_title>
				<para>Osteoporosis and prophylaxis</para>
				<section type="none" id="sidelem4x41">
					<section type="none" id="sidelem4x42">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Hypercalcemia of malignancy, osteolytic metastases, Paget’s disease, osteoporosis (treatment/prevention) in those taking anastrozole</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x47">
				<sec_title>Contraindications:</sec_title>
				<para>Achalasia, esophageal stricture, hypocalcemia, intraarterial administration, renal failure, hypersensitivity to bisphosphonates, inability to stand or sit upright</para>
				<section type="none" id="sidelem4x52">
					<section type="none" id="sidelem4x53">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, anemia, chemotherapy, coagulopathy, dental disease, diabetes mellitus, dysphagia, GI/renal disease, GERD, hypertension, infection, multiple myeloma, phosphate hypersensitivity, vit D deficiency</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x58">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x61">
					<section type="none" id="sidelem4x62">
						<sec_title>Postmenopausal osteoporosis/prophylaxis</sec_title>
						<section type="none" id="sidelem4x70">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x70">
									<item>
										<label>•</label>
										<para> 150 mg/mo;  3 mg q3mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x77">
						<sec_title>Paget’s disease (unlabeled)</sec_title>
						<section type="none" id="sidelem4x85">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x85">
									<item>
										<label>•</label>
										<para> 2 mg as a single dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x89">
						<sec_title>Bone metastases (unlabeled)</sec_title>
						<section type="none" id="sidelem4x97">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x97">
									<item>
										<label>•</label>
										<para> 6 mg over 1 hr × 3 days, repeat q4wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x101">
						<sec_title>Hypercalcemia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x109">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x109">
									<item>
										<label>•</label>
										<para> 2-4 mg over 2 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x113">
						<sec_title>
							<emphasis style="bold">Renal dose</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x122">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;30 ml/min, avoid use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x125">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 150 mg; sol for inj 1 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x130">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x133">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x137">
									<item>
										<label>•</label>
										<para>Give early <emphasis style="smallcaps">am</emphasis> with a glass of water; if monthly, give on same day of each month</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x151">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x155">
									<item>
										<label>•</label>
										<para>Use single-dose prefilled syringe; discard unused portion; give over 15-30 sec; give q3mo; do not use if discolored or contains particulates</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x161">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x164">
					<section type="none" id="sidelem4x165">
						<sec_title>CNS:</sec_title>
						<para> Fever, insomnia, dizziness, headache</para>
					</section>
					<section type="none" id="sidelem4x170">
						<sec_title>CV:</sec_title>
						<para> Hypertension, <emphasis style="bold">atrial fibrillation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x177">
						<sec_title>EENT:</sec_title>
						<para> Ocular pain/inflammation, uveitis</para>
					</section>
					<section type="none" id="sidelem4x182">
						<sec_title>GI:</sec_title>
						<para> Constipation, nausea, vomiting, diarrhea, dyspepsia</para>
					</section>
					<section type="none" id="sidelem4x187">
						<sec_title>INTEG:</sec_title>
						<para> Rash, inj-site reaction</para>
					</section>
					<section type="none" id="sidelem4x192">
						<sec_title>META:</sec_title>
						<para> <emphasis style="italic">Hypomagnesemia, hypophosphatemia, hypocalcemia,</emphasis> hypercholesterolemia</para>
					</section>
					<section type="none" id="sidelem4x200">
						<sec_title>MS:</sec_title>
						<para> Bone pain, myalgia, osteonecrosis of the jaw</para>
					</section>
					<section type="none" id="sidelem4x205">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Stevens-Johnson syndrome, erythema multiforme, dermatitis bullous</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x212">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 5-60 hr, 86%-99% protein binding; taken up mainly by bones, primarily in areas of high bone turnover; eliminated primarily by kidneys</para>
			</section>
			<section type="interactions" id="sidelem4x217">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> GI irritation—NSAIDs, salicylates</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypocalcemia—loop diuretics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> ibandronate effect—calcium/ vit D/iron/aluminum/magnesium salts; separate by 1 hr</para>
				<section type="none" id="sidelem4x232">
					<section type="none" id="sidelem4x233">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x237">
								<item>
									<label>•</label>
									<para>Do not take with food, calcium</para>
								</item>
							</list>
						</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> cholesterol</para>
					</section>
					<section type="none" id="sidelem4x247">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Alk phos, magnesium, calcium, phosphate</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> cholesterol</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x259">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x262">
					<section type="none" id="sidelem4x263">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x271">
							<label>•</label>
							<sec_title>Anaphylaxis<route> swelling of face, lips, mouth, rash, sweating, wheezing, trouble breathing, discontinue immediately, provide supportive treatment</route></sec_title>
						</section>
						<section type="none" id="sidelem4x277">
							<label>•</label>
							<sec_title>Osteoporosis</sec_title>
							<para>
								<list id="lidelem4x277">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Osteoporosis:</emphasis> before and during treatment; scan for bone mineral density, correct electrolyte imbalances (calcium, magnesium, phosphate) before starting therapy</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x281">
								<item>
									<label>•</label>
									<para>Atrial fibrillation</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x289">
							<label>•</label>
							<sec_title>Dental health<route> before dental extraction, give antiinfectives, osteonecrosis of the jaw may occur</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x292">
								<item>
									<label>•</label>
									<para>Blood studies: electrolytes, creatinine/BUN, vit D: correct deficiencies before treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x297">
								<item>
									<label>•</label>
									<para>For bone pain; use analgesics; may begin within 24 hr or even years after treatment; pain usually subsides after treatment is discontinued</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x302">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x306">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased bone mineral density</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x312">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x320">
							<label>•</label>
							<sec_title>To report hypercalcemic relapse</sec_title>
							<para>
								<list id="lidelem4x320">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">To report hypercalcemic relapse:</emphasis> nausea, vomiting, bone pain, thirst, unusual muscle twitching, muscle spasms, severe diarrhea, constipation</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x324">
								<item>
									<label>•</label>
									<para>To continue with dietary recommendations, including calcium, vit D</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x329">
								<item>
									<label>•</label>
									<para>To obtain an analgesic from provider for bone pain</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x334">
								<item>
									<label>•</label>
									<para>That, if nausea, vomiting occur, small, frequent meals may help</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x339">
								<item>
									<label>•</label>
									<para>To report vision symptoms: blurred vision, edema, inflammation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x344">
								<item>
									<label>•</label>
									<para>To report if pregnancy is planned or suspected or if planning to breastfeed, pregnancy (C)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x349">
								<item>
									<label>•</label>
									<para>To exercise regularly, stop smoking, decrease alcohol intake</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x354">
								<item>
									<label>•</label>
									<para>To take PO first thing in <emphasis style="smallcaps">am</emphasis> at least 60 min before other medications, food, beverages, to take monthly dose on same day</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x365">
							<label>•</label>
							<sec_title>
								<route>To sit upright for ≥60 min after PO</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="2" status="active" ha="yes">
			<mono_name> ibrutinib</mono_name>
			<info>
				<pronunciation>(eye-broo′ti-nib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x3750">Imbruvica</tradename>
				</tradenames>
				<class type="func"> Antineoplastic-biologic response modifier</class>
				<class type="chem"> Signal transduction inhibitor (STIs)</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x385">
				<sec_title>Action:</sec_title>
				<para>Irreversible inhibitor of Bruton’s tyrosine kinases in B cells responsible for tumor growth</para>
			</section>
			<section type="uses" id="sidelem4x390">
				<sec_title>Uses:</sec_title>
				<para>Recurrent mantle cell lymphoma who have received at least 1 prior treatment</para>
			</section>
			<section type="contra" id="sidelem4x395">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity</para>
				<section type="none" id="sidelem4x400">
					<section type="none" id="sidelem4x401">
						<sec_title>Precautions:</sec_title>
						<para> Children, geriatric patients, active infections, anticoagulant therapy, bleeding, hepatic/renal disease, neutropenia, surgery</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x406">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x414">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x414">
							<item>
								<label>•</label>
								<para> 560 mg (4×140 mg caps) daily</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x421">
					<label>•</label>
					<sec_title>Dosage adjustment for ≥grade 3 non-hematologic, ≥grade 3 neutropenia with infection or fever, or grade 4 hematologic toxicities<route> Interrupt therapy; resume upon recovery to grade 1 or baseline as indicated below</route></sec_title>
				</section>
				<section type="none" id="sidelem4x427">
					<label>•</label>
					<sec_title>First occurrence<route> Resume dosing at original dose (daily dose = 560 mg/day)</route></sec_title>
				</section>
				<section type="none" id="sidelem4x433">
					<label>•</label>
					<sec_title>Second occurrence<route> Reduce dose by 1 capsule (daily dose = 420 mg/day)</route></sec_title>
				</section>
				<section type="none" id="sidelem4x439">
					<label>•</label>
					<sec_title>Third occurrence<route> Reduce dose by 2 capsules (daily dose = 280 mg/day)</route></sec_title>
				</section>
				<section type="none" id="sidelem4x445">
					<label>•</label>
					<sec_title>Fourth occurrence<route> Discontinue</route></sec_title>
				</section>
				<section type="none" id="sidelem4x448">
					<section type="none" id="sidelem4x449">
						<sec_title>Waldenstrom macroglobulinemia</sec_title>
						<section type="none" id="sidelem4x457">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x457">
									<item>
										<label>•</label>
										<para> 420 mg daily until disease progression</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x461">
						<sec_title>Available forms:</sec_title>
						<para> Caps 140 mg</para>
					</section>
					<section type="none" id="sidelem4x466">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x470">
								<item>
									<label>•</label>
									<para>At same time of day with water, if dose is missed, take as soon as possible on same day, do not double</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not open, break, chew cap</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x482">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x485">
					<section type="none" id="sidelem4x486">
						<sec_title>CNS:</sec_title>
						<para> Fatigue, fever</para>
					</section>
					<section type="none" id="sidelem4x491">
						<sec_title>CV:</sec_title>
						<para> Hypertension, <emphasis style="bold">atrial fibrillation,</emphasis> peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x499">
						<sec_title>EENT:</sec_title>
						<para> Sinusitis</para>
					</section>
					<section type="none" id="sidelem4x504">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, dyspepsia, anorexia, abdominal pain, constipation, stomatitis, diarrhea, GI bleeding</para>
					</section>
					<section type="none" id="sidelem4x509">
						<sec_title>GU:</sec_title>
						<para> Increased serum creatinine, UTI</para>
					</section>
					<section type="none" id="sidelem4x514">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, thrombocytopenia,</emphasis> anemia, bleeding, epistaxis, transient lymphocytosis</para>
					</section>
					<section type="none" id="sidelem4x522">
						<sec_title>INTEG:</sec_title>
						<para> Rash, skin infections</para>
					</section>
					<section type="none" id="sidelem4x527">
						<sec_title>MS:</sec_title>
						<para> Pain, arthralgia, muscle cramps</para>
					</section>
					<section type="none" id="sidelem4x532">
						<sec_title>RESP:</sec_title>
						<para> Cough, dyspnea</para>
					</section>
					<section type="none" id="sidelem4x537">
						<sec_title>SYST:</sec_title>
						<para> Secondary malignancy, infection</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x542">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 97.3%; metabolized by CYP3A4/CYP2D6; primarily excreted in feces, small amount in urine; peak 1-2 hr, terminal half-life 4-8 hr</para>
			</section>
			<section type="interactions" id="sidelem4x547">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> ibrutinib effect—avoid use with moderate or strong CYP3A4 inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> ibrutinib effect—avoid use with moderate or strong CYP3A4 inducers</para>
				<section type="none" id="sidelem4x558">
					<section type="none" id="sidelem4x559">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> SUNItinib concentration—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x566">
						<sec_title>Drug/Food Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> plasma concentrations grapefruit juice</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x573">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x576">
					<section type="none" id="sidelem4x577">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x585">
							<label>•</label>
							<sec_title>Bleeding</sec_title>
							<para>
								<list id="lidelem4x585">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bleeding:</emphasis> bruising, grade 3 or higher bleeding events may occur; CBC</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x589">
								<item>
									<label>•</label>
									<para>Hepatic/renal function; signs and symptoms infections</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x594">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x598">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in progression of disease</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x604">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x609">
								<item>
									<label>•</label>
									<para>To report adverse reactions immediately: SOB bleeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x614">
								<item>
									<label>•</label>
									<para>About reason for treatment, expected result</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x619">
								<item>
									<label>•</label>
									<para>That many adverse reactions may occur: high B/P, bleeding, mouth swelling</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x624">
								<item>
									<label>•</label>
									<para>To avoid persons with known upper respiratory infections; that immunosuppression is common</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x629">
								<item>
									<label>•</label>
									<para>To avoid grapefruit juice or medications, herbs; there are many interactions</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x637">
							<label>•</label>
							<sec_title>
								<route>To report if pregnancy is planned or suspected, pregnancy (D)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x640">
								<item>
									<label>•</label>
									<para>To report bleeding, severe infections, renal toxicity (maintain hydration), development of second malignancies, diarrhea (contact physician if it persists)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x645">
								<item>
									<label>•</label>
									<para>To take with water (avoid food because it increases drug levels) at same time each day; do not open, break, or chew</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active">
			<mono_name>ibuprofen (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<pronunciation>(eye-byoo-proe′fen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x6589">Advil</tradename>
					<tradename id="tnidelem4x6588">Caldolor</tradename>
					<tradename id="tnidelem4x6587">Ibuprohm</tradename>
					<tradename id="tnidelem4x6586">Ibutab</tradename>
					<tradename id="tnidelem4x6585">Midol</tradename>
					<tradename id="tnidelem4x6584">
						<country code="CAN">Motrin </country>
					</tradename>
					<tradename id="tnidelem4x6583">Motrin IB</tradename>
					<tradename id="tnidelem4x6582">
						<country code="CAN">Pamprin IB </country>
					</tradename>
					<tradename id="tnidelem4x6581">Profen</tradename>
					<tradename id="tnidelem4x6580">Tab-Profen</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="4" status="active">
			<mono_name>ibuprofen lysine (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x6690">NeoProfen</tradename>
				</tradenames>
				<class type="func">NSAID</class>
				<class type="chem"> Propionic acid derivative</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg> <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x679">
				<para>
					<confusion>
						<tradename id="tnidelem4x6790">Nuprin</tradename>
						<drug type="generic" refid="idelem4x6790">Lupron</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x683">
				<sec_title>Action:</sec_title>
				<para>Inhibits COX-1, COX-2 by blocking arachidonate; analgesic, antiinflammatory, antipyretic</para>
			</section>
			<section type="uses" id="sidelem4x688">
				<sec_title>Uses:</sec_title>
				<para>Rheumatoid arthritis, osteoarthritis, primary dysmenorrhea, dental pain, musculoskeletal disorders, fever, migraine, patent ductus arteriosus</para>
				<section type="none" id="sidelem4x693">
					<section type="none" id="sidelem4x694">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Ankylosing spondylitis, bone pain, cystic fibrosis, gouty arthritis, psoriatic arthritis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x699">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>) 3rd trimester; hypersensitivity to this product, NSAIDs, salicylates; asthma; severe renal/hepatic disease</para>
				<para>
					<bbw>Perioperative pain in CABG</bbw>
				</para>
				<section type="none" id="sidelem4x715">
					<section type="none" id="sidelem4x716">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>) 1st and 2nd trimesters, breastfeeding, children, geriatric patients, bleeding disorders, GI disorders, cardiac disorders, hypersensitivity to other antiinflammatory agents, CHF, CCr &lt;25 ml/min</para>
						<para>
							<bbw>GI bleeding, MI, stroke</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x731">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x734">
					<section type="none" id="sidelem4x735">
						<sec_title>Self-treatment of minor aches/pains</sec_title>
						<section type="none" id="sidelem4x743">
							<label>•</label>
							<sec_title>Adult/adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x743">
									<item>
										<label>•</label>
										<para> (OTC product) 200 mg q4-6hr, may increase to 400 mg q4-6hr if needed, max 1200 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x747">
						<sec_title>Analgesic</sec_title>
						<section type="none" id="sidelem4x755">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x755">
									<item>
										<label>•</label>
										<para> 200-400 mg q4-6hr, max 3.2 g/day; OTC use max 1200 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x762">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x762">
									<item>
										<label>•</label>
										<para> 4-10 mg/kg/dose q6-8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x766">
						<sec_title>Moderate to severe pain (hospitalized patients) (Caldolor)</sec_title>
						<section type="none" id="sidelem4x774">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x774">
									<item>
										<label>•</label>
										<para> 400-800 mg q6hr as an adjunct to opiate-agonist therapy</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x778">
						<sec_title>Dysmenorrhea</sec_title>
						<section type="none" id="sidelem4x786">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x786">
									<item>
										<label>•</label>
										<para> 400 mg q4-6hr, max 1200 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x790">
						<sec_title>Antipyretic</sec_title>
						<section type="none" id="sidelem4x798">
							<label>•</label>
							<sec_title>Child 6 mo-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x798">
									<item>
										<label>•</label>
										<para> 5 mg/kg (temperature &lt;102.5° F or 39.2° C), 10 mg/kg (temperature &gt;102.5° F), may repeat q6-8hr, max 40 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x802">
						<sec_title>Antiinflammatory</sec_title>
						<section type="none" id="sidelem4x810">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x810">
									<item>
										<label>•</label>
										<para> 400-800 mg tid-qid, max 3.2 g/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x817">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x817">
									<item>
										<label>•</label>
										<para> 30-40 mg/kg/day in 3-4 divided doses, max 50 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x821">
						<sec_title>Patent ductus arteriosus (PDA) (NeoProfen)</sec_title>
						<section type="none" id="sidelem4x829">
							<label>•</label>
							<sec_title>Premature neonate ≤32 wk gestation who weighs 500-1500 g<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x829">
									<item>
										<label>•</label>
										<para> 10 mg/kg initially, then, if needed, 2 doses of 5 mg/kg at 24-hr intervals; if oliguria occurs, hold dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x833">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 100, 200, 400, 600, 800 mg; cap, liq gels 200 mg; oral susp 100 mg/5 ml; liq 100 mg/5 ml; chew tabs 100 mg; drops 50 mg/1.25 ml; inj 10 mg/ml (NeoProfen)</para>
					</section>
					<section type="none" id="sidelem4x838">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x841">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x846">
									<item>
										<label>•</label>
										<para>With food, milk, or antacid to decrease GI symptoms; if nausea and vomiting occur or persist, notify prescriber</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x851">
									<item>
										<label>•</label>
										<para>Shake susp well before use</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x859">
								<label>•</label>
								<sec_title>
									<route>Do not use in pregnancy after 30 wk gestation</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x862">
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x867">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x872">
									<item>
										<label>•</label>
										<para>Patient must be well hydrated before administration</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x877">
									<item>
										<label>•</label>
										<para>Dilute to ≤4 mg/ml with 0.9% NaCl, LR, D<emphasis style="inf">5</emphasis>W; infuse over ≥30 min; do not give IM</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x885">
									<item>
										<label>•</label>
										<para>Discard unused portion</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x890">
									<item>
										<label>•</label>
										<para>Visually inspect for particulate</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x898">
								<label>•</label>
								<sec_title>Ibuprofen lysine</sec_title>
								<para>
									<list id="lidelem4x898">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Ibuprofen lysine:</emphasis> dilute with dextrose or saline to appropriate volume (10 mg/ml of ibuprofen is recommended); give within 30 min of preparation; give via IV port nearest insertion site; give over 15 min</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x902">
									<item>
										<label>•</label>
										<para>Check for extravasation; do not give in same line with TPN; interrupt TPN for 15 min before and after product administration</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x907">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x910">
					<section type="none" id="sidelem4x911">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> dizziness, drowsiness, fatigue, tremors, confusion, insomnia, anxiety, depression</para>
					</section>
					<section type="none" id="sidelem4x919">
						<sec_title>CV:</sec_title>
						<para> Tachycardia, peripheral edema, palpitations, dysrhythmias, <emphasis style="bold">CV thrombotic events, MI, stroke</emphasis></para>
					</section>
					<section type="none" id="sidelem4x926">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, hearing loss, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x931">
						<sec_title>GI:</sec_title>
						<para> Nausea, <emphasis style="italic">anorexia,</emphasis> vomiting, diarrhea, jaundice, <emphasis style="bold">hepatitis,</emphasis> constipation, flatulence, cramps, dry mouth, peptic ulcer, <emphasis style="bold">GI bleeding, ulceration, necrotizing enterocolitis, GI perforation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x944">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Nephrotoxicity:</emphasis> dysuria, hematuria, oliguria, azotemia</para>
					</section>
					<section type="none" id="sidelem4x952">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Blood dyscrasias,</emphasis> increased bleeding time</para>
					</section>
					<section type="none" id="sidelem4x960">
						<sec_title>INTEG:</sec_title>
						<para> Purpura, rash, pruritus, sweating, urticaria, <emphasis style="bold">nectrotizing fasciitis,</emphasis> photosensitivity, photophobia</para>
					</section>
					<section type="none" id="sidelem4x968">
						<sec_title>META:</sec_title>
						<para> Hyperkalemia, hyperuricemia, hypoglycemia, hyponatremia</para>
					</section>
					<section type="none" id="sidelem4x974">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x981">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x984">
					<section type="none" id="sidelem4x985">
						<sec_title>PO:</sec_title>
						<para> Onset <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, peak 1-2 hr, half-life 1.8-2 hr, metabolized in liver (inactive metabolites), excreted in urine (inactive metabolites), 90%-99% plasma protein binding, does not enter breast milk, well absorbed</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x996">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—valproic acid, thrombolytics, antiplatelets, anticoagulants, salicylates</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> blood dyscrasia risk—antineoplastics, radiation</para>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—lithium, oral anticoagulants, cycloSPORINE, methotrexate</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> GI reactions—aspirin, corticosteroids, NSAIDs, alcohol, tobacco</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemia—oral antidiabetics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of antihypertensives, thiazides, furosemide</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> ibuprofen action—aspirin</para>
				<section type="none" id="sidelem4x1026">
					<section type="none" id="sidelem4x1027">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> bleeding risk—feverfew, garlic, ginger, ginkgo, ginseng <emphasis style="italic">(Panax)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1036">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> BUN, creatinine, LFTs</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb/Hct, blood glucose, WBC, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1047">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1050">
					<section type="none" id="sidelem4x1051">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x1055">
								<item>
									<label>•</label>
									<para>Renal, hepatic, blood studies: BUN, creatinine, AST, ALT, Hgb, stool guaiac, before treatment, periodically thereafter, monitor electrolytes as needed</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>Perioperative pain in CABG: MI and stroke can result for 10-14 days; can be fatal; those taking NSAIDs are at greater risk of MI and stroke, even in first few weeks of therapy</bbw>
						</para>
						<section type="none" id="sidelem4x1076">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x1076">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> note type, duration, location, intensity with ROM 1 hr after administration</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1080">
								<item>
									<label>•</label>
									<para>Audiometric, ophthalmic exam before, during, after long-term treatment; for eye, ear problems: blurred vision, tinnitus; may indicate toxicity</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1088">
							<label>•</label>
							<sec_title>
								<route>Infection,</route>
							</sec_title>
							<para>
								<list id="lidelem4x1088">
									<item>
										<label>•</label>
										<para> may mask symptoms; fever: temperature before and 1 hr after administration</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1092">
								<item>
									<label>•</label>
									<para>Cardiac status: edema (peripheral), tachycardia, palpitations; monitor B/P, pulse for character, quality, rhythm, especially in patients with cardiac disease, geriatric patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1097">
								<item>
									<label>•</label>
									<para>For history of peptic ulcer disorder; asthma, aspirin, hypersensitivity; check closely for hypersensitivity reactions
<bbw>GI bleeding/perforation: chronic use can cause gastritis with or without bleeding, those with a prior history of peptic ulcer disease or GI bleeding, initiate treatment at lower dose; geriatric patients are at greater risk and those who consume &gt;3 alcohol drinks/day</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1111">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1115">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased pain, stiffness in joints; decreased swelling in joints; ability to move more easily; reduction in fever or menstrual cramping</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1121">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1126">
								<item>
									<label>•</label>
									<para>To use sunscreen, sunglasses, and protective clothing to prevent photosensitivity, photophobia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1131">
								<item>
									<label>•</label>
									<para>To report blurred vision, ringing, roaring in ears (may indicate toxicity); that eye and hearing tests should be done during long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1136">
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activities if dizziness or drowsiness occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1142">
								<item>
									<para>
										<emphasis alert="nurse">Nephrotoxicity: to report change in urinary pattern, increased weight, edema, increased pain in joints, fever, blood in urine; monitor fluid status, BUN, creatinine</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1147">
								<item>
									<label>•</label>
									<para>That therapeutic antiinflammatory effects may take up to 1 mo</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1153">
								<item>
									<para>
										<emphasis alert="nurse">To avoid alcohol, NSAIDs, salicylates; bleeding may occur</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1158">
								<item>
									<label>•</label>
									<para>To report use of this product to all health care providers</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1167">
							<label>•</label>
							<sec_title>Pregnancy<route> notify prescriber if pregnancy (C) is planned or suspected; avoid during 3rd trimester pregnancy (D) IV after 30 wk</route></sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x1179">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Lavage, activated charcoal, induce diuresis</para>
			</section>
		</monograph>
<monograph id="5" status="active" ha="yes">
			<mono_name> ibutilide (Rx)</mono_name>
			<info>
				<pronunciation>(eye-byoo′tih-lide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x11910">Corvert</tradename>
				</tradenames>
				<class type="func"> Antidysrhythmic (class III)</class>
				<class type="chem"> Methane sulfonamide</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x1201">
				<sec_title>Action:</sec_title>
				<para>Prolongs duration of action potential and effective refractory period</para>
			</section>
			<section type="uses" id="sidelem4x1206">
				<sec_title>Uses:</sec_title>
				<para>For rapid conversion of atrial fibrillation/flutter, including within 1 wk of coronary artery bypass or valve surgery</para>
			</section>
			<section type="contra" id="sidelem4x1211">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x1216">
					<section type="none" id="sidelem4x1217">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;18 yr, geriatric patients, sinus node dysfunction, 2nd- or 3rd-degree AV block, electrolyte imbalances, bradycardia, renal/hepatic disease, CHF</para>
						<para>
							<bbw>QT prolongation, torsades de pointes, ventricular arrhythmias, ventricular tachycardia, cardiac dysrhythmias, atrial fibrillation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1232">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1235">
					<section type="none" id="sidelem4x1236">
						<sec_title>Atrial fibrillation/flutter</sec_title>
						<section type="none" id="sidelem4x1244">
							<label>•</label>
							<sec_title>Adult ≥60 kg<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x1244">
									<item>
										<label>•</label>
										<para> 1 vial (1 mg) given over 10 min, may repeat same dose after 10 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1251">
							<label>•</label>
							<sec_title>Adult &lt;60 kg<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x1251">
									<item>
										<label>•</label>
										<para> 0.01 mg/kg given over 10 min, may repeat same dose after 10 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1255">
						<sec_title>Available forms:</sec_title>
						<para> Inj 1 mg/10 ml</para>
					</section>
					<section type="none" id="sidelem4x1260">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x1268">
							<label>•</label>
							<sec_title>
								<route>Ice compress after stopping infusion for extravasation; tubing should be removed and attempt to aspirate product; elevate affected areas</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x1271">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x1275">
									<item>
										<label>•</label>
										<para>Undiluted or diluted in 50 ml 0.9% NaCl, or D<emphasis style="inf">5</emphasis>W (0.017 mg/ml); give over 10 min</para>
									</item>
									<item>
										<label>•</label>
										<para>Solution is stable for 48 hr refrigerated or 24 hr at room temperature</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not admix with other sol, products</para>
									</item>
									<item>
										<label>•</label>
										<para>Reduce dosage slowly with ECG monitoring</para>
									</item>
									<item>
										<label>•</label>
										<para>Stop infusion as soon as arrhythmia is controlled</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not use if discolored or particulate is present</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1309">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1312">
					<section type="none" id="sidelem4x1313">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1320">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypotension, bradycardia,</emphasis><emphasis style="bold">sinus arrest, CHF, dysrhythmias, torsades de pointes,</emphasis> hypertension, extrasystoles, ventricular tachycardia, bundle branch block, AV block, palpitations, supraventricular extrasystoles, syncope, <emphasis style="bold">prolonged QT interval</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1332">
						<sec_title>GI:</sec_title>
						<para> Nausea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1337">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Elimination half-life 6 hr, metabolized by liver, excreted by kidneys</para>
			</section>
			<section type="interactions" id="sidelem4x1342">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> prodysrhythmia—phenothiazines, tricyclics, tetracyclics, antidepressants, H<emphasis style="inf">1</emphasis>-receptor antagonists, antihistamines</para>
				<section type="none" id="sidelem4x1360">
					<label>•</label>
					<sec_title>Do not use within 5 hr of ibutilide<route> class Ia antidysrhythmics (disopyramide, quiNIDine, procainamide), class III agents (amiodarone, sotalol), QT prolongation may occur</route></sec_title>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1364">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1367">
					<section type="none" id="sidelem4x1368">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>ECG continuously for ≥4 hr to determine product effectiveness; measure PR, QRS, QT intervals, check for PVCs, other dysrhythmias; discontinue if atrial fibrillation/flutter ceases; continue until QT interval corrected for heart rate (QTc) returned to baseline; if used ≥2 days, anticoagulation must be adequate</bbw>
						</para>
						<para>
							<list id="lidelem4x1382">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; electrolytes: potassium, sodium, chlorine</para>
								</item>
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, bilirubin, alk phos</para>
								</item>
								<item>
									<label>•</label>
									<para>Dehydration or hypovolemia</para>
								</item>
								<item>
									<label>•</label>
									<para>Rebound hypertension after 1-2 hr</para>
								</item>
								<item>
									<label>•</label>
									<para>Cardiac rate, respiration: rate, rhythm, character, chest pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1408">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1412">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in atrial fibrillation/flutter</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1418">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1422">
								<item>
									<label>•</label>
									<para>To report side effects immediately</para>
								</item>
								<item>
									<label>•</label>
									<para>About reason for medication</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="6" status="active">
			<mono_name>icosapent</mono_name>
			<info>
				<pronunciation>(eye-koe′sa-pent)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x14380">Vascepa</tradename>
				</tradenames>
				<class type="func"> Antilipidemic</class>
				<class type="chem"> Omega-3 fatty acid ethylester</class>
			</info>
			<section type="actions" id="sidelem4x1448">
				<sec_title>Action:</sec_title>
				<para>Inhibits hepatic very low density lipoprotein (VLDL) and triglyceride synthesis; enhances clearance of triglycerides from circulating VLDL particles</para>
			</section>
			<section type="uses" id="sidelem4x1453">
				<sec_title>Uses:</sec_title>
				<para>As adjunct to diet in adults with severe hypertriglyceridemia (≥500 mg/dl)</para>
			</section>
			<section type="contra" id="sidelem4x1458">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to icosapent ethyl</para>
				<section type="none" id="sidelem4x1463">
					<section type="none" id="sidelem4x1464">
						<sec_title>Precautions:</sec_title>
						<para> Hepatic disease, bleeding, breastfeeding, children, fish/shellfish hypersensitivity, thrombolytic/anticoagulation therapy, pregnancy (C)</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1469">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1477">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1477">
							<item>
								<label>•</label>
								<para> 2 g bid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1481">
					<section type="none" id="sidelem4x1482">
						<sec_title>Available forms:</sec_title>
						<para> Soft gel cap 1 g</para>
					</section>
					<section type="none" id="sidelem4x1487">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1491">
								<item>
									<label>•</label>
									<para>Give with food, swallow whole</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1502">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1505">
					<section type="none" id="sidelem4x1506">
						<sec_title>HEMA:</sec_title>
						<para> Ecchymosis, epistaxis</para>
					</section>
					<section type="none" id="sidelem4x1511">
						<sec_title>MS:</sec_title>
						<para> Arthralgia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1516">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 5 hr, protein binding 99%, half-life 89 hr</para>
			</section>
			<section type="interactions" id="sidelem4x1521">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of anticoagulants, platelet inhibitors, thrombolytics</para>
				<section type="none" id="sidelem4x1528">
					<section type="none" id="sidelem4x1529">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> bleeding time</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1536">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1539">
					<section type="none" id="sidelem4x1540">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1548">
							<label>•</label>
							<sec_title>Hypertriglyceridemia</sec_title>
							<para>
								<list id="lidelem4x1548">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertriglyceridemia:</emphasis> Obtain diet history including fat, cholesterol in diet; cholesterol, triglyceride levels periodically during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1555">
							<label>•</label>
							<sec_title>Liver disease</sec_title>
							<para>
								<list id="lidelem4x1555">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Liver disease:</emphasis> Monitor LFTs baseline, periodically in those with liver disease</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1562">
							<label>•</label>
							<sec_title>Bleeding</sec_title>
							<para>
								<list id="lidelem4x1562">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bleeding:</emphasis> Monitor for ecchymosis, epistaxis, bleeding time; use cautiously in anticoagulant/thrombolytic therapy</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1569">
							<label>•</label>
							<sec_title>Fish/shellfish hypersensitivity</sec_title>
							<para>
								<list id="lidelem4x1569">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Fish/shellfish hypersensitivity:</emphasis> Identify fish hypersensitivity, use cautiously</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1573">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1577">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in triglycerides</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1583">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1587">
								<item>
									<label>•</label>
									<para>That blood work may be necessary during treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>To report bleeding if anticoagulants or thrombolytics are used</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to break, crush, open, or dissolve caps</para>
								</item>
								<item>
									<label>•</label>
									<para>That previously prescribed regimen will continue: low-cholesterol diet, exercise program, smoking cessation</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="7" status="active" ha="yes">
			<mono_name> IDArubicin (Rx)</mono_name>
			<info>
				<pronunciation>(eye-dah-roob′ih-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x16160">Idamycin PFS</tradename>
				</tradenames>
				<class type="func"> Antineoplastic, antibiotic</class>
				<class type="chem"> Anthracycline glycoside</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1626">
				<para>
					<confusion>
						<tradename id="tnidelem4x16260">IDArubicin</tradename>
						<drug type="generic" refid="idelem4x16260">DOXOrubicin/ DAUNOrubicin/epirubicin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1633">
				<sec_title>Action:</sec_title>
				<para>Non–cell-cycle specific; topoisomerase II inhibitor; vesicant; intercalcalating between DNA base pairs, causing shape change, low free radicals</para>
			</section>
			<section type="uses" id="sidelem4x1638">
				<sec_title>Uses:</sec_title>
				<para>Used in combination with other antineoplastics for acute myelocytic leukemia in adults</para>
				<section type="none" id="sidelem4x1643">
					<section type="none" id="sidelem4x1644">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Breast cancer, liquid tumors, non-Hodgkin’s lymphoma, ALL, CML, NHL</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1649">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity</para>
				<para>
					<bbw>Myelosuppression, bilirubin &gt;5 mg/dl</bbw>
				</para>
				<section type="none" id="sidelem4x1664">
					<section type="none" id="sidelem4x1665">
						<sec_title>Precautions:</sec_title>
						<para> Children, gout, bone marrow depression, preexisting CV disease</para>
						<para>
							<bbw>Renal/hepatic disease, heart failure</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1680">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1688">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x1688">
							<item>
								<label>•</label>
								<para> 8-12 mg/m<emphasis style="sup">2</emphasis>/day × 3 days in combination with cytarabine (induction)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1698">
					<label>•</label>
					<sec_title>Adolescent/child (unlabeled)<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x1698">
							<item>
								<label>•</label>
								<para> 10-12 mg/m<emphasis style="sup">2</emphasis>/day × 3 days</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1705">
					<section type="none" id="sidelem4x1706">
						<sec_title>
							<emphasis style="bold">Renal/hepatic dose</emphasis>
						</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Adult: IV</emphasis> CCr &gt;2.5 mg/dl, reduce dose; bilirubin 2.5-5 mg/dl, reduce dose by 50%; bilirubin &gt;5 mg/dl, do not use</bbw>
						</para>
					</section>
					<section type="none" id="sidelem4x1723">
						<sec_title>Available forms:</sec_title>
						<para> Inj 1 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x1728">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1732">
								<item>
									<label>•</label>
									<para>Ice compress after stopping infusion for extravasation</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature for 3 days after reconstituting or 7 days refrigerated</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1743">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x1748">
									<item>
										<label>•</label>
										<para>Do not give IM/SUBCUT</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x1753">
									<item>
										<label>•</label>
										<para>Use cytotoxic handling procedures after preparing in biologic cabinet wearing gown, gloves, mask</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x1758">
									<item>
										<label>•</label>
										<para>Antiemetic 30-60 min before product and 6-10 hr after treatment to prevent vomiting</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x1763">
									<item>
										<label>•</label>
										<para>After reconstituting 5-mg vial with 5 ml 0.9% NaCl (1 mg/1 ml); give over 10-15 min through <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock of infusion of D<emphasis style="inf">5</emphasis>W or NS; discard unused portion; use caution when needle inserted into vial (negative pressure)</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x1777">
								<label>•</label>
								<sec_title>
									<route>Use a free-flowing IV, do not give IM/SUBCUT</route>
								</sec_title>
							</section>
							<section type="none" id="sidelem4x1783">
								<label>•</label>
								<sec_title>
									<route>A vesicant, monitor for necrosis</route>
								</sec_title>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Amifostine, amikacin, aztreonam, cimetidine, cladribine, cyclophosphamide, cytarabine, diphenhydrAMINE, droperidol, erythromycin, filgrastim, granisetron, imipenem/CISplatin, magnesium sulfate, mannitol, melphalan, metoclopramide, potassium chloride, ranitidine, sargramostim, thiotepa, vinorelbine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1790">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1793">
					<section type="none" id="sidelem4x1794">
						<sec_title>CNS:</sec_title>
						<para> Fever, chills, <emphasis style="italic">headache,</emphasis><emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1803">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Dysrhythmias, CHF, pericarditis, myocarditis,</emphasis> peripheral edema, angina, <emphasis style="bold">MI, myocardial toxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1813">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, abdominal pain, mucositis, diarrhea,</emphasis><emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1822">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Nephrotoxicity,</emphasis> red urine</para>
					</section>
					<section type="none" id="sidelem4x1830">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1837">
						<sec_title>INTEG:</sec_title>
						<para> Rash, <emphasis style="bold">extravasation,</emphasis> dermatitis, <emphasis style="italic">reversible alopecia,</emphasis> urticaria; thrombophlebitis and tissue necrosis at inj site; radiation recall</para>
					</section>
					<section type="none" id="sidelem4x1849">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Infection, tumor lysis syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1856">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 22 hr; metabolized by liver; crosses placenta; excreted in bile, urine (primarily as metabolites); 97% protein binding</para>
			</section>
			<section type="interactions" id="sidelem4x1861">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—anticoagulants, salicylates, NSAIDs, thrombolytics; avoid concurrent use</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> IDArubicin effect—corticosteroids</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CHF, ventricular dysfunction—trastuzumab</para>
				<para>
					<emphasis alert="lifethreat">Increase: ECG changes (QT prolongation, changes in QRS voltage)—class IA/III antidysrhythmias, some phenothiazines, and other products that increase QT prolongation</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: cardiotoxicity—cyclophosphamide</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—other antineoplastics or radiation</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antibody response—live virus vaccines</para>
				<section type="none" id="sidelem4x1890">
					<section type="none" id="sidelem4x1891">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> calcium, platelets, neutrophils</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> uric acid, phosphate, potassium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1902">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1905">
					<section type="none" id="sidelem4x1906">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>CBC, differential, platelet count weekly; notify prescriber of results, severe myelosuppression can occur</bbw>
						</para>
						<para>
							<list id="lidelem4x1921">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, serum uric acid, urine CCr, electrolytes before, during therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1927">
								<item>
									<para>
										<emphasis alert="nurse">Tumor lysis syndrome: hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1932">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; report fall in urine output to &lt;30 ml/hr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1937">
								<item>
									<label>•</label>
									<para>Monitor temperature; fever may indicate beginning infection</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>Hepatic studies before, during therapy: bilirubin, AST, ALT, alk phos prn or monthly; check for jaundice of skin and sclera, dark urine, clay-colored stools, itchy skin, abdominal pain, fever, diarrhea, do not use if bilirubin &gt;5 mg/dl</bbw>
						</para>
						<para>
							<bbw>Cardiac toxicity: CHF, dysrythmias, cardiomyopathy; cardiac studies before and periodically during treatment: ECG, chest x-ray, MUGA; ECG: watch for ST-T wave changes, low QRS and T, possible dysrhythmias (sinus tachycardia, heart block, PVCs)</bbw>
						</para>
						<section type="none" id="sidelem4x1966">
							<label>•</label>
							<sec_title>Bleeding</sec_title>
							<para>
								<list id="lidelem4x1966">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bleeding:</emphasis> hematuria, guaiac stools, bruising or petechiae, mucosa or orifices</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1970">
								<item>
									<label>•</label>
									<para>Effects of alopecia on body image; discuss feelings about body changes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1975">
								<item>
									<label>•</label>
									<para>Inflammation of mucosa, breaks in skin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1980">
								<item>
									<label>•</label>
									<para>Buccal cavity for dryness, sores, ulceration, white patches, oral pain, bleeding, dysphagia</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>Local irritation, pain, burning at inj site; extravasation (vesicant)•GI symptoms: frequency of stools, cramping•Increase fluid intake to 2-3 L/day to prevent urate and calculi formation</bbw>
						</para>
					</section>
					<section type="none" id="sidelem4x2006">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2010">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased liquid tumor, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2016">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x2024">
							<label>•</label>
							<sec_title>
								<route>To report signs of CHF, cardiac toxicity, beginning infection</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2027">
								<item>
									<label>•</label>
									<para>That hair may be lost during treatment; that wig or hairpiece may make patient feel better; that new hair may be different in color, texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2032">
								<item>
									<label>•</label>
									<para>To avoid foods with citric acid, hot or rough texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2037">
								<item>
									<label>•</label>
									<para>To avoid crowds, persons with upper respiratory illness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2043">
								<item>
									<label>•</label>
									<para>To report any bleeding, white spots, ulcerations in mouth; to examine mouth daily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2048">
								<item>
									<label>•</label>
									<para>That urine may be red-orange for 48 hr</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2056">
							<label>•</label>
							<sec_title>
								<route>To report if pregnancy is planned or suspected, pregnancy (D)</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x2062">
							<label>•</label>
							<sec_title>
								<route>To use contraception during treatment, for ≥4 mo after treatment</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2065">
								<item>
									<label>•</label>
									<para>That all body fluids will change color</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="8" status="active">
			<mono_name>idelalisib</mono_name>
			<info>
				<pronunciation>(eye-del′a-lis′ib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x20750">Zydelig</tradename>
				</tradenames>
				<class type="func"> Antineoplastic-biologic response modifier</class>
				<class type="chem"> Signal transduction inhibitor (STI)</class>
			</info>
			<section type="actions" id="sidelem4x2085">
				<sec_title>Action:</sec_title>
				<para> Selective, small-molecule inhibitor of one kinase (expressed in both normal and malignant B-cells). Induces apoptosis and inhibited proliferation, inhibits several cell signaling pathways</para>
			</section>
			<section type="uses" id="sidelem4x2090">
				<sec_title>Uses:</sec_title>
				<para> Treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in those whom rituximab alone should not be used; non-Hodgkin’s lymphoma (NHL), relapsed follicular B-cell non-Hodgkin’s lymphoma in those who have received at least 2 prior systemic therapies</para>
			</section>
			<section type="contra" id="sidelem4x2095">
				<sec_title>Contraindications:</sec_title>
				<para> Infusion-related reaction, serious rash, pregnancy (D)</para>
				<section type="none" id="sidelem4x2100">
					<section type="none" id="sidelem4x2101">
						<sec_title>Precautions:</sec_title>
						<para> Serious allergic reactions, grade 3 or 4 neutropenia, breastfeeding, hyperglycemia/hypoglycemia</para>
						<para>
							<bbw>Serious hepatotoxicity, grade 3 or higher diarrhea or colitis, fatal/serious pneumonitis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2116">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2119">
					<section type="none" id="sidelem4x2120">
						<sec_title>Treatment of relapsed chronic lymphocytic leukemia (CLL)</sec_title>
						<section type="none" id="sidelem4x2128">
							<label>•</label>
							<sec_title>Adults<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2128">
									<item>
										<label>•</label>
										<para> 150 mg bid until disease progression or unacceptable toxicity, with 8 doses of rituximab (given as 375 mg/m<emphasis style="sup">2</emphasis> IV on day 1, then 2 wk later rituximab 500 mg/m<emphasis style="sup">2</emphasis> IV q2wk × 3 more doses, followed by rituximab 500 mg/m<emphasis style="sup">2</emphasis> IV q4wk × 4 doses)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2141">
						<sec_title>Treatment of small lymphocytic lymphoma (SLL) in those who have received at least 2 prior systemic therapies</sec_title>
						<section type="none" id="sidelem4x2149">
							<label>•</label>
							<sec_title>Adults<route> PO 150 mg bid until disease progression or unacceptable toxicity</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2152">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x2160">
							<label>•</label>
							<sec_title>AST/ALT &gt;3-5 × ULN<route> No change; monitor AST/ALT at least every week until ≤1 × ULN</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2166">
							<label>•</label>
							<sec_title>AST/ALT &gt;5-20 × ULN<route> Hold doses, monitor AST/ALT at least every week, when AST/ALT are ≤1 × ULN, resume at 100 mg bid</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2172">
							<label>•</label>
							<sec_title>AST/ALT &gt;20 × ULN<route> Permanently discontinue</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2178">
							<label>•</label>
							<sec_title>Bilirubin &gt;1.5-3 × ULN<route> No change; monitor bilirubin at least every week until ≤1 × ULN</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2184">
							<label>•</label>
							<sec_title>Bilirubin &gt;3-10 × ULN<route> Hold treatment; monitor bilirubin at least every week; when bilirubin is ≤1 × ULN, resume treatment at 100 mg bid</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2190">
							<label>•</label>
							<sec_title>Bilirubin &gt;10 × ULN<route> Permanently discontinue</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2193">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 100, 150 mg</para>
					</section>
					<section type="none" id="sidelem4x2198">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2202">
								<item>
									<label>•</label>
									<para>Take without regard to food, do not crush or dissolve tabs</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not take 2 doses at the same time, if a dose is missed by &lt;6 hr, take the dose, take next dose at usual time</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2214">
						<sec_title>Therapeutic drug monitoring: dosage adjustments due to treatment-related toxicity</sec_title>
						<section type="none" id="sidelem4x2222">
							<label>•</label>
							<sec_title>Moderate diarrhea (4-6 stools/day over baseline)<route> Continue current dosing; monitor at least every week until diarrhea is resolved</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2228">
							<label>•</label>
							<sec_title>Severe diarrhea (≥7 stools/day over baseline) or diarrhea requiring hospitalization<route> Hold treatment, and monitor at least every week for resolution. When diarrhea has resolved, resume with 100 mg bid</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2234">
							<label>•</label>
							<sec_title>Life-threatening diarrhea<route> Permanently discontinue treatment</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2240">
							<label>•</label>
							<sec_title>Neutropenia<route> ANC 1000-1499 cells/mm</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2266">
							<label>•</label>
							<sec_title>Thrombocytopenia<route> Platelet count 50,000-75,000 cells/mm</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2292">
							<label>•</label>
							<sec_title>Symptomatic pneumonitis (any severity)<route> Discontinue treatment</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2298">
							<label>•</label>
							<sec_title>Other severe or life-threatening toxicities<route> Hold until toxicity is resolved; if resuming treatment, reduce the dose to 100 mg bid; permanently discontinue treatment for any recurrence of severe or life-threatening toxicity after rechallenge</route></sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2301">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2304">
					<section type="none" id="sidelem4x2305">
						<sec_title>CNS:</sec_title>
						<para> Insomnia, fatigue, fever, headache</para>
					</section>
					<section type="none" id="sidelem4x2310">
						<sec_title>RESP:</sec_title>
						<para> Pneumonitis, dyspnea, cough</para>
					</section>
					<section type="none" id="sidelem4x2315">
						<sec_title>ENDO:</sec_title>
						<para> Hypoglycemia, hyperglycemia, hyponatremia</para>
					</section>
					<section type="none" id="sidelem4x2320">
						<sec_title>INTEG:</sec_title>
						<para> Rash</para>
					</section>
					<section type="none" id="sidelem4x2325">
						<sec_title>EENT:</sec_title>
						<para> Sinusitis</para>
					</section>
					<section type="none" id="sidelem4x2330">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, hepatic failure, GI perforation, stomatitis, colitis, diarrhea, anorexia, abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x2335">
						<sec_title>HEMA:</sec_title>
						<para> Thrombocytopenia, neutropenia, anemia</para>
					</section>
					<section type="none" id="sidelem4x2340">
						<sec_title>SYST:</sec_title>
						<para> Serious/fatal rashes</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2345">
				<sec_title>Pharmacokinetics</sec_title>
				<para>84% protein binding, half-life 8.2 hr, peak 1.5 hr</para>
			</section>
			<section type="interactions" id="sidelem4x2350">
				<sec_title>Interactions</sec_title>
				<para>Avoid use with CYP3A4 inhibitors, inducers, substrates</para>
				<section type="none" id="sidelem4x2355">
					<section type="none" id="sidelem4x2356">
						<sec_title>Drug/lab test</sec_title>
						<para>Increase: LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2361">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2364">
					<section type="none" id="sidelem4x2365">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2373">
							<label>•</label>
							<sec_title>Hepatic failure<route> Increased LFTs generally occurred within the first 12 wk of treatment and were reversible with dose interruption. Monitor LFTs q2wk × 3 mo of treatment, then q4wk for 3 mo, and q1-3 mo thereafter; monitor weekly if AST or ALT are &gt;3 times the upper limit of normal (ULN) or bilirubin &gt;1.5 × ULN. Hepatotoxicity may require treatment interruption, dose reduction, or discontinuation of therapy</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2379">
							<label>•</label>
							<sec_title>Severe diarrhea/GI perforation<route> Generally responds poorly to antimotility agents. The occurrence of ≥7 stools/day over baseline or hospitalization due to diarrhea may result in interruption of therapy, dose reduction, or permanent discontinuation. Assess for new or worsening abdominal pain, chills, fever, or nausea/vomiting. If intestinal perforation occurs, permanently discontinue treatment</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2385">
							<label>•</label>
							<sec_title>Pneumonitis<route> Monitor for cough, dyspnea, hypoxia, and bilateral interstitial infiltrates, or a decline in oxygen saturation by &gt;5%. If pneumonitis is suspected, hold therapy. Permanently discontinue treatment for pneumonitis and consider treatment with corticosteroids</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2388">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2392">
								<item>
									<label>•</label>
									<para>Therapeutic response</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2398">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x2406">
							<label>•</label>
							<sec_title>
								<route>To report planned or suspected pregnancy (D), use effective contraception during treatment and for at least 1 month after the last dose</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x2412">
							<label>•</label>
							<sec_title>
								<route>Avoid breastfeeding</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2415">
								<item>
									<label>•</label>
									<para>To report new or worsening side effects</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="9" status="active" ha="yes">
			<mono_name> ifosfamide (Rx)</mono_name>
			<info>
				<pronunciation>(i-foss′fa-mide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x24280">Ifex</tradename>
				</tradenames>
				<class type="func"> Antineoplastic alkylating agent</class>
				<class type="chem"> Nitrogen mustard</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x2438">
				<para>
					<confusion>
						<tradename id="tnidelem4x24380">ifosfamide</tradename>
						<drug type="generic" refid="idelem4x24380">cyclophosphamide</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x2442">
				<sec_title>Action:</sec_title>
				<para>Alkylates DNA, inhibits enzymes that allow synthesis of amino acids in proteins; also responsible for cross-linking DNA strands; activity is not cell-cycle–stage specific</para>
			</section>
			<section type="uses" id="sidelem4x2447">
				<sec_title>Uses:</sec_title>
				<para>Testicular cancer</para>
				<section type="none" id="sidelem4x2452">
					<section type="none" id="sidelem4x2453">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Soft-tissue sarcoma, Ewing’s sarcoma, non-Hodgkin’s lymphoma, lung/pancreatic sarcoma, bladder, breast, cervical, thymic cancer, desmoid tumor, Ewing’s sarcoma, rhabdomyosarcoma</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x2458">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity</para>
				<para>
					<bbw>Bone marrow suppression</bbw>
				</para>
				<section type="none" id="sidelem4x2473">
					<section type="none" id="sidelem4x2474">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, renal/hepatic disease, accidental exposure, dehydration, dental disease, infection, IM injection, ocular exposure varicella</para>
						<para>
							<bbw>Coma, hemorrhagic cystitis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2489">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2497">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x2497">
							<item>
								<label>•</label>
								<para> 1.2-2 g/m<emphasis style="sup">2</emphasis>/day × 5 days, repeat course q3wk, given with mesna, in combination with 1-2 other antineoplastic agents</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2504">
					<section type="none" id="sidelem4x2505">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x2513">
							<label>•</label>
							<sec_title>Adult<route> IV CCr 31-60 ml/min, give 75% of dose; CCr 10-30 ml/min, give 50% of dose; CCr &lt;10 ml/min, do not give</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2516">
						<sec_title>Available forms:</sec_title>
						<para> Inj 1-, 3-g vials</para>
					</section>
					<section type="none" id="sidelem4x2521">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2525">
								<item>
									<label>•</label>
									<para>Antiemetic 30-60 min before product to prevent vomiting</para>
								</item>
								<item>
									<label>•</label>
									<para>Visually inspect parenteral products for particulate matter and discoloration before use</para>
								</item>
								<item>
									<label>•</label>
									<para>Store powder at room temperature</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2541">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x2545">
									<item>
										<label>•</label>
										<para>Give as an intermittent infusion or continuous infusion</para>
									</item>
									<item>
										<label>•</label>
										<para>Well hydrate with ≥2 L/day of oral or IV fluids to prevent bladder toxicity</para>
									</item>
									<item>
										<label>•</label>
										<para>Must be given in combination with mesna to prevent hemorrhagic cystitis</para>
									</item>
									<item>
										<label>•</label>
										<para>Close hematologic monitoring is recommended; WBC count, platelet count, and hemoglobin should be obtained before each use and periodically thereafter</para>
									</item>
									<item>
										<label>•</label>
										<para>A urinalysis should be performed before each dose to monitor for hematuria</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2571">
							<sec_title>Reconstitution and further dilution:</sec_title>
							<para>
								<list id="lidelem4x2575">
									<item>
										<label>•</label>
										<para>Reconstitute 1 or 3 g with 20 or 60 ml, respectively, of sterile water for injection or bacteriostatic water for injection containing parabens or benzyl alcohol to give IV solutions containing 50 mg/ml</para>
									</item>
									<item>
										<label>•</label>
										<para>Solutions may be diluted further to achieve concentrations of 0.6-20 mg/ml in the following solutions: D<emphasis style="inf">5</emphasis>W, NS, LR, or sterile water for injection</para>
									</item>
									<item>
										<label>•</label>
										<para>Infuse slowly over at least 30 min</para>
									</item>
									<item>
										<label>•</label>
										<para>Diluted and reconstituted solutions must be refrigerated and used within 24 hr</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alatrofloxacin, alemtuzumab, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone amphotericin B cholesteryl (amphotec), amphotericin B conventional colloidal, amphotericin B lipid complex (abelcet), amphotericin B liposome (ambisome), ampicillin, ampicillin-sulbactam, anidulafungin, argatroban, arsenic trioxide, atenolol, atracurium, azithromycin, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, ceFAZolin, cefoperazone, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftazidime (L-arginine), ceftizoxime, cefTRIAXone, cefuroxime, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, codeine, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, DAUNOrubicin liposome, dexamethasone phosphate, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doripenem, doxacurium, DOXOrubicin, DOXOrubicin liposomal, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, gallium nitrate, ganciclovir, gatifloxacin, gemcitabine, gemtuzumab, gentamicin, granisetron, haloperidol, heparin, hydrocortisone phosphate/succinate, HYDROmorphone, hydrOXYzine, IDArubicin, imipenem-cilastatin, inamrinone, insulin (regular), isoproterenol, ketorolac, labetalol, lansoprazole, lepirudin, leucovorin, levofloxacin, levorphanol, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, melphalan, meperidine, meropenem, mesna, methohexital, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, minocycline, mitoMYcin, mitoXANtrone, mivacurium, morphine, moxifloxacin, nalbuphine, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ofloxacin, ondansetron, oxaliplatin, PACLitaxel (solvent/surfactant), palonosetron, pamidronate, pancuronium, PEMEtrexed, pentamidine, PENTobarbital, PHENobarbital, phenylephrine, piperacillin, piperacillin-tazobactam, potassium acetate/chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, quinupristin-dalfopristin, ranitidine, rapacuronium, remifentanil, riTUXimab, rocuronium, sargramostim, sodium acetate/, bicarbonate/phosphates, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, teniposide, theophylline, thiopental s, thiotepa, ticarcillin, ticarcillin -clavulanate, tigecycline, tirofiban, tna (3-in-1), tobramycin, topotecan, tpn (2-in-1), trastuzumab, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2605">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2608">
					<section type="none" id="sidelem4x2609">
						<sec_title>CNS:</sec_title>
						<para> Facial paresthesia, fever, malaise, somnolence, confusion, depression, hallucinations, dizziness, disorientation, <emphasis style="bold">seizures, coma,</emphasis> cranial nerve dysfunction, <emphasis style="bold">encephalopathy</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2619">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, anorexia, <emphasis style="bold">hepatotoxicity,</emphasis> stomatitis, dyslipidemia, hyperglycemia, constipation, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x2627">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Hematuria, nephrotoxicity, hemorrhagic cystitis,</emphasis> dysuria, urinary frequency</para>
					</section>
					<section type="none" id="sidelem4x2635">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, anemia,</emphasis> retrograde ejaculation</para>
					</section>
					<section type="none" id="sidelem4x2643">
						<sec_title>INTEG:</sec_title>
						<para> Dermatitis, alopecia, pain at inj site, hyperpigmentation</para>
					</section>
					<section type="none" id="sidelem4x2648">
						<sec_title>META:</sec_title>
						<para> Metabolic acidosis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2653">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver, saturation occurs at high doses, excreted in urine, half-life 7-15 hr, depends on dose</para>
			</section>
			<section type="interactions" id="sidelem4x2658">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> myelosuppression—other antineoplastics, radiation</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—CYP3A4, a weak P-gp inhibitor, inducers, barbiturates, allopurinol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—NSAIDs, anticoagulants, salicylates, thrombolytics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antibody response—live virus vaccines</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of ifosfamide—CYP3A4 inhibitors<list id="lidelem4x2682">
						<item>
							<label>•</label>
							<para>Do not use within 24 hr of hematopoietic progenitor cells</para>
						</item>
					</list></para>
			</section>
			<section type="considerations" id="sidelem4x2688">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2691">
					<section type="none" id="sidelem4x2692">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x2696">
								<item>
									<label>•</label>
									<para>Hepatic studies before, during therapy (bilirubin, AST, ALT, LDH) monthly or as needed; jaundice of skin and sclera, dark urine, clay-colored stools, itchy skin, abdominal pain, fever, diarrhea
<bbw>CBC, differential, platelet count weekly; withhold product if WBC &lt;2000 or platelet count &lt;50,000; notify prescriber; severe myelosuppression may occur</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>Monitor temperature (may indicate beginning infection)</para>
								</item>
								<item>
									<label>•</label>
									<para>Blood dyscrasias (anemia, granulocytopenia); bruising, fatigue, bleeding, poor healing</para>
								</item>
								<item>
									<label>•</label>
									<para>Allergic reactions: dermatitis, exfoliative dermatitis, pruritus, urticaria
<bbw>I&amp;O ratio; monitor for hematuria; hemorrhagic cystitis can occur; increase fluids to 3 L/day; urinalysis before each dose, not to give at night</bbw>

<bbw>Neurologic symptoms: hallucinations, confusion, disorientation, coma; product should be discontinued</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>Bleeding: hematuria, guaiac, bruising or petechiae, mucosa or orifices</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2749">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2753">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in size and spread of tumor</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2759">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x2767">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of sore throat, swollen lymph nodes, malaise, fever; other infections may occur, to discuss encephalopathy, neurotoxicity</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2770">
								<item>
									<label>•</label>
									<para>Not to have live virus vaccinations during or for 3 mo-1 yr after treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2775">
								<item>
									<label>•</label>
									<para>That hair may be lost during treatment; that wig or hairpiece may make the patient feel better; that new hair may be different in color, texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2780">
								<item>
									<label>•</label>
									<para>To report signs of anemia: fatigue, headache, faintness, SOB, irritability</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2785">
								<item>
									<label>•</label>
									<para>To report bleeding; to avoid use of razors, commercial mouthwash</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2790">
								<item>
									<label>•</label>
									<para>To avoid use of aspirin products, NSAIDs, ibuprofen because hemorrhage can occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2798">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected, pregnancy (D)</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x2804">
							<label>•</label>
							<sec_title>
								<route>To use contraceptive measures during therapy; not to breastfeed</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2807">
								<item>
									<label>•</label>
									<para>To avoid crowds, persons with infections</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2812">
								<item>
									<label>•</label>
									<para>To report confusion, hallucinations, extreme drowsiness, numbness, tingling; to avoid alcohol use for ≥4 mo after treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2817">
								<item>
									<label>•</label>
									<para>To avoid driving, hazardous activities until reaction is known</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2825">
							<label>•</label>
							<sec_title>
								<route>To use excessive fluids and urinate often to prevent hemorrhagic cystitis</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="10" status="active">
			<mono_name>iloperidone (Rx)</mono_name>
			<info>
				<pronunciation>(ill-o-pehr′ih-dohn)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x28330">Fanapt</tradename>
				</tradenames>
				<class type="func"> Antipsychotic</class>
				<class type="chem"> Benzisoxazole derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x2843">
				<sec_title>Action:</sec_title>
				<para>Unknown; may be mediated through both DOPamine type 2 (D2) and serotonin type 2 (5-HT2) antagonism, high receptor binding affinity for norepinephrine (alpha 1)</para>
			</section>
			<section type="uses" id="sidelem4x2848">
				<sec_title>Uses:</sec_title>
				<para>Schizophrenia</para>
			</section>
			<section type="contra" id="sidelem4x2853">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, hypersensitivity</para>
				<section type="none" id="sidelem4x2858">
					<section type="none" id="sidelem4x2859">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), children, geriatric patients, renal/hepatic disease, breast cancer, Parkinson’s disease, dementia with Lewy bodies, seizure disorder, QT prolongation, bundle branch block, acute MI, ambient temperature increase, AV block, stroke, substance abuse, suicidal ideation, tardive dyskinesia, torsade de pointes, blood dyscrasias, dysphagia</para>
						<para>
							<bbw>Increased mortality in elderly patients with dementia-related psychosis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2875">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2883">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2883">
							<item>
								<label>•</label>
								<para> 1 mg bid, may increase to target dose of 6-12 mg bid with daily dose adjustment of max 2 mg bid, titrate slowly; max 24 mg/day in 2 divided doses; </para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2889">
					<section type="none" id="sidelem4x2890">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 1, 2, 4, 6, 8, 10, 12 mg; titration pack</para>
					</section>
					<section type="none" id="sidelem4x2895">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2899">
								<item>
									<label>•</label>
									<para>Use without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Reduced dose in geriatric patients</para>
								</item>
								<item>
									<label>•</label>
									<para>Anticholinergic agent for EPS</para>
								</item>
								<item>
									<label>•</label>
									<para>Avoid use with CNS depressants</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight, light-resistant container</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2925">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2928">
					<section type="none" id="sidelem4x2929">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">EPS, pseudoparkinsonism, akathisia, dystonia, tardive dyskinesia; drowsiness,</emphasis><emphasis style="bold">seizures, neuroleptic malignant syndrome,</emphasis> dizziness, delirium, depression, paranoia, fatigue, hostility, lethargy, restlessness, vertigo, tremor</para>
					</section>
					<section type="none" id="sidelem4x2939">
						<sec_title>CV:</sec_title>
						<para> Orthostatic hypotension, <emphasis style="bold">heart failure, AV block, QT prolongation,</emphasis> tachycardia</para>
					</section>
					<section type="none" id="sidelem4x2947">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, cataracts, nystagmus, tinnitus</para>
					</section>
					<section type="none" id="sidelem4x2952">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, <emphasis style="italic">anorexia, constipation,</emphasis> jaundice, weight gain/loss, abdominal pain, stomatitis, xerostomia</para>
					</section>
					<section type="none" id="sidelem4x2963">
						<sec_title>GU:</sec_title>
						<para> Hyperprolactinemia, urinary retention/incontinence, testicular pain, <emphasis style="bold">renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2970">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, leukopenia, neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2977">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Renal artery occlusion, hyperglycemia, dyslipidemia</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2984">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x2987">
					<section type="none" id="sidelem4x2988">
						<sec_title>PO:</sec_title>
						<para> Extensively metabolized by liver to major active metabolite by CYP2D6, CYP3A4; protein binding 95%; peak 2-4 hr; excreted in urine and feces; terminal half-life 18 hr in extensive metabolizers; 33 hr in poor metabolizers</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x2993">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome, neuroleptic malignant syndrome—SSRIs, SNRI</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> sedation—other CNS depressants, alcohol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> iloperidone effect, decreased clearance—CYP2D6, CYP3A4 inhibitors (delavirdine, indinavir, isoniazid, itraconazole, dalfopristin, ritonavir, tipranavir), reduce dose</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—class IA/III antidysrhythmics, some phenothiazines, β-agonists, local anesthetics, tricyclics, haloperidol, methadone, chloroquine, clarithromycin, droperidol, erythromycin, pentamidine</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> iloperidone action—CYP2D6, CYP3A4 inducers (carBAMazepine, barbiturates, phenytoins, rifampin)</para>
				<section type="none" id="sidelem4x3014">
					<section type="none" id="sidelem4x3015">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> prolactin levels, cholesterol, glucose, lipids, triglycerides</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> potassium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3026">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3029">
					<section type="none" id="sidelem4x3030">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x3035">
								<item>
									<label>•</label>
									<para>AIMS assessment, lipid panel, blood glucose, CBC, glycosylated hemoglobin A1c, LFTs, neurologic function, pregnancy test, serum creatinine, electrolytes, prolactin, thyroid function studies, weight</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3040">
								<item>
									<label>•</label>
									<para>Affect, orientation, LOC, reflexes, gait, coordination, sleep-pattern disturbances</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3045">
								<item>
									<label>•</label>
									<para>B/P standing and lying; pulse, respirations; q4hr during initial treatment; establish baseline before starting treatment; report drops of 30 mm Hg; watch for ECG changes; QT prolongation may occur; dizziness, faintness, palpitations, tachycardia on rising</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3053">
							<para>
								<list id="lidelem4x3053">
									<item>
										<label>•</label>
										<para>EPS, including akathisia, tardive dyskinesia (bizarre movements of the jaw, mouth, tongue, extremities), pseudoparkinsonism (rigidity, tremors, pill rolling, shuffling gait)
<bbw>
												<emphasis alert="lifethreat">Serious reactions in geriatric patients:</emphasis> fatal pneumonia, heart failure, sudden death, not to be used in the elderly with dementia</bbw>

<bbw>
												<emphasis alert="lifethreat">Neuroleptic malignant syndrome:</emphasis> hyperthermia, increased CPK, altered mental status, muscle rigidity</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3078">
								<item>
									<label>•</label>
									<para>Constipation, urinary retention daily; if these occur, increase bulk and water in diet</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3083">
								<item>
									<label>•</label>
									<para>Weight gain, hyperglycemia, metabolic changes in diabetes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3088">
								<item>
									<label>•</label>
									<para>Supervised ambulation until patient is stabilized on medication; do not involve patient in strenuous exercise program because fainting is possible; patient should not stand still for long periods</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3093">
								<item>
									<label>•</label>
									<para>Sips of water, candy, gum for dry mouth</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3098">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3102">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in emotional excitement, hallucinations, delusions, paranoia; reorganization of patterns of thought, speech</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3108">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3113">
								<item>
									<label>•</label>
									<para>That orthostatic hypotension may occur; to rise from sitting or lying position gradually</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3118">
								<item>
									<label>•</label>
									<para>To avoid hot tubs, hot showers, tub baths because hypotension may occur; that heat stroke may occur in hot weather; to take extra precautions to stay cool</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3123">
								<item>
									<label>•</label>
									<para>To avoid abrupt withdrawal of product because EPS may result; that product should be withdrawn slowly, to review symptoms of neuroleptic malignant syndrome</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3128">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations (cough, hay fever, cold) unless approved by prescriber because serious product interactions may occur; to avoid use of alcohol because increased drowsiness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3133">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if drowsy or dizzy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3138">
								<item>
									<label>•</label>
									<para>To comply with product regimen</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3143">
								<item>
									<label>•</label>
									<para>To report impaired vision, tremors, muscle twitching</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3151">
							<label>•</label>
							<sec_title>
								<route>To use contraception; to inform prescriber if pregnancy is planned or suspected</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x3154">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Lavage if orally ingested; provide airway; <emphasis style="italic">do not induce vomiting</emphasis></para>
			</section>
		</monograph>
<monograph id="11" status="active" ha="yes">
			<mono_name> imatinib (Rx)</mono_name>
			<info>
				<pronunciation>(im-ah-tin′ib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x31680">Gleevec</tradename>
				</tradenames>
				<class type="func"> Antineoplastic—miscellaneous</class>
				<class type="chem"> Protein-tyrosine kinase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x3178">
				<sec_title>Action:</sec_title>
				<para>Inhibits Bcr-Abl tyrosine kinase created in patients with chronic myeloid leukemia (CML), also inhibits tyrosine kinases</para>
			</section>
			<section type="uses" id="sidelem4x3183">
				<sec_title>Uses:</sec_title>
				<para>Treatment of CML; Philadelphia-chromosome–positive (Ph+) patients in blast-cell crisis or patients in chronic failure; gastrointestinal stromal tumors (GIST) positive for c-Kit; chronic eosinophilic leukemia, Ph+ acute lymphocytic leukemia, dermatofibrosarcoma protuberans, myelodysplastic syndrome, systemic mastocytosis</para>
				<section type="none" id="sidelem4x3188">
					<section type="none" id="sidelem4x3189">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Desmoid tumor</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3194">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity</para>
				<section type="none" id="sidelem4x3199">
					<section type="none" id="sidelem4x3200">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, geriatric patients, cardiac/renal/hepatic/dental disease, GI bleeding, bone marrow suppression, infection, thrombocytopenia, neutropenia, immunosuppression</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3205">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3208">
					<section type="none" id="sidelem4x3209">
						<sec_title>For the treatment of Ph+ CML chronic phase as initial therapy</sec_title>
						<section type="none" id="sidelem4x3217">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3217">
									<item>
										<label>•</label>
										<para> 400 mg/day, continue as long as beneficial; may increase to 600 mg/day in the absence of severe adverse reactions and severe non–leukemia-related neutropenia or thrombocytopenia</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3225">
							<label>•</label>
							<sec_title>Adolescent/child &gt;2 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3225">
									<item>
										<label>•</label>
										<para> 340 mg/m<emphasis style="sup">2</emphasis>/day, max 600 mg/day; the daily dose may be given as a single dose or split into 2 doses given once in the morning and once in the evening</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3232">
						<sec_title>Adult with Ph+ CML in chronic phase after the failure of interferon-alfa therapy</sec_title>
						<section type="none" id="sidelem4x3240">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3240">
									<item>
										<label>•</label>
										<para> 400 mg every day; continue as long as beneficial, may increase to 600 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3244">
						<sec_title>Pediatric patients with Ph+ chronic phase CML whose disease has recurred after hematopoietic stem cell transplant or who are resistant to interferon-alfa therapy</sec_title>
						<section type="none" id="sidelem4x3252">
							<label>•</label>
							<sec_title>Adolescent/child &gt;3 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3252">
									<item>
										<label>•</label>
										<para> 260 mg/m<emphasis style="sup">2</emphasis>/day as a single daily dose, or the dose may be divided given once in the morning and once in the evening; may increase to 340 mg/m<emphasis style="sup">2</emphasis>/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3262">
						<sec_title>Patients with Ph+ CML in accelerated phase or blast crisis</sec_title>
						<section type="none" id="sidelem4x3270">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3270">
									<item>
										<label>•</label>
										<para> 600 mg every day, continue as long as beneficial, may increase to 800 mg/day (400 mg bid)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3274">
						<sec_title>Resistant or relapsed Ph+ acute lymphocytic leukemia (ALL)</sec_title>
						<section type="none" id="sidelem4x3282">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3282">
									<item>
										<label>•</label>
										<para> 600 mg every day, continue as long as beneficial</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3286">
						<sec_title>
							<emphasis style="bold">
								<emphasis style="italic">Kit</emphasis>
							</emphasis> (CD117)-positive unresectable and/or metastatic GIST</sec_title>
						<section type="none" id="sidelem4x3297">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3297">
									<item>
										<label>•</label>
										<para> 400-600 mg every day, may increase to 400 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3301">
						<sec_title>Adjuvant treatment of <emphasis style="bold">
								<emphasis style="italic">Kit</emphasis>
							</emphasis> (CD117)-positive GIST after complete gross resection</sec_title>
						<section type="none" id="sidelem4x3313">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3313">
									<item>
										<label>•</label>
										<para> 400 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3317">
						<sec_title>Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIPL1L1-PDGFR α-fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIPL1L-PDGFR α-fusion kinase negative or unknown</sec_title>
						<section type="none" id="sidelem4x3325">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3325">
									<item>
										<label>•</label>
										<para> 400 mg/day in those who are FIPL1L-PDGFR α-fusion kinase negative or unknown; for HES/CEL patients with demonstrated FIP1L1-PDGFR α-fusion kinase, 100 mg/day, may increase to 400 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3329">
						<sec_title>Myelodysplastic syndrome (MDS)/myeloproliferative disease (MPD) associated with the platelet-derived growth factor receptor (PDGFR) gene rearrangements</sec_title>
						<section type="none" id="sidelem4x3337">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3337">
									<item>
										<label>•</label>
										<para> 400 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3341">
						<sec_title>Aggressive systemic mastocytosis (ASM) without D816V c-Kit mutation or with c-Kit mutation status unknown</sec_title>
						<section type="none" id="sidelem4x3349">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3349">
									<item>
										<label>•</label>
										<para> 400 mg/day in those without the FIP1L1-PDGFR-α c-Kit mutation; if c-Kit status is unknown or not available, give 400 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3353">
						<sec_title>Unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans (DFSP)</sec_title>
						<section type="none" id="sidelem4x3361">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3361">
									<item>
										<label>•</label>
										<para> 400 mg bid (800 mg/day)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3365">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x3373">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 40-59 ml/min, max 600 mg/day; CCr 20-39 ml/min, decrease initial dose by 50%, max 400 mg/day; CCr &lt;20 ml/min, use with caution, 100 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3376">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x3384">
							<label>•</label>
							<sec_title>Adult<route> PO Total bilirubin 1.5-3 × ULN and any AST, decrease initial dose to 400 mg/day; total bilirubin &gt;3 × ULN and any AST, decrease initial dose to 300 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3387">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 100, 400 mg</para>
					</section>
					<section type="none" id="sidelem4x3392">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3396">
								<item>
									<label>•</label>
									<para>With meal and large glass of water to decrease GI symptoms; doses of 800 mg should be given as 400 mg bid</para>
								</item>
								<item>
									<label>•</label>
									<para>Tab may be dispersed in a glass of water or apple juice, use 50 ml of liquid for 100-mg tab, 200 ml liquid for 400-mg tab</para>
								</item>
								<item>
									<label>•</label>
									<para>Continue as long as beneficial</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at 77° F (25° C)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3417">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3420">
					<section type="none" id="sidelem4x3421">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">CNS hemorrhage,</emphasis> headache, dizziness, insomnia, <emphasis style="bold">subdural hematoma</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3432">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Hemorrhage, heart failure, cardiac tamponade, cardiac toxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3439">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, conjunctivitis</para>
					</section>
					<section type="none" id="sidelem4x3444">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis><emphasis style="bold">hepatotoxicity, vomiting, dyspepsia,</emphasis> GI hemorrhage, <emphasis style="italic">anorexia, abdominal pain,</emphasis><emphasis style="bold">GI perforation,</emphasis> diarrhea</para>
					</section>
					<section type="none" id="sidelem4x3459">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, thrombocytopenia, bleeding, hypereosinophilia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3466">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, pruritus,</emphasis> alopecia, photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x3474">
						<sec_title>META:</sec_title>
						<para> Fluid retention, hypokalemia, edema</para>
					</section>
					<section type="none" id="sidelem4x3479">
						<sec_title>MISC:</sec_title>
						<para> Fatigue, epistaxis, pyrexia, night sweats, increased weight, flulike symptoms, hypothyroidism</para>
					</section>
					<section type="none" id="sidelem4x3484">
						<sec_title>MS:</sec_title>
						<para> Cramps, pain, arthralgia, myalgia</para>
					</section>
					<section type="none" id="sidelem4x3489">
						<sec_title>RESP:</sec_title>
						<para> Cough, dyspnea, nasopharyngitis, pneumonia, upper respiratory tract infection, <emphasis style="bold">pleural effusion,</emphasis> edema</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3497">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Well absorbed (98%); protein binding 95%; metabolized by CYP3A4; excreted in feces, small amount in urine; peak 2-4 hr; duration 24 hr (imatinib), 40 hr (metabolite); half-life 18-40 hr</para>
			</section>
			<section type="interactions" id="sidelem4x3502">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: hepatotoxicity—acetaminophen</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> imatinib concentrations—CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin, clarithromycin)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> plasma concentrations of simvastatin, calcium channel blockers, ergots</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> plasma concentration of warfarin; avoid use with warfarin; use low-molecular-weight anticoagulants instead</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> imatinib concentrations—CYP3A4 inducers (dexamethasone, phenytoin, carBAMazepine, rifampin, PHENobarbital)</para>
				<section type="none" id="sidelem4x3524">
					<section type="none" id="sidelem4x3525">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> imatinib concentration—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x3532">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> bilirubin, amylase, LFTs</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> albumin, calcium, potassium, sodium, phosphate, platelets, neutrophils, leukocytes, lymphocytes</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3543">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3546">
					<section type="none" id="sidelem4x3547">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3555">
							<label>•</label>
							<sec_title>Bone marrow suppression<route> ANC, platelets; during chronic phase, if ANC &lt;1 × 10</route></sec_title>
						</section>
						<section type="none" id="sidelem4x3596">
							<label>•</label>
							<sec_title>Renal toxicity<route> if bilirubin &gt;3 × IULN, withhold imatinib until bilirubin levels return to &lt;1.5 × IULN</route></sec_title>
						</section>
						<section type="none" id="sidelem4x3602">
							<label>•</label>
							<sec_title>Hepatotoxicity<route> monitor LFTs, before treatment monthly; if liver transaminases &gt;5 × IULN, withhold imatinib until transaminase levels return to &lt;2.5 × IULN</route></sec_title>
						</section>
						<section type="none" id="sidelem4x3608">
							<label>•</label>
							<sec_title>
								<route>Monitor CBC for first mo, biweekly next mo and periodically thereafter; neutropenia (2-3 wk) and thrombocytopenia (3-4 wk) and anemia may occur; may need dosage decrease or discontinuation</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x3611">
								<item>
									<label>•</label>
									<para>Signs of fluid retention, edema: weigh, monitor lung sounds, assess for edema; some fluid retention is dose dependent</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3616">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3620">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in leukemic cells or size of tumor</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3626">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3631">
								<item>
									<label>•</label>
									<para>To report adverse reactions immediately: shortness of breath, swelling of extremities, bleeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3636">
								<item>
									<label>•</label>
									<para>About reason for treatment, expected results</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3641">
								<item>
									<label>•</label>
									<para>That effect on male infertility is unknown</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3646">
								<item>
									<label>•</label>
									<para>Not to stop or change dose—to avoid hazardous activities until response is known, dizziness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3651">
								<item>
									<label>•</label>
									<para>To take with food and water; for those unable to swallow tabs, to mix in liquid (30 m for 100 mg) or 200 ml for 400 mg) after dissolved, stir and consume</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3656">
								<item>
									<label>•</label>
									<para>To avoid OTC products unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3665">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected, pregnancy (D), do not breastfeed</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="12" status="active">
			<mono_name>imipenem/cilastatin (Rx)</mono_name>
			<info>
				<pronunciation>(i-me-pen′em sye-la-stat′in)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x36731">Primaxin IM</tradename>
					<tradename id="tnidelem4x36730">Primaxin IV</tradename>
				</tradenames>
				<class type="func"> Antiinfective—miscellaneous</class>
				<class type="chem"> Carbapenem</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x3683">
				<para>
					<confusion>
						<tradename id="tnidelem4x36830">imipenem</tradename>
						<drug type="generic" refid="idelem4x36830">Omnipen</drug>
					</confusion>
					<confusion>
						<tradename id="tnidelem4x368301">primaxin</tradename>
						<drug type="generic" refid="idelem4x368301">premarin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x3690">
				<sec_title>Action:</sec_title>
				<para>Interferes with cell-wall replication of susceptible organisms; osmotically unstable cell-wall swells, bursts from osmotic pressure; addition of cilastatin prevents renal inactivation that occurs with high urinary concentrations of imipenem</para>
			</section>
			<section type="uses" id="sidelem4x3695">
				<sec_title>Uses:</sec_title>
				<para>Serious infections caused by gram-positive <emphasis style="italic">Streptococcus pneumoniae,</emphasis> group A β-hemolytic streptococci, <emphasis style="italic">Staphylococcus aureus,</emphasis> enterococcus; gram-negative <emphasis style="italic">Klebsiella, Proteus, Escherichia coli, Acinetobacter, Serratia, Pseudomonas aeruginosa, Salmonella, Shigella, Haemophilus influenzae, Listeria</emphasis> sp.</para>
			</section>
			<section type="contra" id="sidelem4x3709">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, amide local anesthetics, or carbapenems; AV block, shock (IM)</para>
				<section type="none" id="sidelem4x3714">
					<section type="none" id="sidelem4x3715">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, seizure disorders, renal disease, head trauma; hypersensitivity to cephalosporins, penicillins; pseudomembranous colitis, ulcerative colitis, diabetes mellitus</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3720">
				<sec_title>Dosage and routes</sec_title>
				<para>
					<emphasis alert="lifethreat">Doses based on imipenem content</emphasis>
				</para>
				<section type="none" id="sidelem4x3726">
					<section type="none" id="sidelem4x3727">
						<sec_title>Intraabdominal, gynecologic, lower respiratory tract, skin and skin structure, bone and joint infections; septicemia, endocarditis, febrile neutropenia (unlabeled), and polymicrobial infections for fully susceptible organisms including gram-positive or gram-negative aerobes and anaerobes</sec_title>
						<section type="none" id="sidelem4x3735">
							<label>•</label>
							<sec_title>Adult ≥70 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3735">
									<item>
										<label>•</label>
										<para> 250 mg every 6 hr (mild infections); 500 mg every 6-8 hr (moderate infections); 500 mg every 6 hr (severe life-threatening infections)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3742">
							<label>•</label>
							<sec_title>Adult 60 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3742">
									<item>
										<label>•</label>
										<para> 250 mg IV every 8 hr (mild infections); 250 mg every 6 hr (moderate or severe life-threatening infections)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3749">
							<label>•</label>
							<sec_title>Adult 50 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3749">
									<item>
										<label>•</label>
										<para> 125 mg every 6 hr (mild infections); 250 mg every 6 hr (moderate or severe life-threatening infections)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3756">
							<label>•</label>
							<sec_title>Adult 40 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3756">
									<item>
										<label>•</label>
										<para> 125 mg every 6 hr (mild infections); 250 mg every 6-8 hr (moderate infections); 250 mg every 6 hr (severe life-threatening infections)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3763">
							<label>•</label>
							<sec_title>Adult 30 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3763">
									<item>
										<label>•</label>
										<para> 125 mg every 8 hr (mild infections); 125 mg every 6 hr or 250 mg every 8 hr (moderate infections); 250 mg every 8 hr (severe life-threatening infections)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3770">
							<label>•</label>
							<sec_title>Adolescent/child/infant ≥3 mo<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3770">
									<item>
										<label>•</label>
										<para> 15-25 mg/kg every 6 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3777">
							<label>•</label>
							<sec_title>Infant 1-3 mo and ≥1500 g<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3777">
									<item>
										<label>•</label>
										<para> 25 mg/kg every 6 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3784">
							<label>•</label>
							<sec_title>Neonate 1-4 wk and ≥1500 g<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3784">
									<item>
										<label>•</label>
										<para> 25 mg/kg every 8 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3791">
							<label>•</label>
							<sec_title>Neonate &lt;7 days and ≥1500 g<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3791">
									<item>
										<label>•</label>
										<para> 25 mg/kg every 12 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3795">
						<sec_title>Moderately susceptible organisms, primarily some strains of <emphasis style="bold">
								<emphasis style="italic">P. aeruginosa</emphasis>
							</emphasis></sec_title>
						<section type="none" id="sidelem4x3806">
							<label>•</label>
							<sec_title>Adult ≥70 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3806">
									<item>
										<label>•</label>
										<para> 500 mg every 6 hr (mild infections); 500 mg every 6 hr or 1 g every 8 hr (moderate infections); 1 g every 6-8 hr (life-threatening infections)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3813">
							<label>•</label>
							<sec_title>Adult 60 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3813">
									<item>
										<label>•</label>
										<para> 500 mg every 8 hr (mild infections); 500 mg every 8 hr or 750 mg every 8 hr (moderate infections); 0.75-1 g every 8 hr (life-threatening infections)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3820">
							<label>•</label>
							<sec_title>Adult 50 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3820">
									<item>
										<label>•</label>
										<para> 250 mg every 6 hr (mild infections); 250-500 mg every 6 hr (moderate infections); 500 mg every 6 hr or 750 mg every 8 hr (life-threatening infections)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3828">
							<label>•</label>
							<sec_title>Adult 40 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3828">
									<item>
										<label>•</label>
										<para> 250 mg every 6 hr (mild infections); 250 mg every 6 hr or 500 mg every 8 hr (moderate infections); 500 mg every 6-8 hr (life-threatening infections)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3835">
							<label>•</label>
							<sec_title>Adult 30 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3835">
									<item>
										<label>•</label>
										<para> 250 mg every 8 hr (mild infections); 250 mg every 6-8 hr; 250 mg every 6 hr or 500 mg every 8 hr (life-threatening infections)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3842">
							<label>•</label>
							<sec_title>Adolescent/child/infant ≥3 mo<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3842">
									<item>
										<label>•</label>
										<para> 15-25 mg/kg every 6 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3849">
							<label>•</label>
							<sec_title>Infant 1-3 mo weighing ≥1500 g<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3849">
									<item>
										<label>•</label>
										<para> 25 mg/kg every 6 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3856">
							<label>•</label>
							<sec_title>Neonate 1-4 wk weighing ≥1500 g<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3856">
									<item>
										<label>•</label>
										<para> 25 mg/kg every 8 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3863">
							<label>•</label>
							<sec_title>Neonate &lt;7 days weighing ≥1500 g<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3863">
									<item>
										<label>•</label>
										<para> 25 mg/kg every 12 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3867">
						<sec_title>Mild to moderate lower respiratory tract, skin and skin structure, or gynecologic infections</sec_title>
						<section type="none" id="sidelem4x3875">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥12 yr<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x3875">
									<item>
										<label>•</label>
										<para> 500 or 750 mg every 12 hr, max 1.5 g/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3879">
						<sec_title>Mild to moderate intraabdominal infections, including acute gangrenous or perforated appendicitis and appendicitis with peritonitis</sec_title>
						<section type="none" id="sidelem4x3887">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥12 yr<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x3887">
									<item>
										<label>•</label>
										<para> 750 mg every 12 hr, max 1.5 g/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3891">
						<sec_title>Community-acquired pneumonia (CAP) in ICU patients with risk factors for Pseudomonas infection</sec_title>
						<para>
							<list id="lidelem4x3896">
								<item>
									<label>•</label>
									<para>Imipenem; cilastatin in combination with ciprofloxacin or an aminoglycoside plus a respiratory fluoroquinolone or an advanced macrolide</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3904">
							<label>•</label>
							<sec_title>Adult ≥70 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3904">
									<item>
										<label>•</label>
										<para> 500 mg every 6-8 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3911">
							<label>•</label>
							<sec_title>Adult 60 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3911">
									<item>
										<label>•</label>
										<para> 250 mg every 6 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3918">
							<label>•</label>
							<sec_title>Adult 50 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3918">
									<item>
										<label>•</label>
										<para> 250 mg every 6 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3925">
							<label>•</label>
							<sec_title>Adult 40 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3925">
									<item>
										<label>•</label>
										<para> 250 mg every 6-8 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3932">
							<label>•</label>
							<sec_title>Adult 30 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3932">
									<item>
										<label>•</label>
										<para> 125 mg every 6 hr or 250 mg every 8 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3936">
						<sec_title>Empiric treatment of aspiration pneumonia</sec_title>
						<section type="none" id="sidelem4x3944">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3944">
									<item>
										<label>•</label>
										<para> 500-1000 mg every 6 hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3948">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x3956">
							<label>•</label>
							<sec_title>Adult ≥70 kg (reduce normal dose of 1 g/day to)<route> IV CCr 41-70 ml/min, 250 mg q8hr; CCr 6-40 ml/min, 250 mg q12hr; (reduce normal dose of 1.5 g/day to)</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3959">
						<sec_title>Available forms:</sec_title>
						<para> Powder for sol inj 250, 500 mg; powder for inj susp 500 mg</para>
					</section>
					<section type="none" id="sidelem4x3964">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3968">
								<item>
									<label>•</label>
									<para>After C&amp;S is taken</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3974">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x3979">
									<item>
										<label>•</label>
										<para>Reconstitute 500 mg/2 ml lidocaine without EPINEPHrine; shake</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x3987">
								<label>•</label>
								<sec_title>
									<route>product for IM is not for IV use</route>
								</sec_title>
								<para>
									<list id="lidelem4x3987">
										<item>
											<label>•</label>
											<para>Inject deeply in large muscle, aspirate, </para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x3991">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x3995">
									<item>
										<label>•</label>
										<para>After reconstitution of 250 or 500 mg with 10 ml of diluent and shake; add to ≥100 ml of same infusion sol</para>
									</item>
									<item>
										<label>•</label>
										<para>250-500 mg over 20-30 min; ≥750 mg over 40-60 min; give through <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock; do not give by IV bolus or if cloudy</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, amifostine, amikacin, aminocaproic acid, anidulafungin, argatroban, ascorbic acid, atenolol, atracurium, atropine, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, CARBOplatin, carmustine, caspofungin, ceFAZolin, cefotaxime, cefoTEtan, cefOXitin, ceftazidime, cefuroxime, chloramphenicol, cimetidine, cisatracurium, CISplatin, clindamycin, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, dexamethasone, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOCEtaxel, dolasetron, DOPamine, doxacurium, DOXOrubicin, DOXOrubicin liposomal, doxycycline, enalaprilat, famotidine, fludarabine, foscarnet, granisetron, IDArubicin, insulin (regular), melphalan, methotrexate, ondansetron, propofol, remifentanil, tacrolimus, teniposide, thiotepa, vinorelbine, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4013">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4016">
					<section type="none" id="sidelem4x4017">
						<sec_title>CNS:</sec_title>
						<para> Fever, somnolence, <emphasis style="bold">seizures,</emphasis> confusion, dizziness, weakness, myoclonus, drowsiness</para>
					</section>
					<section type="none" id="sidelem4x4026">
						<sec_title>CV:</sec_title>
						<para> Hypotension, palpitations, tachycardia</para>
					</section>
					<section type="none" id="sidelem4x4031">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, nausea, vomiting,</emphasis><emphasis style="bold">pseudomembranous colitis, hepatitis,</emphasis> glossitis, gastroenteritis, abdominal pain, jaundice</para>
					</section>
					<section type="none" id="sidelem4x4041">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal toxicity/failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4048">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, eosinophilia, neutropenia,</emphasis> decreased Hgb, Hct</para>
					</section>
					<section type="none" id="sidelem4x4056">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, pruritus, pain at inj site, phlebitis, erythema at inj site, erythema multiform</para>
					</section>
					<section type="none" id="sidelem4x4061">
						<sec_title>MISC:</sec_title>
						<para> Hearing loss, tinnitus, electrolyte abnormalities</para>
					</section>
					<section type="none" id="sidelem4x4066">
						<sec_title>RESP:</sec_title>
						<para> Chest discomfort, dyspnea, hyperventilation</para>
					</section>
					<section type="none" id="sidelem4x4071">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4078">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x4081">
					<section type="none" id="sidelem4x4082">
						<sec_title>IV:</sec_title>
						<para> Onset immediate, peak 20 min-1 hr, half-life 1 hr, 70%-80% excreted unchanged in urine</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x4087">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> imipenem plasma levels—probenecid</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> antagonistic effect—β-lactam antibiotics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> seizure risk—ganciclovir, theophylline, aminophylline, cycloSPORINE</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of valproic acid</para>
				<section type="none" id="sidelem4x4106">
					<section type="none" id="sidelem4x4107">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, LDH, BUN, alk phos, bilirubin, creatinine, potassium, chloride</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> sodium</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> direct Coombs’ test</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4122">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4125">
					<section type="none" id="sidelem4x4126">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4131">
								<item>
									<label>•</label>
									<para>Renal studies: creatinine/BUN, electrolytes</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4139">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x4139">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> increased temperature, WBC, characteristics of wounds, sputum, urine or stool culture</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4143">
								<item>
									<label>•</label>
									<para>Sensitivity to penicillin, other β-lactams—may have sensitivity to this product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4148">
								<item>
									<label>•</label>
									<para>Renal disease: lower dose may be required</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4153">
								<item>
									<label>•</label>
									<para>Bowel pattern daily; if severe diarrhea occurs, product should be discontinued; may indicate pseudomembranous colitis</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4159">
								<item>
									<para>
										<emphasis alert="nurse">Allergic reactions, anaphylaxis: rash, urticaria, pruritus, wheezing, laryngeal edema; may occur a few days after therapy begins; have EPINEPHrine, antihistamine, emergency equipment available</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4167">
							<label>•</label>
							<sec_title>Overgrowth of infection</sec_title>
							<para>
								<list id="lidelem4x4167">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Overgrowth of infection:</emphasis> perineal itching, fever, malaise, redness, pain, swelling, drainage, rash, diarrhea, change in cough, sputum</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4171">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4175">
								<item>
									<label>•</label>
									<para>Therapeutic response: negative C&amp;S; absence of signs and symptoms of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4181">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4187">
								<item>
									<para>
										<emphasis alert="nurse">To report severe diarrhea; may indicate pseudomembranous colitis</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4193">
								<item>
									<para>
										<emphasis alert="nurse">To report sore throat, bruising, bleeding, joint pain; may indicate blood dyscrasias (rare)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4201">
							<label>•</label>
							<sec_title>
								<route>To report seizures, immediately</route>
							</sec_title>
						</section>
						<para>
							<emphasis style="bold">Treatment of anaphylaxis:</emphasis> EPINEPHrine, antihistamines; resuscitate if needed</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="13" status="active">
			<mono_name>imipramine (Rx)</mono_name>
			<info>
				<pronunciation>(im-ip′ra-meen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x42133">
						<country code="CAN">Impril</country>
					</tradename>
					<tradename id="tnidelem4x42132">
						<country code="CAN">Novo-Pramine</country>
					</tradename>
					<tradename id="tnidelem4x42131">Tofranil</tradename>
					<tradename id="tnidelem4x42130">Tofranil PM</tradename>
				</tradenames>
				<class type="func"> Antidepressant, tricyclic</class>
				<class type="chem"> Dibenzazepine, tertiary amine</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x4229">
				<para>
					<confusion>
						<tradename id="tnidelem4x42290">imipramine</tradename>
						<drug type="generic" refid="idelem4x42290">desipramine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x4233">
				<sec_title>Action:</sec_title>
				<para>Blocks reuptake of norepinephrine, serotonin into nerve endings, thereby increasing action of norepinephrine, serotonin in nerve cells</para>
			</section>
			<section type="uses" id="sidelem4x4238">
				<sec_title>Uses:</sec_title>
				<para>Depression, enuresis in children</para>
				<section type="none" id="sidelem4x4243">
					<section type="none" id="sidelem4x4244">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Chronic pain, migraine headaches, cluster headaches as adjunct, incontinence, ADHD, neuralgia, bulimia, neuropathic pain, social phobia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x4250">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity to this product or carBAMazepine; acute MI</para>
				<section type="none" id="sidelem4x4255">
					<section type="none" id="sidelem4x4256">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, geriatric patients, suicidal patients, severe depression, increased intraocular pressure, closed-angle glaucoma, urinary retention, cardiac/hepatic disease, hyperthyroidism, electroshock therapy, elective surgery, seizure disorders, prostatic hypertrophy, MI, AV block, bundle branch block, ileus, QT prolongation, hypersensitivity to tricyclics</para>
						<para>
							<bbw>Children other than for enuresis; suicidal ideation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4271">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4274">
					<section type="none" id="sidelem4x4275">
						<sec_title>Depression</sec_title>
						<section type="none" id="sidelem4x4283">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4283">
									<item>
										<label>•</label>
										<para> 75-100 mg/day in divided doses, may increase by 25-50 mg to 200 mg/day (outpatients), 300 mg/day (inpatients); may give daily dose at bedtime</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4290">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4290">
									<item>
										<label>•</label>
										<para> 30-40 mg at bedtime, may increase to 100 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4297">
							<label>•</label>
							<sec_title>Child ≥6 yr (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4297">
									<item>
										<label>•</label>
										<para> 1.5 mg/kg/day in divided doses, max 2.5 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4301">
						<sec_title>Enuresis</sec_title>
						<section type="none" id="sidelem4x4309">
							<label>•</label>
							<sec_title>Child 6-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4309">
									<item>
										<label>•</label>
										<para> 10-25 mg at bedtime, max 50 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4313">
						<sec_title>Social phobia/panic disorder (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4321">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4321">
									<item>
										<label>•</label>
										<para> 10 mg at bedtime, titrate q2-4days to 100-200 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4325">
						<sec_title>Overactive bladder (OAB) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4333">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4333">
									<item>
										<label>•</label>
										<para> 10-50 mg daily, may titrate to 150 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4337">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10, 25, 50 mg; caps 75, 100, 125, 150 mg</para>
					</section>
					<section type="none" id="sidelem4x4342">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x4345">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x4349">
									<item>
										<label>•</label>
										<para>Not to break, crush, or chew caps</para>
									</item>
									<item>
										<label>•</label>
										<para>With food or milk for GI symptoms</para>
									</item>
									<item>
										<label>•</label>
										<para>Dosage at bedtime if oversedation occurs during day; may take entire dose at bedtime; geriatric patients may not tolerate once-daily dosing</para>
									</item>
									<item>
										<label>•</label>
										<para>Sugarless gum, hard candy, or frequent sips of water for dry mouth</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in tight container at room temperature; do not freeze</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4375">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4378">
					<section type="none" id="sidelem4x4379">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, drowsiness,</emphasis> confusion, <emphasis style="bold">seizures,</emphasis> headache, anxiety, tremors, stimulation, weakness, insomnia, nightmares, EPS (geriatric patients), increased psychiatric symptoms, paresthesia, ataxia</para>
					</section>
					<section type="none" id="sidelem4x4390">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension, ECG changes, tachycardia,</emphasis> hypertension, palpitations, <emphasis style="bold">dysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4400">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, tinnitus, mydriasis</para>
					</section>
					<section type="none" id="sidelem4x4405">
						<sec_title>ENDO:</sec_title>
						<para> Hyperglycemia, hypo/hyperthyroidism, goiter, SIADH</para>
					</section>
					<section type="none" id="sidelem4x4410">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, dry mouth,</emphasis> nausea, vomiting, <emphasis style="bold">paralytic ileus;</emphasis> increased appetite; cramps, epigastric distress, jaundice, <emphasis style="bold">hepatitis,</emphasis> stomatitis, constipation, taste change, weight gain</para>
					</section>
					<section type="none" id="sidelem4x4424">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Retention,</emphasis><emphasis style="bold">acute renal failure</emphasis>, impotence, decreased libido</para>
					</section>
					<section type="none" id="sidelem4x4434">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, thrombocytopenia, eosinophilia, leukopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4441">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, sweating, pruritus, photosensitivity; hyperpigmentation (rare)</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4446">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Steady-state 2-5 days; metabolized to desipramine by liver; excreted in urine, breast milk, feces; crosses placenta; half-life 6-20 hr</para>
			</section>
			<section type="interactions" id="sidelem4x4451">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Hyperpyretic crisis, seizures, hypertensive episode: MAOIs, cloNIDine</emphasis>
				</para>
				<para>
					<emphasis alert="nurse">Increase: serotonin syndrome, neuroleptic malignant syndrome—SSRIs, SNRIs, serotonin-receptor agonists; avoid concurrent use, linezolid, methylene blue IV</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT interval—class IA/III antidysrhythmics, tricyclics, gatifloxacin, levofloxacin, moxifloxacin, ziprasidone</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of direct-acting sympathomimetics (EPINEPHrine), alcohol, barbiturates, benzodiazepines, CNS depressants</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of guanethidine, cloNIDine, indirect-acting sympathomimetics (ePHEDrine)</para>
				<section type="none" id="sidelem4x4476">
					<section type="none" id="sidelem4x4477">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis alert="lifethreat">Increase: serotonin syndrome—SAM-e, St. John’s wort</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x4483">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> serum bilirubin, alk phos, blood glucose, LFTs</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> 5-HIAA, VMA, urinary catecholamines</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4494">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4497">
					<section type="none" id="sidelem4x4498">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4503">
								<item>
									<label>•</label>
									<para>B/P (lying, standing), pulse q4hr; if systolic B/P drops 20 mm Hg, hold product, notify prescriber; take vital signs q4hr in patients with CV disease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4508">
								<item>
									<label>•</label>
									<para>Blood studies: CBC, leukocytes, differential, cardiac enzymes, serum imipramine levels (125-250 ng/ml) if patient is receiving long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4513">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, bilirubin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4518">
								<item>
									<label>•</label>
									<para>Weight weekly; appetite may increase with product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4524">
								<item>
									<para>
										<emphasis alert="nurse">QT prolongation: ECG for flattening of T wave, bundle branch block, AV block, dysrhythmias in cardiac patients</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4532">
							<para>
								<list id="lidelem4x4532">
									<item>
										<label>•</label>
										<para>EPS primarily in geriatric patients: rigidity, dystonia, akathisia
<bbw>Mental status: mood, sensorium, affect, <emphasis alert="lifethreat">suicidal tendencies</emphasis> especially in children, young adults; increase in psychiatric symptoms: depression, panic</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4547">
								<item>
									<label>•</label>
									<para>Urinary retention, constipation; constipation is more likely to occur in children, geriatric patients; increase fluids, bulk in diet</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4553">
								<item>
									<para>
										<emphasis alert="nurse">Withdrawal symptoms: headache, nausea, vomiting, muscle pain, weakness, diarrhea, insomnia, restlessness; not usual unless product is discontinued abruptly</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4561">
							<label>•</label>
							<sec_title>
								<route>Serotonin syndrome, hypertensive episodes, identify drug interactions before use of product</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x4564">
								<item>
									<label>•</label>
									<para>Alcohol consumption; if alcohol is consumed, hold dose until morning</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4569">
								<item>
									<label>•</label>
									<para>Assistance with ambulation during beginning therapy because drowsiness, dizziness, orthostatic hypotension occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4574">
								<item>
									<label>•</label>
									<para>Safety measures, primarily for geriatric patients</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4579">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4583">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased depression, enuresis, pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4589">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4593">
								<item>
									<label>•</label>
									<para>That therapeutic effects may take 2-3 wk</para>
								</item>
								<item>
									<label>•</label>
									<para>That product is dispensed in small amounts because of suicide potential, especially at beginning of therapy</para>
								</item>
								<item>
									<label>•</label>
									<para>To use caution when driving, performing other activities requiring alertness because of drowsiness, dizziness, blurred vision</para>
								</item>
								<item>
									<label>•</label>
									<para>To report urinary retention immediately</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid alcohol, other CNS depressants during treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to discontinue medication abruptly after long-term use; may cause nausea, headache, malaise</para>
								</item>
								<item>
									<label>•</label>
									<para>To wear sunscreen or large hat because photosensitivity occurs</para>
								</item>
								<item>
									<label>•</label>
									<para>To rise slowly, orthostatic hypotension may occur
<bbw>To report suicidal thoughts, behaviors immediately, more common in children, young adults</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x4644">
				<sec_title>Treatment of overdose:</sec_title>
				<para>ECG monitoring; lavage, activated charcoal; administer anticonvulsant</para>
			</section>
		</monograph>
<monograph id="14" status="active">
			<mono_name>immune globulin IM (IMIG/IGIM) (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x46537">Bay Gam 15%</tradename>
					<tradename id="tnidelem4x46536">Flebogamma 5%</tradename>
					<tradename id="tnidelem4x46535">Flebogamma DIF 5%</tradename>
					<tradename id="tnidelem4x46534">Gammagard</tradename>
					<tradename id="tnidelem4x46533">GamaSTAN S/D</tradename>
					<tradename id="tnidelem4x46532">Gamunex 10%</tradename>
					<tradename id="tnidelem4x46531">Privigen 10%</tradename>
					<tradename id="tnidelem4x46530">Vivaglobin 10%</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="15" status="active">
			<mono_name>immune globulin IV (IGIV, IVIG) (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x465814">Bay Gam 15%</tradename>
					<tradename id="tnidelem4x465813">Carimune NF</tradename>
					<tradename id="tnidelem4x465812">Flebogamma 5%</tradename>
					<tradename id="tnidelem4x465811">Flebogamma 10% DIF</tradename>
					<tradename id="tnidelem4x465810">Gammagard S/D</tradename>
					<tradename id="tnidelem4x46589">Gammagard Liquid 10%</tradename>
					<tradename id="tnidelem4x46588">Gammaked</tradename>
					<tradename id="tnidelem4x46587">Gammaplex</tradename>
					<tradename id="tnidelem4x46586">Gammar-P IV</tradename>
					<tradename id="tnidelem4x46585">Gamunex</tradename>
					<tradename id="tnidelem4x46584">Iveegam EN</tradename>
					<tradename id="tnidelem4x46583">Octagam</tradename>
					<tradename id="tnidelem4x46582">Polygam S/D</tradename>
					<tradename id="tnidelem4x46581">Privigen</tradename>
					<tradename id="tnidelem4x46580">Vivaglobin</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="16" status="active">
			<mono_name>immune globulin SC (SCIG/IGSC)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x46639">Bay Gam 15%</tradename>
					<tradename id="tnidelem4x46638">Flebogamma 5%</tradename>
					<tradename id="tnidelem4x46637">Flebogamma DIF 5%</tradename>
					<tradename id="tnidelem4x46636">Gammagard 10%</tradename>
					<tradename id="tnidelem4x46635">Gammaked</tradename>
					<tradename id="tnidelem4x46634">Gammaplex</tradename>
					<tradename id="tnidelem4x46633">Gamunex 10%</tradename>
					<tradename id="tnidelem4x46632">Privigen 10%</tradename>
					<tradename id="tnidelem4x46631">Vivaglobin</tradename>
					<tradename id="tnidelem4x46630">Hizentra</tradename>
				</tradenames>
				<class type="func"> Immune serum</class>
				<class type="chem"> IgG</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x4673">
				<sec_title>Action:</sec_title>
				<para>Provides passive immunity to hepatitis A, measles, varicella, rubella, immune globulin deficiency; contains gamma globulin antibodies (IgG)</para>
			</section>
			<section type="uses" id="sidelem4x4678">
				<sec_title>Uses:</sec_title>
				<para>Immunodeficiency syndrome; B-cell chronic lymphocytic leukemia; Kawasaki syndrome; bone marrow transplantation; pediatric HIV infection; agammaglobulinemia; hepatitis A, B exposure; measles exposure; measles vaccine complications; purpura; rubella exposure; chickenpox exposure; chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy</para>
				<section type="none" id="sidelem4x4683">
					<section type="none" id="sidelem4x4684">
						<sec_title>Unlabeled uses:</sec_title>
						<para> IV posttransfusion purpura, Guillain-Barré syndrome, refractory pemphigus vulgaris, West Nile virus, meningitis, myasthenia gravis, thrombocytopenia encephalitis, HIV, cytomegalovirus, neonatal jaundice, RSV infection, primary humoral immunodeficiency, refractory pemphigus vulgaris</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x4689">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, coagulopathy, hemophilia, IgA deficiency, thrombocytopenia</para>
				<section type="none" id="sidelem4x4694">
					<section type="none" id="sidelem4x4695">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, agammaglobulinemia, bleeding, hypogammaglobulinemia, infection, IV, viral infection</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4700">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4703">
					<sec_title><tradename id="">Immune globulin IM (IMIG, IGIM)</tradename></sec_title>
					<section type="none" id="sidelem4x4706">
						<sec_title>Hepatitis A prophylaxis</sec_title>
						<section type="none" id="sidelem4x4714">
							<label>•</label>
							<sec_title>Adult/geriatric/adolescent/child/infant (unlabeled)<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x4714">
									<item>
										<label>•</label>
										<para> 0.02 ml/kg for those who have not received hepatitis A vaccine and been exposed during the prior 2 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4718">
						<sec_title>Measles prophylaxis (exposed during prior 6 days)</sec_title>
						<section type="none" id="sidelem4x4726">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x4726">
									<item>
										<label>•</label>
										<para> 0.25 ml/kg (immunocompetent)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4733">
							<label>•</label>
							<sec_title>Child (unlabeled)<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x4733">
									<item>
										<label>•</label>
										<para> 0.5 ml/kg as a single dose, max 15 ml (immunocompromised)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4737">
						<sec_title>Varicella prophylaxis</sec_title>
						<section type="none" id="sidelem4x4745">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x4745">
									<item>
										<label>•</label>
										<para> 0.6-1.2 ml/kg as soon as possible and if varicella-zoster immune globulin is not available</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4749">
						<sec_title>Rubella prophylaxis in exposed/susceptible individual who will not consider a therapeutic abortion</sec_title>
						<section type="none" id="sidelem4x4757">
							<label>•</label>
							<sec_title>Adult pregnant women<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x4757">
									<item>
										<label>•</label>
										<para> 0.55 ml/kg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4761">
						<sec_title>Immunoglobulin deficiency</sec_title>
						<section type="none" id="sidelem4x4769">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x4769">
									<item>
										<label>•</label>
										<para> 1.32 ml/kg, then 0.66 ml/kg (≥100 mg/kg) q3-4wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x4773">
					<sec_title><tradename id="">Immune globulin IV (IVIG, IGIV)</tradename></sec_title>
					<section type="none" id="sidelem4x4776">
						<sec_title>Primary immunodeficiency Gammagard S/D</sec_title>
						<section type="none" id="sidelem4x4784">
							<label>•</label>
							<sec_title>Adult/adolescent/child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4784">
									<item>
										<label>•</label>
										<para> 300-600 mg/kg q3-4wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4788">
						<sec_title>Polygam S/D</sec_title>
						<section type="none" id="sidelem4x4796">
							<label>•</label>
							<sec_title>Adult/adolescent/child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4796">
									<item>
										<label>•</label>
										<para> 100 mg/kg/mo; initially 200-400 mg/kg may be used</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4801">
						<sec_title>Gammar-P IV</sec_title>
						<section type="none" id="sidelem4x4809">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4809">
									<item>
										<label>•</label>
										<para> 200-400 mg/kg q3-4wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4816">
							<label>•</label>
							<sec_title>Adolescent/child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4816">
									<item>
										<label>•</label>
										<para> 200 mg/kg q3-4wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4820">
						<sec_title>Gamunex</sec_title>
						<section type="none" id="sidelem4x4828">
							<label>•</label>
							<sec_title>Adult/adolescent/child<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x4828">
									<item>
										<label>•</label>
										<para> 300-600 mg/kg (3-6 ml/kg) q3-4wk, initial infusion rate 1 mg/kg/min (max 8 mg/kg/min)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4832">
						<sec_title>Iveegam EN</sec_title>
						<section type="none" id="sidelem4x4840">
							<label>•</label>
							<sec_title>Adult/adolescent/child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4840">
									<item>
										<label>•</label>
										<para> 200 mg/kg monthly, max 800 mg/kg/mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4844">
						<sec_title>Carimune NF</sec_title>
						<section type="none" id="sidelem4x4852">
							<label>•</label>
							<sec_title>Adult/adolescent/child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4852">
									<item>
										<label>•</label>
										<para> 200 mg/kg/mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4856">
						<sec_title>Gamagard liquid/Flebogamma 5%</sec_title>
						<section type="none" id="sidelem4x4864">
							<label>•</label>
							<sec_title>Adult/adolescent/child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4864">
									<item>
										<label>•</label>
										<para> 300-600 mg/kg q3-4wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4868">
						<sec_title>Privigen</sec_title>
						<section type="none" id="sidelem4x4876">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥3 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4876">
									<item>
										<label>•</label>
										<para> 200-800 mg q3wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x4880">
					<sec_title>Idiopathic thrombocytopenic purpura (ITP)</sec_title>
					<section type="none" id="sidelem4x4883">
						<sec_title>Carimune NF</sec_title>
						<section type="none" id="sidelem4x4891">
							<label>•</label>
							<sec_title>Adult/child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4891">
									<item>
										<label>•</label>
										<para> 400 mg/kg daily × 2-5 days; with acute ITP of childhood, only 2 of 5 days are needed if initial platelets are 30,000-50,000 mcl after 2 doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4895">
						<sec_title>Gammagard S/D/Polygam S/D</sec_title>
						<section type="none" id="sidelem4x4903">
							<label>•</label>
							<sec_title>Adult/adolescent/child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4903">
									<item>
										<label>•</label>
										<para> 1000 mg/kg as a single dose; may give on alternate days for up to 3 doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4907">
						<sec_title>Gamunex</sec_title>
						<section type="none" id="sidelem4x4915">
							<label>•</label>
							<sec_title>Adult/adolescent/child<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x4915">
									<item>
										<label>•</label>
										<para> total dose of 2000 mg/kg on 2 consecutive days; initial rate is 1 mg/kg/min (max 8 mg/kg/min); if after 1st dose adequate platelets are observed after 24 hr, may withhold 2nd dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4919">
						<sec_title>Privigen</sec_title>
						<section type="none" id="sidelem4x4927">
							<label>•</label>
							<sec_title>Adult/adolescent ≥15 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4927">
									<item>
										<label>•</label>
										<para> 1 g/kg/day × 2 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x4931">
					<sec_title>Kawasaki disease</sec_title>
					<section type="none" id="sidelem4x4934">
						<sec_title>Iveegam EN</sec_title>
						<section type="none" id="sidelem4x4942">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4942">
									<item>
										<label>•</label>
										<para> 400 mg/kg daily × 4 consecutive days or a single dose of 2000 mg/kg over 10 hr, given with aspirin 100 mg/kg/day through 14th day of illness, then 3-5 mg/kg each day thereafter for 5 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4946">
						<sec_title>Gammagard S/D/Polygam S/D</sec_title>
						<section type="none" id="sidelem4x4954">
							<label>•</label>
							<sec_title>Infant/child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4954">
									<item>
										<label>•</label>
										<para> 1000 mg/kg as a single dose or 400 mg/kg/day × 4 days beginning within 7 days of fever onset, with aspirin 80-100 mg/kg/day × 4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4958">
						<sec_title>Immune globulin SC (SCIG/IGSC)</sec_title>
						<section type="none" id="sidelem4x4966">
							<label>•</label>
							<sec_title>Adult/child &gt;2 yr<route> SUBCUT INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x4966">
									<item>
										<label>•</label>
										<para> 100-200 mg/kg weekly,  brand of SCIG 160 mg IgG/ml,  inj 15 ml/inj site, given at max of 20 ml/hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4976">
						<sec_title>Hizentra</sec_title>
						<section type="none" id="sidelem4x4984">
							<label>•</label>
							<sec_title>Adult/child</sec_title>
							<para>
								<list id="lidelem4x4984">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult/child:</emphasis> multiply the previous IVIG dose by 1.37, then divide into wk dose based on previous wk treatment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4988">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="bold">IM:</emphasis> Inj 2-, 10-ml vial (Bay Gam); <emphasis style="bold">IV:</emphasis> 5%, 10% sol (Gamimune N); powder for inj 1-, 3-, 6-, 12-g vials (Carimune NF); 50 mg protein/ml in 2.5-, 5-, 10-g vials (Gammagard S/D); 1-, 2.5-, 5-, 10-g vials (Gammar-P IV); 500 mg, 1-, 2.5-, 5-g vials (Iveegam); 6-, 12-g vials (Panglobulin); 2.5-, 5-, 10-g vials (Polygam S/D); sol for inj 1-, 2.5-, 5-, 10-, 20-g vials (Gamunex); Human sol for inj: Flebogamma 5%, 10% DIF; subcut inj 10, 16, 20% single use</para>
					</section>
					<section type="none" id="sidelem4x4999">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5003">
								<item>
									<label>•</label>
									<para>IM ≤3 ml at 1 site; use large muscle mass</para>
								</item>
								<item>
									<label>•</label>
									<para>Only with EPINEPHrine 1:1000, resuscitative equipment available</para>
								</item>
								<item>
									<label>•</label>
									<para>Only within 2 wk of exposure to hepatitis A</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at 36° F-46° F (2° C-8° C)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5024">
							<sec_title>IV route</sec_title>
							<section type="none" id="sidelem4x5032">
								<label>•</label>
								<sec_title>Gamimune N</sec_title>
								<para>
									<list id="lidelem4x5032">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Gamimune N:</emphasis> IV undiluted or dilute with D<emphasis style="inf">5</emphasis>W; give 0.01 ml/kg/min; may increase to 0.02-0.04 ml/kg/min</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x5042">
								<label>•</label>
								<sec_title>Venoglobulin-I</sec_title>
								<para>
									<list id="lidelem4x5042">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Venoglobulin-I:</emphasis> (50 mg/ml sol) give 0.01-0.02 ml/kg/min; if no adverse reaction within <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, increase to 0.04 ml/kg/min; store at room temperature</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x5055">
								<label>•</label>
								<sec_title>Gammagard</sec_title>
								<para>
									<list id="lidelem4x5055">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Gammagard:</emphasis> reconstitute with sterile water for inj (50 mg protein/ml); give 0.5 ml/kg/hr, may increase to 4 ml/kg/hr; use infusion set provided</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x5062">
								<label>•</label>
								<sec_title>Gammar-IV</sec_title>
								<para>
									<list id="lidelem4x5062">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Gammar-IV:</emphasis> give 0.01 ml/kg/min (50 mg/ml sol) × 15-30 min, may increase to 0.02 ml/kg/min, may increase to 0.03-0.06 ml/kg/min</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Fluconazole, sargramostim</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5072">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5075">
					<section type="none" id="sidelem4x5076">
						<sec_title>CNS:</sec_title>
						<para> Headache, fatigue, malaise</para>
					</section>
					<section type="none" id="sidelem4x5081">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x5086">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thromboembolism (Vivaglobin)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5093">
						<sec_title>INTEG:</sec_title>
						<para> Pain at inj site, rash, pruritus, chills</para>
					</section>
					<section type="none" id="sidelem4x5098">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, chest pain</para>
					</section>
					<section type="none" id="sidelem4x5103">
						<sec_title>SYST:</sec_title>
						<para> Lymphadenopathy, <emphasis style="bold">anaphylaxis; life-threatening hypoglycemia (Octagam 5, 10%)</emphasis></para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x5110">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x5114">
						<item>
							<label>•</label>
							<para>Do not administer live virus vaccines within 3 mo of this product</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x5120">
					<section type="none" id="sidelem4x5121">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Interference:</emphasis> glucose testing system</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5128">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5131">
					<section type="none" id="sidelem4x5132">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x5140">
							<label>•</label>
							<sec_title>Exposure date</sec_title>
							<para>
								<list id="lidelem4x5140">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Exposure date:</emphasis> this product should be given within 6 days of measles, 7 days of hepatitis B, 14 days of hepatitis A</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5147">
							<label>•</label>
							<sec_title>Anaphylaxis<route> diaphoresis, wheezing, chest tightness, hypotension</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5150">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5154">
								<item>
									<label>•</label>
									<para>Prevention of infection, increased platelets</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5160">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5165">
								<item>
									<label>•</label>
									<para>That passive immunity is temporary</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5173">
							<label>•</label>
							<sec_title>About the treatment of anaphylaxis<route> EPINEPHrine, diphenhydrAMINE, oxygen, vasopressors, corticosteroids</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="17" status="active">
			<mono_name>indacaterol</mono_name>
			<info>
				<pronunciation>(in-da-kat′er-ol)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x51810">Arcapta Neohaler</tradename>
				</tradenames>
				<class type="func"> β-2 agonist, long-acting respiratory</class>
			</info>
			<section type="actions" id="sidelem4x5187">
				<sec_title>Action:</sec_title>
				<para>An agonist at β-2 receptors. These receptors are present in large numbers in the lungs and are located on bronchiolar smooth muscle. Stimulation of β-2 receptors in the lung causes relaxation of bronchial smooth muscle, which produces bronchodilation and an increase in bronchial airflow. These effects may be mediated, in part, by increased activity of adenyl cyclase, an intracellular enzyme responsible for the formation of cyclic-3′,5′-adenosine monophosphate (cAMP); has &gt;24-fold agonist activity at β-2 receptors (primarily in the lung) compared to β-1 receptors (primarily in the heart)</para>
			</section>
			<section type="uses" id="sidelem4x5192">
				<sec_title>Uses:</sec_title>
				<para>Bronchitis, chronic obstructive pulmonary disease (COPD), emphysema</para>
			</section>
			<section type="contra" id="sidelem4x5197">
				<sec_title>Contraindications:</sec_title>
				<para>Acute bronchospasm, acute asthma attack, status asthmaticus, acute respiratory insufficiency, monotherapy of asthma, hypersensitivity</para>
				<section type="none" id="sidelem4x5202">
					<section type="none" id="sidelem4x5203">
						<sec_title>Precautions:</sec_title>
						<para> Ischemic cardiac disease (coronary artery disease), hypertension, cardiac arrhythmias, tachycardia, QT prolongation, congenital long QT syndrome, torsades de pointes history, hyperthyroidism (thyrotoxicosis, thyroid disease), pheochromocytoma, unusual responsiveness to other sympathomimetic amines, seizure disorder, diabetes mellitus, hypokalemia, milk protein hypersensitivity, severe hepatic disease; not indicated for neonates, infants, children, or adolescents under the age of 18 yr, pregnancy (C), breastfeeding</para>
						<para>
							<bbw>Asthma-related deaths</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5218">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5226">
					<label>•</label>
					<sec_title>Adult<route> INH</route></sec_title>
					<para>
						<list id="lidelem4x5226">
							<item>
								<label>•</label>
								<para> 75 mcg (contents of 1 capsule) inhaled once daily; administer at the same time every day, max 1 dose in 24 hours</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5230">
					<section type="none" id="sidelem4x5231">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inhalation 75 mcg</para>
					</section>
					<section type="none" id="sidelem4x5236">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x5239">
							<sec_title>Inhalation route</sec_title>
							<para>
								<list id="lidelem4x5243">
									<item>
										<label>•</label>
										<para>For oral inhalation use only; DO NOT swallow the capsules; always use the Neohaler Inhaler; this inhaler should not be used with any other products; DO NOT use with a spacer</para>
									</item>
									<item>
										<label>•</label>
										<para>Use dry hands to remove a capsule from the blister pack immediately before use and place into the capsule chamber of the Neohaler Inhaler; click closed; do not place capsule into the mouthpiece; then, holding the inhaler upright, depress buttons fully once to pierce capsule, a click will be heard; have patient breathe out fully away from inhaler, place inhaler in the mouth with buttons positioned to the left and right (not up and down), close lips around mouthpiece, then breathe deeply, rapidly, and steadily in through the inhaler; a whirring sound should be heard; if no sound is heard, check the chamber because the capsule may be stuck; gently tap the base of the device to loosen capsule, if necessary; after inhalation, patient should hold the breath as long as comfortable while removing inhaler from the mouth; check the chamber to see if any powder remains in the capsule; repeat inhalation steps until no powder remains; most patients empty the capsule in 1 or 2 inhalations; after administration, open chamber and discard empty capsule</para>
									</item>
									<item>
										<label>•</label>
										<para>Advise patient that coughing after administration is not problematic; as long as the capsule is empty the full dose has been administered</para>
									</item>
									<item>
										<label>•</label>
										<para>The gelatin capsule might break into small pieces that pass through the inhaler screen and reach the mouth; accidental inhalation or ingestion of these pieces is harmless; piercing capsule more than once increases risk of shattering capsule: do not wash inhaler; keep it dry; a clean, dry, lint-free cloth may be used to wipe out the inhaler</para>
									</item>
									<item>
										<label>•</label>
										<para>Use the new inhaler provided with each new prescription</para>
									</item>
									<item>
										<label>•</label>
										<para>To avoid the spread of infection, do not share inhaler</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5276">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5279">
					<section type="none" id="sidelem4x5280">
						<sec_title>CNS:</sec_title>
						<para> Headache, tremor</para>
					</section>
					<section type="none" id="sidelem4x5285">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Sinus tachycardia, hypertension, QT prolongation and ST-T wave changes, prolonged QTc (an increase of &gt;60 ms from baseline), nonsustained ventricular tachycardia, supraventricular tachycardia (SVT) episodes, intermittent ectopic atrial rhythm</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5292">
						<sec_title>ENDO:</sec_title>
						<para> Hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x5297">
						<sec_title>GI:</sec_title>
						<para> Nausea, dry mouth (xerostomia)</para>
					</section>
					<section type="none" id="sidelem4x5302">
						<sec_title>META:</sec_title>
						<para> Hypokalemia</para>
					</section>
					<section type="none" id="sidelem4x5307">
						<sec_title>MS:</sec_title>
						<para> Muscle cramps/spasm, musculo-skeletal pain</para>
					</section>
					<section type="none" id="sidelem4x5312">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Paradoxical bronchospasm,</emphasis> cough, dyspnea, sputum purulence or volume, wheezing, nasopharyngitis, pneumonia, sinusitis and upper respiratory tract infection</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5320">
				<sec_title>Pharmacokinetics:</sec_title>
				<para>Protein binding 94%-96%, approximately <emphasis style="sup">1</emphasis>/<emphasis style="inf">3</emphasis> of total drug-related AUC over 24 hours, a hydroxylated derivative, glucuronate and dealkylate metabolites are present; metabolized by CYP3A4, CYP1A1, CYP2D6, UGT1A1; elimination multiphasic with terminal half-life of 45.5-126 hours; excreted renally (2%-6%), fecally (&gt;90%); onset 5 min, peak 15 min, steady-state 12-15 days</para>
			</section>
			<section type="interactions" id="sidelem4x5331">
				<sec_title>Interactions: </sec_title>
				<para>
					<emphasis alert="lifethreat">Increase QT prolongation: Class IA/III antiarrhythmics, flecainide, propafenone some antipsychotics (phenothiazines, pimozide, haloperidol risperiDONE, sertindole ziprasidone), amoxapine, arsenic trioxide, astemizole, bepridil, cisapride, citalopram, chloroquine, clarithromycin, dasatinib, dolasetron, dronedarone, droperidol, erythromycin, halofantrine, halogenated anesthetics, levomethadyl, maprotiline, methadone, some quinolones (ofloxacin, gatifloxacin, gemifloxacin, grepafloxacin, levofloxacin, moxifloxacin, sparfloxacin), ondansetron, paliperidone, palonosetron, pentamidine, probucol, propafenone, ranolazine, SUNItinib, terfenadine, thioridazine, tricyclic antidepressants, troleandomycin, vorinostat, tetrabenazine</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase hypokalemia:</emphasis> Theophylline, aminophylline, corticosteroids</para>
				<para>
					<emphasis style="bold">Increase cardiovascular reactions:</emphasis> MAOIs, furazolidone, procarbazine, rasagiline</para>
			</section>
			<section type="considerations" id="sidelem4x5346">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5349">
					<section type="none" id="sidelem4x5350">
						<sec_title>Assess</sec_title>
						<para>
							<bbw>Asthma-related death; not to be used in asthma</bbw>
						</para>
						<para>
							<list id="lidelem4x5365">
								<item>
									<label>•</label>
									<para>COPD, emphysema, bronchospasm: monitor pulmonary function tests</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5373">
							<label>•</label>
							<sec_title>QT prolongation<route> monitor ECG, ejection fraction for QT prolongation</route></sec_title>
						</section>
						<section type="none" id="sidelem4x5379">
							<label>•</label>
							<sec_title>Paradoxical bronchospasm<route> if paradoxical bronchospasm occurs, discontinue product immediately, use a short-acting β-agonist for rescue therapy, as appropriate</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5382">
						<sec_title>Teach patient/family</sec_title>
						<para>
							<list id="lidelem4x5387">
								<item>
									<label>•</label>
									<para>To report dyspnea, wheezing, bronchospasm</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5395">
							<label>•</label>
							<sec_title>
								<route>Not to use with other products unless approved by prescriber; there are many interactions</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="18" status="active">
			<mono_name>indapamide (Rx)</mono_name>
			<info>
				<pronunciation>(in-dap′a-mide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x54120">
						<country code="CAN">Lozide </country>
					</tradename>
				</tradenames>
				<class type="func"> Diuretic—thiazide-like, antihypertensive</class>
				<class type="chem"> Indoline</class>
			</info>
			<section type="actions" id="sidelem4x5424">
				<sec_title>Action:</sec_title>
				<para>Acts on proximal section of distal renal tubule by inhibiting reabsorption of sodium; may act by direct vasodilation caused by blocking of calcium channels</para>
			</section>
			<section type="uses" id="sidelem4x5429">
				<sec_title>Uses:</sec_title>
				<para>Edema of CHF, hypertension</para>
			</section>
			<section type="contra" id="sidelem4x5434">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or sulfonamides; anuria, hepatic coma</para>
				<section type="none" id="sidelem4x5439">
					<section type="none" id="sidelem4x5440">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, hypokalemia, dehydration, ascites, hepatic disease, severe renal disease, CCr &lt;30 ml/min (not effective), diabetes mellitus, gout, pregnancy (C), cardiac dysrhythmias</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5445">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5448">
					<section type="none" id="sidelem4x5449">
						<sec_title>Edema</sec_title>
						<section type="none" id="sidelem4x5457">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5457">
									<item>
										<label>•</label>
										<para> 2.5 mg/day in <emphasis style="smallcaps">am</emphasis>; may be increased to 5 mg/day if needed after 1 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5464">
						<sec_title>Antihypertensive</sec_title>
						<section type="none" id="sidelem4x5472">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5472">
									<item>
										<label>•</label>
										<para> 1.25 mg/day; may increase to 5 mg/day over 8 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5476">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 1.25, 2.5 mg</para>
					</section>
					<section type="none" id="sidelem4x5481">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5485">
								<item>
									<label>•</label>
									<para>In <emphasis style="smallcaps">am</emphasis> to avoid interference with sleep</para>
								</item>
								<item>
									<label>•</label>
									<para>With food if nausea occurs; absorption may be decreased slightly</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5499">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5502">
					<section type="none" id="sidelem4x5503">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness, fatigue,</emphasis> weakness, nervousness, agitation, extremity numbness, depression</para>
					</section>
					<section type="none" id="sidelem4x5511">
						<sec_title>CV:</sec_title>
						<para> Orthostatic hypotension, volume depletion, palpitations, dysrhythmias, PVCs, vasculitis</para>
					</section>
					<section type="none" id="sidelem4x5516">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, nasal congestion, increased intraocular pressure</para>
					</section>
					<section type="none" id="sidelem4x5521">
						<sec_title>ELECT:</sec_title>
						<para> <emphasis style="italic">Hypochloremic alkalosis, hypomagnesemia, hyperuricemia, hypercalcemia, hyponatremia, hypokalemia,</emphasis> hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x5529">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> diarrhea, dry mouth, vomiting, anorexia, cramps, constipation, abdominal pain, hypercholesterolemia</para>
					</section>
					<section type="none" id="sidelem4x5537">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Polyuria,</emphasis> nocturia, urinary frequency, impotence</para>
					</section>
					<section type="none" id="sidelem4x5545">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5552">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, pruritus,</emphasis><emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5561">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Cramps</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5568">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Well absorbed (PO); widely distributed; metabolized by liver; excreted by kidney (small amounts); onset 1-2 hr; peak 2 hr; duration up to 36 hr; excreted in urine, feces; half-life 14-18 hr</para>
			</section>
			<section type="interactions" id="sidelem4x5574">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperglycemia—diazoxide</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity of muscle relaxants, steroids, lithium, digoxin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypokalemia—corticosteroids, amphotericin B, loop diuretics, thiazide diuretics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects—antidiabetics, antigout agents, anticoagulants</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption—cholestyramine, colestipol</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> hypotensive effect—indomethacin, NSAIDs</para>
				<section type="none" id="sidelem4x5601">
					<section type="none" id="sidelem4x5602">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> severe hypokalemia—licorice</para>
					</section>
					<section type="none" id="sidelem4x5609">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—hawthorn</para>
					</section>
					<section type="none" id="sidelem4x5616">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> calcium, parathyroid test, glucose, uric acid</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5623">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5626">
					<section type="none" id="sidelem4x5627">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5631">
								<item>
									<label>•</label>
									<para>Weight, I&amp;O daily to determine fluid loss; effect of product may be decreased if used daily</para>
								</item>
								<item>
									<label>•</label>
									<para>Rate, depth, rhythm of respirations, effect of exertion</para>
								</item>
								<item>
									<label>•</label>
									<para>B/P lying, standing; postural hypotension may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>Electrolytes: potassium, magnesium, sodium, chloride: include BUN, CBC, serum creatinine, blood pH, ABGs, uric acid, Ca, glucose</para>
								</item>
								<item>
									<label>•</label>
									<para>Signs of metabolic alkalosis, hypokalemia</para>
								</item>
								<item>
									<label>•</label>
									<para>Rashes, fever daily; allergy to sulfa products</para>
								</item>
								<item>
									<label>•</label>
									<para>Confusion, especially in geriatric patients; take safety precautions if needed</para>
								</item>
								<item>
									<label>•</label>
									<para>Hydration: skin turgor, thirst, dry mucous membranes</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5672">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5676">
								<item>
									<label>•</label>
									<para>Therapeutic response: improvement in edema of feet, legs, sacral area daily; decreased B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5682">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5687">
								<item>
									<label>•</label>
									<para>To consume diet high in potassium; to rise slowly from lying or sitting position</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5692">
								<item>
									<label>•</label>
									<para>To recognize adverse reactions: muscle cramps, weakness, nausea, dizziness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5697">
								<item>
									<label>•</label>
									<para>To take with food, milk for GI symptoms; to take early in day to prevent nocturia; to avoid alcohol</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5705">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if urinary output decreases; to monitor daily weight</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x5708">
								<item>
									<label>•</label>
									<para>Not to stop product abruptly</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x5713">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Lavage if taken orally; monitor electrolytes, administer IV fluids; monitor hydration, CV, renal status</para>
			</section>
		</monograph>
<monograph id="19" status="active" ha="yes">
			<mono_name> indinavir (Rx)</mono_name>
			<info>
				<pronunciation>(en-den′a-veer)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x57250">Crixivan</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Protease inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x5735">
				<para>
					<confusion>
						<tradename id="tnidelem4x57350">indinavir</tradename>
						<drug type="generic" refid="idelem4x57350">Denavir</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x5739">
				<sec_title>Action:</sec_title>
				<para>Inhibits human immunodeficiency virus (HIV-1) protease; this prevents the maturation of the virus</para>
			</section>
			<section type="uses" id="sidelem4x5744">
				<sec_title>Uses:</sec_title>
				<para>HIV-1 in combination with other antiretrovirals</para>
				<section type="none" id="sidelem4x5749">
					<section type="none" id="sidelem4x5750">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Prevention of HIV-1 after exposure</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5755">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, breastfeeding</para>
				<section type="none" id="sidelem4x5760">
					<section type="none" id="sidelem4x5761">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), children, renal/hepatic disease, history of renal stones, diabetes, hypercholesterolemia, hemophilia, autoimmune disease, immune reconstitution syndrome</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5766">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5774">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5774">
							<item>
								<label>•</label>
								<para> 800 mg q8hr; 600 mg q8hr with delavirdine 400 mg tid; 600 mg q8hr with itraconazole 200 mg bid or ketoconazole</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5779">
					<section type="none" id="sidelem4x5780">
						<sec_title>Mild to moderate hepatic impairment</sec_title>
						<section type="none" id="sidelem4x5788">
							<label>•</label>
							<sec_title>Adult<route> PO 600 mg q8h</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5791">
						<sec_title>Available forms:</sec_title>
						<para> Caps 200, 400 mg</para>
					</section>
					<section type="none" id="sidelem4x5796">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5800">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew caps</para>
								</item>
								<item>
									<label>•</label>
									<para>With water, 1 hr before or 2 hr after meals; may be given with other liquids or small meal; do not give with high-fat, high-protein meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Dosage adjustment will need to be considered when given with other antiretrovirals</para>
								</item>
								<item>
									<label>•</label>
									<para>Increase water to 1.5 L/day minimum to prevent nephrolithiasis</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5821">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5824">
					<section type="none" id="sidelem4x5825">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, insomnia,</emphasis> dizziness, somnolence</para>
					</section>
					<section type="none" id="sidelem4x5833">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, abdominal pain, nausea, vomiting,</emphasis> anorexia, dry mouth</para>
					</section>
					<section type="none" id="sidelem4x5841">
						<sec_title>GU:</sec_title>
						<para> Nephrolithiasis</para>
					</section>
					<section type="none" id="sidelem4x5846">
						<sec_title>INTEG:</sec_title>
						<para> Rash</para>
					</section>
					<section type="none" id="sidelem4x5851">
						<sec_title>MS:</sec_title>
						<para> Pain</para>
					</section>
					<section type="none" id="sidelem4x5856">
						<sec_title>OTHER:</sec_title>
						<para> Asthenia, <emphasis style="bold">insulin-resistant hyperglycemia,</emphasis> hyperlipidemia, <emphasis style="bold">ketoacidosis,</emphasis> lipodystrophy</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5867">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Terminal half-life 2 hr; 60% protein binding; metabolized liver; excreted &lt;20% unchanged in urine, 83% in feces</para>
			</section>
			<section type="interactions" id="sidelem4x5872">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Life-threatening dysrhythmias: ergots, midazolam, rifampin, triazolam, amiodarone, pimozide, alfazosin</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myopathy—statins (atorvastatin, lovastatin, simvastatin)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> indinavir levels—CYP3A4 inhibitors (arepitant, protease inhibitors, azole antifungals, nefazodone, verap amil); phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of both products—clarithromycin, zidovudine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of isoniazid, oral contraceptives</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> indinavir levels—CYP3A4 inducers (barbiturates, carBAMazepine, nonnucleoside reverse transcriptase inhibitors, phenytoins, rifamycins, modafinil)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of both products—anticonvulsants</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect—CYP3A4 substrates (calcium channel blockers, immunosuppressants, benzodiazepines, azole antifungals, macrolides, SSRIs, statins)</para>
				<section type="none" id="sidelem4x5908">
					<section type="none" id="sidelem4x5909">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> indinavir levels—St. John’s wort; avoid concurrent use</para>
					</section>
					<section type="none" id="sidelem4x5916">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> indinavir absorption—grapefruit juice; high-fat, high-protein foods</para>
					</section>
					<section type="none" id="sidelem4x5923">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, amylase, total bilirubin</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5930">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5933">
					<section type="none" id="sidelem4x5934">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5938">
								<item>
									<label>•</label>
									<para>Complaints of lower back, flank pain; indicates kidney stones</para>
								</item>
								<item>
									<label>•</label>
									<para>Signs of infection, anemia, presence of other sexually transmitted diseases</para>
								</item>
								<item>
									<label>•</label>
									<para>Blood/hepatic studies: ALT, AST; total bilirubin, amylase, blood glucose, serum cholesterol/lipid profile, may be elevated</para>
								</item>
								<item>
									<label>•</label>
									<para>Plasma HIV RNA, viral load, CD4 during treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment; if severe abdominal pain with bleeding occurs, product should be discontinued; monitor hydration</para>
								</item>
								<item>
									<label>•</label>
									<para>Skin eruptions; rash, urticaria, itching</para>
								</item>
								<item>
									<label>•</label>
									<para>Allergies before treatment, reaction of each medication; place allergies on chart</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5974">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5978">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreasing viral load, symptoms of HIV</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5984">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5989">
								<item>
									<label>•</label>
									<para>To take as prescribed; if dose is missed, to take as soon as remembered up to 1 hr before next dose; not to double dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5994">
								<item>
									<label>•</label>
									<para>That product must be taken in equal intervals around the clock to maintain blood levels for duration of therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6000">
								<item>
									<para>
										<emphasis alert="nurse">That hyperglycemia may occur; to watch for increased thirst, weight loss, hunger, and dry, itchy skin; to notify prescriber</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6005">
								<item>
									<label>•</label>
									<para>To increase fluids to prevent kidney stones; if stone formation occurs, that treatment may need to be interrupted</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6010">
								<item>
									<label>•</label>
									<para>That product does not cure AIDS, only controls symptoms; not to donate blood</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="20" status="active">
			<mono_name>indomethacin (Rx)</mono_name>
			<info>
				<pronunciation>(in-doe-meth′a-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x60211">Indocin</tradename>
					<tradename id="tnidelem4x60210">
						<country code="CAN">Nu-Indo </country>
					</tradename>
				</tradenames>
				<class type="func"> Nonsteroidal antiinflammatory product (NSAID), antirheumatic</class>
				<class type="chem"> Acetic acid derivative</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg> <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x6033">
				<para>
					<confusion>
						<tradename id="tnidelem4x60330">Indocin</tradename>
						<drug type="generic" refid="idelem4x60330">Endocet/minocin/Vicodin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x6037">
				<sec_title>Action:</sec_title>
				<para>Inhibits prostaglandin synthesis by decreasing enzyme needed for biosynthesis; analgesic, antiinflammatory, antipyretic</para>
			</section>
			<section type="uses" id="sidelem4x6042">
				<sec_title>Uses:</sec_title>
				<para>RA, ankylosing spondylitis, osteoarthritis, bursitis, tendinitis, acute gouty arthritis; closure of patent ductus arteriosus in premature infants (IV)</para>
				<section type="none" id="sidelem4x6047">
					<section type="none" id="sidelem4x6048">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Bone pain, headache, heterotopic ossification, juvenile rheumatoid arthritis, pericarditis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x6053">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>) 3rd trimester, aortic coarctation, bleeding salicylate/NSAID hypersensitivity, GI bleeding</para>
				<para>
					<bbw>Perioperative pain in CABG</bbw>
				</para>
				<section type="none" id="sidelem4x6068">
					<section type="none" id="sidelem4x6069">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>) 1st trimester, breastfeeding, children, bleeding disorders, GI disorders, cardiac disorders, depression, renal/hepatic disease, asthma, diabetes, acute bronchospasm, ulcerative colitis, seizures, Parkinson’s disease, neonates</para>
						<para>
							<bbw>Stroke, GI bleeding, MI, those taking NSAIDs are at greater risk of MI and stroke, even in first few weeks of therapy</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6084">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6087">
					<section type="none" id="sidelem4x6088">
						<sec_title>Arthritis/antiinflammatory</sec_title>
						<section type="none" id="sidelem4x6096">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6096">
									<item>
										<label>•</label>
										<para> 25-50 mg bid-tid; max 200 mg/day;  75 mg/day, may increase to 75 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6103">
						<sec_title>Acute gouty arthritis</sec_title>
						<section type="none" id="sidelem4x6111">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6111">
									<item>
										<label>•</label>
										<para> 50 mg tid; use only for acute attack, then reduce dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6115">
						<sec_title>Patent ductus arteriosus</sec_title>
						<section type="none" id="sidelem4x6123">
							<label>•</label>
							<sec_title>Neonates &gt;7 days<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x6123">
									<item>
										<label>•</label>
										<para> Initially, 0.2 mg/kg, then, if necessary, 2 more doses of 0.25 mg/kg at 12-hr intervals if urine output is &gt;1 ml/kg/hr after prior dose or at 24-hr intervals if urine output is &lt;1 ml/kg/hr; hold in cases of oliguria (&lt;0.6 ml/kg/hr) or anuria</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6130">
							<label>•</label>
							<sec_title>Neonates 2-7 days<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x6130">
									<item>
										<label>•</label>
										<para> Initially, 0.2 mg/kg, then, if necessary, 2 more doses of 0.2 mg/kg at 12-hr intervals if urine output is &gt;1 ml/kg/hr after prior dose or at 24-hr intervals if urine output is &lt;ml/kg/hr; hold in cases of oliguria (&lt;0.6 ml/kg/hr) or anuria</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6137">
							<label>•</label>
							<sec_title>Neonates &lt;2 days<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x6137">
									<item>
										<label>•</label>
										<para> Initially, 0.2 mg/kg, then, if necessary, 1 or 2 doses of 0.1 mg/kg at 12-hr intervals if urine output is &gt;1 ml/kg/hr after prior dose or at 24-hr intervals if urine output is &lt;1 ml/kg/hr; hold in cases of oliguria (&lt;0.6 ml/kg/hr) or anuria</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6144">
							<label>•</label>
							<sec_title>Neonates<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6144">
									<item>
										<label>•</label>
										<para> Doses of 0.3 mg/kg q day × 2 days have been used</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6148">
						<sec_title>Available forms:</sec_title>
						<para> Caps 25, 50 mg; ext rel caps 75 mg; inj 1-mg vial; supp 50 mg; oral susp 5 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x6153">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x6156">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x6160">
									<item>
										<label>•</label>
										<para>Do not break, crush, or chew sus rel cap or reg caps</para>
									</item>
									<item>
										<label>•</label>
										<para>With food to decrease GI symptoms and prevent ulcerations</para>
									</item>
									<item>
										<label>•</label>
										<para>Shake susp; do not mix with other liquids</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6181">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x6185">
									<item>
										<label>•</label>
										<para>After reconstituting 1 mg with 1 or 2 ml NS or sterile water for inj without preservative; to give 1 or 0.5 mg/ml, respectively; do not dilute further</para>
									</item>
									<item>
										<label>•</label>
										<para>Infuse over 20-35 min; avoid extravasation</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not inject/infuse via umbilical catheter to avoid dramatic shift in cerebral blood flow</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6201">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6204">
					<section type="none" id="sidelem4x6205">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, drowsiness, fatigue, confusion, insomnia, anxiety, depression, <emphasis style="italic">headache</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6213">
						<sec_title>CV:</sec_title>
						<para> Tachycardia, peripheral edema, palpitations, dysrhythmias, hypertension, <emphasis style="bold">CV thrombotic events, MI, stroke</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6220">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, hearing loss, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x6225">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> anorexia, <emphasis style="italic">vomiting,</emphasis> diarrhea, jaundice, <emphasis style="bold">cholestatic hepatitis,</emphasis><emphasis style="italic">constipation,</emphasis> flatulence, cramps, peptic ulcer, <emphasis style="bold">ulceration, perforation, GI bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6243">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Nephrotoxicity: dysuria, hematuria, oliguria, azotemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6250">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Blood dyscrasias,</emphasis> prolonged bleeding</para>
					</section>
					<section type="none" id="sidelem4x6258">
						<sec_title>INTEG:</sec_title>
						<para> Purpura, rash, pruritus, sweating</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6263">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x6266">
					<section type="none" id="sidelem4x6267">
						<sec_title>PO:</sec_title>
						<para> Onset 30 min; peak 2 hr; duration 4-6 hr; metabolized in liver, kidneys; excreted in urine 60%, feces 33%; crosses placenta; excreted in breast milk; 99% protein binding; half-life 1 hr 1st pass, 2.6-11.2 hr 2nd pass</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x6272">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia—potassium-sparing diuretics</para>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—lithium, methotrexate, cycloSPORINE, probenecid, cidofovir</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of—digoxin, phenytoin, aminoglycosides</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—anticoagulants, abciximab, clopidogrel, eptifibatide, plicamycin, ticlopidine, tirofiban, thrombolytics, aspirin, SSRIs, SNRIs</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of—antihypertensives</para>
			</section>
			<section type="considerations" id="sidelem4x6294">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6297">
					<section type="none" id="sidelem4x6298">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x6306">
							<label>•</label>
							<sec_title>Arthritis symptoms</sec_title>
							<para>
								<list id="lidelem4x6306">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Arthritis symptoms:</emphasis> ROM, pain, swelling before and 2 hr after treatment
<bbw>Cardiac disease, CV, thrombotic events (MI, stroke) before administration, not to be used in perioperative pain in CABG surgery</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6319">
								<item>
									<label>•</label>
									<para>Patent ductus arteriosus: respiratory rate, character, heart sounds</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6324">
								<item>
									<label>•</label>
									<para>Renal, hepatic, blood studies: BUN, creatinine, AST, ALT, Hgb before treatment, periodically thereafter; if renal function has decreased, do not give subsequent doses</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6329">
								<item>
									<label>•</label>
									<para>Eye/ear problems: blurred vision, tinnitus; may indicate toxicity; audiometric, ophthalmic exam before, during, after treatment if patient receiving long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6334">
								<item>
									<label>•</label>
									<para>Confusion, mood changes, hallucinations, especially among geriatric patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6339">
								<item>
									<label>•</label>
									<para>Asthma, nasal polyps, aspirin sensitivity, may develop hypersensitivity to indomethacin
<bbw>GI bleeding/perforation: chronic use can lead to GI bleeding, use cautiously in those with a history of active GI disease</bbw>

<bbw>MI, stroke: may be greater with longer-term use and those with CV risk factors</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6362">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6366">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased pain, stiffness, swelling in joints; ability to move more easily</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6372">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x6380">
							<label>•</label>
							<sec_title>
								<route>To report blurred vision, ringing, roaring in ears; may indicate toxicity</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x6383">
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activities if dizziness, drowsiness occurs</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6391">
							<label>•</label>
							<sec_title>
								<route>To report change in urine pattern, increased weight, edema, increased pain in joints, fever, blood in urine; may indicate nephrotoxicity</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x6394">
								<item>
									<label>•</label>
									<para>To report mood changes: anxiety, depression</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6399">
								<item>
									<label>•</label>
									<para>That therapeutic antiinflammatory effects may take up to 1 mo</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6404">
								<item>
									<label>•</label>
									<para>To avoid alcohol, NSAIDs, salicylates because bleeding may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6409">
								<item>
									<label>•</label>
									<para>To report use to all health care providers
<bbw>MI/Stroke: to immediately report and seek medical attention for signs/symptoms of MI/stroke, discontinue product</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="21" status="active">
			<mono_name>inFLIXimab (Rx)</mono_name>
			<info>
				<pronunciation>(in-fliks′ih-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x64290">Remicade</tradename>
				</tradenames>
				<class type="func"> Biologic response modifiers</class>
				<class type="chem"> Tumor necrosis factor modifiers</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x6439">
				<para>
					<confusion>
						<tradename id="tnidelem4x64390">Remicade</tradename>
						<drug type="generic" refid="idelem4x64390">Renacidin/inFLIXimab/riTUXimab</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x6443">
				<sec_title>Action:</sec_title>
				<para>Monoclonal antibody that neutralizes the activity of tumor necrosis factor-alpha (TNF-α) found in Crohn’s disease; decreased infiltration of inflammatory cells</para>
			</section>
			<section type="uses" id="sidelem4x6448">
				<sec_title>Uses:</sec_title>
				<para>Crohn’s disease, fistulizing (moderate to severe); RA, given with methotrexate; plaque psoriasis, ankylosing spondylitis, ulcerative colitis, psoriasis</para>
				<section type="none" id="sidelem4x6453">
					<section type="none" id="sidelem4x6454">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Psoriatic arthritis, Behçet’s syndrome, uveitis, juvenile arthritis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x6459">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to murines, moderate to severe CHF (NYHA class III/IV)</para>
				<section type="none" id="sidelem4x6464">
					<section type="none" id="sidelem4x6465">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, COPD, hepatotoxicity, hemalologic abnormalities, hepatitis B, Guillain-Barré syndrome, seizures, multiple sclerosis</para>
						<para>
							<bbw>Infection, neoplastic disease, TB</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6480">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6483">
					<section type="none" id="sidelem4x6484">
						<sec_title>Crohn’s disease (moderate to severe)/(fistulizing)/ankylosing spondylitis</sec_title>
						<section type="none" id="sidelem4x6492">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥6 yr<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x6492">
									<item>
										<label>•</label>
										<para> 5 mg/kg initially, then at 2 wk, 6 wk, then q8wk; may increase to 10 mg/kg/dose if needed (adults)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6496">
						<sec_title>Ulcerative colitis/plaque psoriasis</sec_title>
						<section type="none" id="sidelem4x6504">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥6 yr<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x6504">
									<item>
										<label>•</label>
										<para> 5 mg/kg initially and at 2, 4 wk, then 5 mg/kg q8wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6508">
						<sec_title>Rheumatoid arthritis</sec_title>
						<section type="none" id="sidelem4x6516">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x6516">
									<item>
										<label>•</label>
										<para> 3 mg/kg initially, then at 2 wk, 6 wk, q8wk thereafter; max 10 mg/kg/dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6520">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 100 mg</para>
					</section>
					<section type="none" id="sidelem4x6525">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x6528">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x6532">
									<item>
										<label>•</label>
										<para>Pretreat with diphenhydrAMINE, acetaminophen, predniSONE if a reaction is infusion related</para>
									</item>
									<item>
										<label>•</label>
										<para>Give immediately after reconstitution; reconstitute each vial with 10 ml sterile water for inj; further dilute total dose/250 ml of 0.9% NaCl inj to a total concentration of 0.4-4 mg/ml; use 21-G or smaller needle for reconstitution; direct sterile water at glass wall of vial; gently swirl; do not shake; may foam; allow to stand for 5 min, give within 3 hr</para>
									</item>
									<item>
										<label>•</label>
										<para>Give over ≥2 hr, use polyethylene-lined infusion with in-line, sterile, low-protein-bind filter</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not admix</para>
									</item>
									<item>
										<label>•</label>
										<para>Refrigerated storage; do not freeze</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6558">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6561">
					<section type="none" id="sidelem4x6562">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness, depression, vertigo, fatigue, anxiety, fever,</emphasis><emphasis style="bold">seizures,</emphasis><emphasis style="italic">chills, flulike symptoms,</emphasis> demy- elinating disease</para>
					</section>
					<section type="none" id="sidelem4x6574">
						<sec_title>CV:</sec_title>
						<para> Chest pain, hypo/hypertension, <emphasis style="bold">tachycardia,</emphasis> CHF, <emphasis style="bold">acute coronary syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6584">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, abdominal pain, stomatitis, constipation, dyspepsia, flatulence</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6591">
						<sec_title>GU:</sec_title>
						<para> Dysuria, urinary frequency</para>
					</section>
					<section type="none" id="sidelem4x6596">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Anemia, leukopenia, thrombocytopenia, pancytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6603">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, dermatitis, urticaria,</emphasis> dry skin, sweating, flushing, hematoma, pruritus, keratoderma blenorrhagicum</para>
					</section>
					<section type="none" id="sidelem4x6611">
						<sec_title>MS:</sec_title>
						<para> Myalgia, back pain, arthralgia</para>
					</section>
					<section type="none" id="sidelem4x6616">
						<sec_title>RESP:</sec_title>
						<para> URI, pharyngitis, bronchitis, cough, dyspnea, sinusitis</para>
					</section>
					<section type="none" id="sidelem4x6622">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, fatal infections, sepsis, malignancies, immunogenicity, Stevens-Johnson syndrome, toxic epidermal necrolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6629">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Distributed to vascular compartment, half-life 9.5 days</para>
			</section>
			<section type="interactions" id="sidelem4x6634">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> infections neutropenia—TNF blockers (abatacept, anakinra, golimumab, rilonacept), avoid concurrent use<list id="lidelem4x6641">
						<item>
							<label>•</label>
							<para>Do not administer live vaccines concurrently</para>
						</item>
					</list></para>
			</section>
			<section type="considerations" id="sidelem4x6647">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6650">
					<section type="none" id="sidelem4x6651">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6656">
								<item>
									<label>•</label>
									<para>For RA, ROM, pain</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6661">
								<item>
									<label>•</label>
									<para>GI symptoms: nausea, vomiting, abdominal pain</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6666">
								<item>
									<label>•</label>
									<para>Periodic blood counts (CBC), ANA titer, LFTs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6671">
								<item>
									<label>•</label>
									<para>CV status: B/P, pulse, chest pain</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6677">
								<item>
									<para>
										<emphasis alert="nurse">Allergic reaction, anaphylaxis: rash, dermatitis, urticaria, dyspnea, hypotension, fever, chills; discontinue if severe, administer EPINEPHrine, corticosteroids, antihistamines; assess for allergies to murine proteins before starting therapy</emphasis>
<bbw>Fatal infections: discontinue if infection occurs, do not administer to patients with active infection; identify TB before beginning treatment; a TB test should be obtained; if present, TB should be treated before patient receives product; exercise caution when switching from 1 DMARD to another</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6691">
								<item>
									<label>•</label>
									<para>Report suspected adverse reactions to the FDA (1-800-FDA-1088)
<bbw>For neoplastic disease in those &lt;18 yr, including hepatosplenic T-cell lymphoma, usually occurs in those with inflammatory bowel disease</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6705">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6709">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of fever, mucus in stools</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6715">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6719">
								<item>
									<label>•</label>
									<para>Infusion reaction should be reported immediately</para>
								</item>
								<item>
									<label>•</label>
									<para>If infection occurs, notify prescriber immediately</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to breastfeed while taking this product</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of GI symptoms, hypersensitivity reactions, heart symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to operate machinery, drive if dizziness, vertigo occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid live virus vaccinations; bring up to date before use</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="22" status="active">
			<mono_name>insulin, inhaled</mono_name>
			<info>
				<pronunciation>(in′su-lin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x67550">Afrezza</tradename>
				</tradenames>
				<class type="func"> Antidiabetic—insulin</class>
			</info>
			<section type="actions" id="sidelem4x6761">
				<sec_title>Action:</sec_title>
				<para> Endogenous insulin regulates carbohydrate, fat, and protein metabolism by the storage of and inhibiting the breakdown of glucose, fat, and amino acids. Insulin decreases glucose concentrations by the uptake of glucose in muscle and adipose tissue, and by inhibiting hepatic glucose production. Insulin also regulates fat metabolism by the storage of fat and inhibiting the mobilization of fat for energy in adipose tissues (lipolysis and free fatty acid oxidation)</para>
			</section>
			<section type="uses" id="sidelem4x6766">
				<sec_title>Uses:</sec_title>
				<para> Diabetes mellitus types 1 and 2</para>
			</section>
			<section type="contra" id="sidelem4x6771">
				<sec_title>Contraindications:</sec_title>
				<para> Hypersensitivity, lung cancer, asthma, COPD, hypoglycemia, smoking</para>
				<section type="none" id="sidelem4x6776">
					<section type="none" id="sidelem4x6777">
						<sec_title>Precautions:</sec_title>
						<para> Hepatic disease, renal impairment, renal failure, diabetic ketoacidosis (DKA), hypokalemia, pregnancy C, breastfeeding, child &lt;18 yr</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6782">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6790">
					<label>•</label>
					<sec_title>Adult</sec_title>
					<para>
						<list id="lidelem4x6790">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Adult:</emphasis> INH: (type 1) the average initial dose is 0.5-0.6 unit/kg/day, usually ≥3 administrations/day; (type 2) the average initial dose is 0.2-0.6 unit/kg/day. When used in combination with oral hypoglycemic agents, may only need a single dose of a longer-acting insulin at a dosage of 10 units or 0.2 unit/kg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6795">
					<section type="none" id="sidelem4x6796">
						<sec_title>Available forms:</sec_title>
						<para> Inhalation 4 units powder</para>
					</section>
					<section type="none" id="sidelem4x6801">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6805">
								<item>
									<label>•</label>
									<para>Give by inhalation only; use at beginning of a meal; (blue cartridge = 4 units of regular insulin, green cartridge = 8 units of regular insulin), multiple cartridges may be needed, for single-use only, inhaler should be discarded after 15 days; store unopened cartridge packages in refrigerator, if not refrigerated, use within 10 days</para>
								</item>
								<item>
									<label>•</label>
									<para>Sealed (unopened) blister cards and strips must be used within 10 days. Cartridges left over in an opened strip must be used within 3 days. Remove a blister card from the foil package. Tear along a perforation to remove one strip. Press the clear side of the strip to push the cartridge out. To load the cartridge, hold the inhaler level in one hand with the white mouthpiece on the top and purple base on the bottom; open the inhaler by lifting the white mouthpiece to a vertical position. Before placing the cartridge in the inhaler, both the cartridge and the inhaler should be at room temperature for 10 minutes. Hold the cartridge with the cup facing down and line up the cartridge with the opening in the inhaler. The pointed end of the cartridge should line up with the pointed end in the inhaler. The cartridge can be placed into the inhaler; ensure that the cartridge lies flat in the inhaler. Once the cartridge is loaded, keep level</para>
								</item>
								<item>
									<label>•</label>
									<para>Remove the purple mouthpiece cover. Hold the inhaler away from the mouth and fully exhale. While keeping the head level, place the mouthpiece in the mouth and tilt the inhaler down toward the chin. Close lips around the mouthpiece to form a seal. Inhale deeply through the inhaler. Have the patient hold his or her breath for as long as comfortable and at the same time remove the inhaler from the mouth. Exhale and continue to breathe normally</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6821">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6824">
					<section type="none" id="sidelem4x6825">
						<sec_title>CNS:</sec_title>
						<para> Headache, fatigue</para>
					</section>
					<section type="none" id="sidelem4x6830">
						<sec_title>GI:</sec_title>
						<para> Nausea, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x6835">
						<sec_title>MISC:</sec_title>
						<para> Urinary tract infection, weight gain, hypokalemia, peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x6840">
						<sec_title>RESP:</sec_title>
						<para> Cough, throat irritation/pain, productive cough, decreased pulmonary function tests, bronchitis, <emphasis style="bold">acute bronchospasm</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6847">
						<sec_title>ENDO:</sec_title>
						<para> Hypoglycemia</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x6852">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x6855">
					<section type="none" id="sidelem4x6856">
						<sec_title>Increase:</sec_title>
						<para> inhaled insulin effect—bronchodilators, other inhaled products, agonists, salicylates, alcohol, fenfluramine, MAOIs</para>
					</section>
					<section type="none" id="sidelem4x6861">
						<sec_title>Increase:</sec_title>
						<para> heart failure, ischemic events—pioglitazone, troglitazone</para>
					</section>
					<section type="none" id="sidelem4x6866">
						<sec_title>Increase:</sec_title>
						<para> hypoglycemia—β-blockers, ACE inhibitors, angiotensin II receptor antagonists, disopyramide, guanethidine, octreotide</para>
					</section>
					<section type="none" id="sidelem4x6871">
						<sec_title>Increase or decrease:</sec_title>
						<para> hypoglycemic effects—clonidine, metoclopramide, tegaserod, testosterone derivatives, or anabolic steroids</para>
					</section>
					<section type="none" id="sidelem4x6876">
						<sec_title>Increase:</sec_title>
						<para> hyperglycemia—niacin (nicotinic acid), bumetanide, furosemide, torsemide</para>
					</section>
					<section type="none" id="sidelem4x6881">
						<sec_title>Decrease:</sec_title>
						<para> hypoglycemic effects—dextrothyroxine, triamterene, thiazide diuretics; thyroid hormones, estrogens, progestins, or oral contraceptives; danazol, corticosteroids, epinephrine</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6886">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6889">
					<section type="none" id="sidelem4x6890">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6894">
								<item>
									<label>•</label>
									<para>Fasting blood glucose, A1c may be drawn to identify treatment effectiveness</para>
								</item>
								<item>
									<label>•</label>
									<para>Urine ketones during illness, insulin requirements may increase during times of stress, trauma, illness, surgery</para>
								</item>
								<item>
									<label>•</label>
									<para>Hypoglycemic reaction can occur during peak times (sweating, weakness, dizziness, chills, confusion, headache, nausea, rapid, weak pulse)</para>
								</item>
								<item>
									<label>•</label>
									<para>Hyperglycemia: acetone breath, polyuria, fatigue, polydipsia, flushed dry skin, lethargy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6915">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6919">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in blood glucose levels</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6925">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6929">
								<item>
									<label>•</label>
									<para>That blurred vision occurs, not to operate machinery until effect is known, do not change corrective lens for at least 1 month</para>
								</item>
								<item>
									<label>•</label>
									<para>To keep all insulin equipment available at all times</para>
								</item>
								<item>
									<label>•</label>
									<para>That product does not cure, but controls symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>To carry ID as diabetic</para>
								</item>
								<item>
									<label>•</label>
									<para>About the symptoms of hypoglycemia, hyperglycemia, ketoacidosis</para>
								</item>
								<item>
									<label>•</label>
									<para>About dosage and how to use product, that the rest of the plan must be followed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<group id="g1">
	<group_title>insulins</group_title>
	<group id="g2">
		<group_title>Rapid acting</group_title>
		<monograph id="2.1" status="active" ha="yes">
			<mono_name>insulin glulisine (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x70740">Apidra</tradename>
					<tradename id="tnidelem4x707401">Apidra SoloStar</tradename>
				</tradenames>	
			</info>
		</monograph>
		<monograph id="2.2" status="active" ha="yes">
			<mono_name>insulin aspart (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x707402">NovoLOG</tradename>
					<tradename id="tnidelem4x707403">NovoLOG Flexpen</tradename>
					<tradename id="tnidelem4x707404">NovoLOG Pen Fill</tradename>
					<tradename id="tnidelem4x707405"><country code="CAN">NovoMix 30</country></tradename>
					<tradename id="tnidelem4x707406"><country code="CAN">Novo Rapid</country></tradename>
				</tradenames>	
			</info>
		</monograph>
		<monograph id="2.3" status="active" ha="yes">
			<mono_name>insulin lispro (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x707407">HumaLOG</tradename>
					<tradename id="tnidelem4x707408">Humalog U-200 KwikPen</tradename>
				</tradenames>	
			</info>
		</monograph>
	</group>
	<group id="g3">
		<group_title>Short Acting</group_title>
		<monograph id="2.4" status="active" ha="yes">
			<mono_name>insulin, regular (<emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x707409">HumuLIN R</tradename>
					<tradename id="tnidelem4x7074010">NovoLIN R</tradename>
					<tradename id="tnidelem4x7074011">ReliOn R</tradename>
				</tradenames>	
			</info>
		</monograph>
		<monograph id="2.5" status="active" ha="yes">
			<mono_name>insulin, regular concentrated (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x7074012">HumuLIN R U-500</tradename>
				</tradenames>	
			</info>
		</monograph>
	</group>
	<group id="g4">
		<group_title>Intermediate Acting</group_title>
		<monograph id="2.6" status="active" ha="yes">
			<mono_name>insulin, isophane suspension (NPH) (<emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x7074013">HumuLIN N</tradename>
					<tradename id="tnidelem4x7074014"><country code="CAN">NovoLIN ge NPH</country></tradename>
					<tradename id="tnidelem4x7074015">NovoLIN N</tradename>
					<tradename id="tnidelem4x7074016">NovoLIN N Prefilled</tradename>
					<tradename id="tnidelem4x7074017">ReliOn N</tradename>
				</tradenames>	
			</info>
		</monograph>
	</group>
	<group id="g5">
		<group_title>Long Acting</group_title>
		<monograph id="2.7" status="active" ha="yes">
			<mono_name>insulin detemir (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x7074018">Levemir</tradename>
				</tradenames>	
			</info>
		</monograph>
		<monograph id="2.8" status="active" ha="yes">
			<mono_name>insulin glargine (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x7074019">Lantus</tradename>
					<tradename id="tnidelem4x7074020">Toujeo SoloStar</tradename>
				</tradenames>	
			</info>
		</monograph>
	</group>
	<group id="g6">
		<group_title>Mixtures</group_title>
		<monograph id="2.9" status="active" ha="yes">
			<mono_name>insulin, isophane suspension and regular insulin (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x7074021">HumuLIN 70/30</tradename>
					<tradename id="tnidelem4x7074022"><country code="CAN">HumuLIN 30/70 </country></tradename>
					<tradename id="tnidelem4x7074023">NovoLIN 70/30 Prefilled</tradename>
					<tradename id="tnidelem4x7074024">ReliOn 70/30</tradename>
				</tradenames>	
			</info>
		</monograph>
		<monograph id="2.10" status="active" ha="yes">
			<mono_name>isophane insulin suspension (NPH) and insulin mixtures (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x7074025">HumuLIN 50/50</tradename>
				</tradenames>	
			</info>
		</monograph>
		<monograph id="2.11" status="active" ha="yes">
			<mono_name>insulin lispro mixture (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x7074026">HumaLOG KwikPen Mix 50/50</tradename>
					<tradename id="tnidelem4x7074027"><country code="CAN">HumaLOG Mix 25</country></tradename>
					<tradename id="tnidelem4x7074028"><country code="CAN">HumaLOG Mix 50</country></tradename>
					<tradename id="tnidelem4x7074029">HumaLOG Mix 75/25</tradename>
					<tradename id="tnidelem4x7074030">HumaLOG Mix 50/50</tradename>
				</tradenames>	
			</info>
		</monograph>
		<monograph id="2.12" status="active" ha="yes">
			<mono_name>insulin aspart mixture (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x7074031">NovoLOG 70/30</tradename>
					<tradename id="tnidelem4x7074032">NovoLOG Mix Flexpen Prefilled Syringe 70/30</tradename>
				</tradenames>	
				<class type="func">Antidiabetic, pancreatic hormone</class>
				<class type="chem">Modified structures of endogenous human insulin</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x7074">
				<para>
					<confusion>
						<tradename id="tnidelem4x70740">Lantus</tradename>
						<drug type="generic" refid="idelem4x70740">lente</drug>
					</confusion>
					<confusion>
						<tradename id="tnidelem4x8030">NovoLIN 70/30 PenFill</tradename>
						<drug type="generic" refid="idelem4x8030">NovoLIN 70/30 Prefilled</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x7083">
				<sec_title>Action:</sec_title>
				<para>Decreases blood glucose; by transport of glucose into cells and the conversion of glucose to glycogen, indirectly increases blood pyruvate and lactate, decreases phosphate and potassium; insulin may be human (processed by recombinant DNA technologies)</para>
			</section>
			<section type="uses" id="sidelem4x7088">
				<sec_title>Uses:</sec_title>
				<para>Type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes; insulin lispro may be used in combination with sulfonylureas in children &gt;3 yr</para>
			</section>
			<section type="contra" id="sidelem4x7094">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to protamine; creosol (aspart)</para>
				<section type="none" id="sidelem4x7099">
					<section type="none" id="sidelem4x7100">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>) lispro, detemir, regular aspart; (C) all others</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7105">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7108">
					<sec_title><tradename id="">Insulin glulisine</tradename></sec_title>
					<section type="none" id="sidelem4x7116">
						<label>•</label>
						<sec_title>Adult/adolescent/child ≥4 yr<route> SUBCUT</route></sec_title>
						<para>
							<list id="lidelem4x7116">
								<item>
									<label>•</label>
									<para> dosage individualized, give within 15 min before or 20 min after starting a meal;  dilute to 1 unit/ml in infusion systems with 0.9% NaCl, use PVC Viaflex infusion bags and PVC tubing, use dedicated line</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x7123">
					<sec_title><tradename id="">Insulin aspart</tradename></sec_title>
					<section type="none" id="sidelem4x7131">
						<label>•</label>
						<sec_title>Adult/adolescent/child ≥6 yr<route> INTERMITTENT SUBCUT</route></sec_title>
						<para>
							<list id="lidelem4x7131">
								<item>
									<label>•</label>
									<para> Total daily dose is given as 2-4 inj/day just before beginning of meal; in general, 50%-70% of total daily insulin may be given as insulin aspart, remainder should be intermediate- or long-acting insulin;  used with external insulin pump via cont SUBCUT insulin infusion (CSII), insulin dose should be based on insulin dose from previous regimen</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x7138">
					<sec_title><tradename id="">Insulin lispro</tradename></sec_title>
					<section type="none" id="sidelem4x7146">
						<label>•</label>
						<sec_title>Adult/adolescent/child ≥3 yr<route> SUBCUT</route></sec_title>
						<para>
							<list id="lidelem4x7146">
								<item>
									<label>•</label>
									<para> 15 min before meals; <emphasis style="bold">CONT SUBCUT INFUSION (external insulin pump):</emphasis> total daily dose should be based on insulin dose from previous regimen, 50% of total dose can be given as meal-related boluses, remainder as basal infusion</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x7153">
					<sec_title>Human regular</sec_title>
					<section type="none" id="sidelem4x7161">
						<label>•</label>
						<sec_title>Adult<route> SUBCUT</route></sec_title>
						<para>
							<list id="lidelem4x7161">
								<item>
									<label>•</label>
									<para>
										<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr before meals</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x7170">
					<sec_title><tradename id="">Insulin, isophane suspension</tradename></sec_title>
					<section type="none" id="sidelem4x7178">
						<label>•</label>
						<sec_title>Adult<route> SUBCUT</route></sec_title>
						<para>
							<list id="lidelem4x7178">
								<item>
									<label>•</label>
									<para> dosage individualized by blood, urine glucose; usual dose 7-26 units; may increase by 2-10 units/day if needed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x7182">
					<sec_title><tradename id="">Insulin detemir</tradename></sec_title>
					<section type="none" id="sidelem4x7190">
						<label>•</label>
						<sec_title>Adult/adolescent/child ≥2 yr<route> SUBCUT</route></sec_title>
						<para>
							<list id="lidelem4x7190">
								<item>
									<label>•</label>
									<para> 1-2×/day; if 1×, give with evening meal</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x7194">
					<sec_title><tradename id="">Insulin glargine</tradename></sec_title>
					<section type="none" id="sidelem4x7202">
						<label>•</label>
						<sec_title>Adult and child ≥6 yr<route> SUBCUT</route></sec_title>
						<para>
							<list id="lidelem4x7202">
								<item>
									<label>•</label>
									<para> 10 international units/day, range 2-100 international units/day</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x7206">
					<sec_title>Regular insulin (ketoacidosis)</sec_title>
					<section type="none" id="sidelem4x7214">
						<label>•</label>
						<sec_title>Adult<route> IV</route></sec_title>
						<para>
							<list id="lidelem4x7214">
								<item>
									<label>•</label>
									<para> 5-10 units, then 5-10 units/hr until desired response, then switch to  dose;  2-12 units (50 units/500 ml of normal saline)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7227">
						<label>•</label>
						<sec_title>Child<route> IV</route></sec_title>
						<para>
							<list id="lidelem4x7227">
								<item>
									<label>•</label>
									<para> 0.1 units/kg</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x7231">
					<sec_title>Replacement</sec_title>
					<section type="none" id="sidelem4x7239">
						<label>•</label>
						<sec_title>Adult and child<route> SUBCUT</route></sec_title>
						<para>
							<list id="lidelem4x7239">
								<item>
									<label>•</label>
									<para> 0.5-1 units/kg/day qid given 30 min before meals</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7246">
						<label>•</label>
						<sec_title>Adolescent<route> SUBCUT</route></sec_title>
						<para>
							<list id="lidelem4x7246">
								<item>
									<label>•</label>
									<para> 0.8-1.2 mg/kg/day; this dosage is used during rapid growth</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7250">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="bold">
								<emphasis style="italic">NPH</emphasis>
							</emphasis> Inj 100 units/ml; <emphasis style="bold">
								<emphasis style="italic">regular</emphasis>
							</emphasis> inj 100 units/ml, cartridges 100 units/ml; <emphasis style="bold">
								<emphasis style="italic">insulin analog</emphasis>
							</emphasis> inj 100 units/ml; <emphasis style="bold">
								<emphasis style="italic">isophane insulin</emphasis>
							</emphasis> inj 100 units/ml, cartridges 100 units/ml; <emphasis style="bold">insulin lispro</emphasis> 100 units/ml, 1.5-ml cartridges, <emphasis style="bold">
								<emphasis style="italic">insulin lispro</emphasis>
							</emphasis> HumaLOG Pen sol for inj 100 units/ml, Humalog KwikPen 200 U/ml prefilled Pen solution for injection; <emphasis style="bold">
								<emphasis style="italic">insulin glulisine</emphasis>
							</emphasis> inj 100 units/ml; <emphasis style="bold">
								<emphasis style="italic">insulin glargine</emphasis>
							</emphasis> inj 100, 300 units/ml; <emphasis style="bold">
								<emphasis style="italic">insulin detemir</emphasis>
							</emphasis> inj 100 units/ml in 10 vials, 3-ml cartridges; <emphasis style="bold">
								<emphasis style="italic">insulin aspart</emphasis>
							</emphasis> inj 100 mg/ml (Flexpen, Pen Fill)</para>
					</section>
					<section type="none" id="sidelem4x7294">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7298">
								<item>
									<label>•</label>
									<para>Store at room temperature for &lt;1 mo (some insulins); keep away from heat and sunlight; refrigerate all other supply; NPH, premixed insulins are cloudy; regular, rapid-acting analogs, long-acting analogs are clear; do not freeze—IV route, regular only</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7304">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x7308">
									<item>
										<label>•</label>
										<para>After warming to room temperature by rotating in palms to prevent injecting cold insulin; use only insulin syringes with markings or syringe matching units/ml; rotate inj sites within one area: abdomen, upper back, thighs, upper arm, buttocks; keep record of sites</para>
									</item>
									<item>
										<label>•</label>
										<para>Increased dosages if tolerance occurs</para>
									</item>
									<item>
										<label>•</label>
										<para>Premixed insulins, NPH are cloudy suspensions</para>
									</item>
									<item>
										<label>•</label>
										<para>Regular human insulin, rapid-acting analogs, long-acting analogs are clear; do not use if cloudy, thick, or discolored</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7330">
							<sec_title>CONT SUBCUT route (insulin infusion CSII)</sec_title>
							<para>
								<list id="lidelem4x7334">
									<item>
										<label>•</label>
										<para>Do not mix with other insulins when using a pump</para>
									</item>
									<item>
										<label>•</label>
										<para>Insulin lispro 3-ml cartridges to be used in Disetronic H-TRON plus V100 pump using Disetronic rapid infusion sets; infusion set and cartridge adapter should be changed q3days; replace 3-ml cartridge q6days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7345">
							<sec_title>IV route (insulin glulisine only)</sec_title>
							<para>
								<list id="lidelem4x7349">
									<item>
										<label>•</label>
										<para>Dilute to 1 international unit/ml in infusion systems with 0.9% NaCl using PVC viaflex infusion bags and PVC tubing; use dedicated line; do not admix</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7355">
							<sec_title>IV route (regular only)</sec_title>
							<para>
								<list id="lidelem4x7361">
									<item>
										<para>
											<emphasis alert="nurse">When regular insulin is administered IV, monitor glucose, potassium often to prevent fatal hypoglycemia, hypokalemia</emphasis>
										</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x7366">
									<item>
										<label>•</label>
										<para>IV direct, undiluted via vein, <emphasis style="sans-serif">Y</emphasis>-site, 3-way stopcock; give at ≤50 units/min</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x7374">
									<item>
										<label>•</label>
										<para>By cont infusion after diluting with IV sol and run at prescribed rate; use IV infusion pump for correct dosing; give reduced dose at serum glucose level of 250 mg/100 ml</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Additive compatibilities:</emphasis> Cimetidine, lidocaine, meropenem, ranitidine, verapamil</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Amiodarone, ampicillin, ampicillin/sulbactam, aztreonam, ceFAZolin, cefoTEtan, DOBUTamine, esmolol, famotidine, gentamicin, heparin, heparin/hydrocortisone, imipenem/ cilastatin, indomethacin, magnesium sulfate, meperidine, meropenem, midazolam, morphine, nitroglycerin, oxytocin, PENTobarbital, potassium chloride, propofol, ritodrine, sodium bicarbonate, sodium nitroprusside, tacrolimus, terbutaline, ticarcillin, ticarcillin/clavulanate, tobramycin, vancomycin, vit B/C</para>
						</section>
					</section>
				</section>
			</section>			
			<section type="effects" id="sidelem4x7387">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7390">
					<section type="none" id="sidelem4x7391">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, dry mouth</para>
					</section>
					<section type="none" id="sidelem4x7396">
						<sec_title>INTEG:</sec_title>
						<para> Flushing, rash, urticaria, warmth, lipodystrophy, lipohypertrophy, swelling, redness</para>
					</section>
					<section type="none" id="sidelem4x7401">
						<sec_title>META:</sec_title>
						<para> <emphasis style="italic">Hypoglycemia,</emphasis> rebound hyperglycemia (Somogyi effect 12-72 hr or longer)</para>
					</section>
					<section type="none" id="sidelem4x7409">
						<sec_title>MISC:</sec_title>
						<para> Peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x7414">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7421">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x7424">
					<section type="none" id="sidelem4x7425">
						<sec_title>Rapid acting</sec_title>
						<para>
							<emphasis style="bold">Insulin glulisine:</emphasis> Onset 15-30 min, peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, duration 3-4 hr</para>
						<para>
							<emphasis style="bold">Insulin aspart:</emphasis> Onset 10-20 min, peak 1-3 hr, duration 3-5 hr</para>
						<para>
							<emphasis style="bold">Insulin lispro:</emphasis> Onset 15-30 min, peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, duration 3-5 hr</para>
					</section>
					<section type="none" id="sidelem4x7464">
						<sec_title>Short acting</sec_title>
						<para>
							<emphasis style="bold">Insulin regular:</emphasis> Onset 30 min, peak 2.5-5 hr, duration up to 7 hr</para>
					</section>
					<section type="none" id="sidelem4x7471">
						<sec_title>Intermediate acting</sec_title>
						<para>
							<emphasis style="bold">Insulin, isophane suspension (NPH):</emphasis> Onset 1.5-4 hr, peak 4-12 hr, duration ≤24 hr</para>
					</section>
					<section type="none" id="sidelem4x7478">
						<sec_title>Long acting</sec_title>
						<para>
							<emphasis style="bold">Insulin detemir:</emphasis> Onset 0.8-2 hr, peak unknown, duration ≤24 hr (concentration dependent)</para>
					</section>
					<section type="none" id="sidelem4x7485">
						<sec_title>Insulin glargine:</sec_title>
						<para> Onset 1.5 hr, no peak identified, duration ≥24 hr</para>
					</section>
					<section type="none" id="sidelem4x7490">
						<sec_title>Mixtures</sec_title>
						<para>
							<emphasis style="bold">Insulin, isophane suspension and regular insulin (70/30):</emphasis> Onset 10-20 min, peak 2.4 hr, duration ≤24 hr</para>
						<para>
							<emphasis style="bold">Insophane insulin suspension (NPH) and insulin mixtures (50/50):</emphasis> Onset <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr, peak dual, duration 10-16 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x7507">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemia—salicylate, alcohol, β-blockers, anabolic steroids, phenylbutazone, sulfinpyrazone, guanethidine, oral hypoglycemics, MAOIs, tetracycline</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> hypoglycemia—thiazides, thyroid hormones, oral contraceptives, corticosteroids, estrogens, DOBUTamine, EPINEPHrine</para>
				<section type="none" id="sidelem4x7518">
					<section type="none" id="sidelem4x7519">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> VMA</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> potassium, calcium</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> LFTs, thyroid function studies</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7534">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7537">
					<section type="none" id="sidelem4x7538">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x7543">
								<item>
									<label>•</label>
									<para>Fasting blood glucose; A1c may be drawn to identify treatment effectiveness q3mo</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7549">
								<item>
									<label>•</label>
									<para>Urine ketones during illness; insulin requirements may increase during stress, illness, surgery</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7554">
								<item>
									<label>•</label>
									<para>Hypoglycemic reaction that can occur during peak time (sweating, weakness, dizziness, chills, confusion, headache, nausea, rapid weak pulse, fatigue, tachycardia, memory lapses, slurred speech, staggering gait, anxiety, tremors, hunger)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7562">
							<label>•</label>
							<sec_title>Hyperglycemia</sec_title>
							<para>
								<list id="lidelem4x7562">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hyperglycemia:</emphasis> acetone breath; polyuria; fatigue; polydipsia; flushed, dry skin; lethargy</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7566">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7570">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in polyuria, polydipsia, polyphagia; clear sensorium; absence of dizziness; stable gait</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7576">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7581">
								<item>
									<label>•</label>
									<para>That blurred vision occurs; not to change corrective lens until vision is stabilized after 1-2 mo</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7589">
							<label>•</label>
							<sec_title>
								<route>To keep insulin, equipment available at all times; to carry a glucagon kit, candy, or lump of sugar to treat hypoglycemia</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x7592">
								<item>
									<label>•</label>
									<para>That product does not cure diabetes but controls symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7597">
								<item>
									<label>•</label>
									<para>To carry emergency ID as diabetic</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7602">
								<item>
									<label>•</label>
									<para>To recognize hypoglycemia reaction: headache, tremors, fatigue, weakness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7607">
								<item>
									<label>•</label>
									<para>To recognize hyperglycemia reaction: frequent urination, thirst, fatigue, hunger</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7612">
								<item>
									<label>•</label>
									<para>About the dosage, route, mixing instructions, diet restrictions (if any), disease process</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7620">
							<label>•</label>
							<sec_title>About the symptoms of ketoacidosis<route> nausea; thirst; polyuria; dry mouth; decreased B/P; dry, flushed skin; acetone breath; drowsiness; Kussmaul respirations</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x7623">
								<item>
									<label>•</label>
									<para>That a plan is necessary for diet, exercise; that all food on diet should be eaten; that exercise routine should not vary</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7628">
								<item>
									<label>•</label>
									<para>About blood glucose testing; how to determine glucose level</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7633">
								<item>
									<label>•</label>
									<para>To avoid OTC products unless directed by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x7638">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Glucose 25 g IV, via dextrose 50% sol, 50 ml or glucagon 1 mg</para>
			</section>
		</monograph>
	</group>
</group>

<monograph id="3.1" status="active">
			<mono_name>interferon alfacon-1 (Rx)</mono_name>
			<info>
				<pronunciation>(in-ter-feer′on al′fa-kon)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x76480">Infergen</tradename>
				</tradenames>
				<class type="func"> Recombinant type 1 interferon</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x7654">
				<sec_title>Action:</sec_title>
				<para>Induces biologic responses and has antiviral, antiproliferative, and immunomodulatory effects</para>
			</section>
			<section type="uses" id="sidelem4x7659">
				<sec_title>Uses:</sec_title>
				<para>Chronic hepatitis C infections in those ≥18 yr with compensated liver disease who have anti-HCV antibodies or HCV RNA, may use in combination with ribavirin</para>
			</section>
			<section type="contra" id="sidelem4x7664">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to α-interferons or products from <emphasis style="italic">Escherichia coli;</emphasis> decompensated hepatic disease, autoimmune hepatitis</para>
				<section type="none" id="sidelem4x7672">
					<section type="none" id="sidelem4x7673">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;18 yr, geriatric patients, thyroid disorders, myelosuppression, hepatic disease, seizure disorder, alcoholism, hepatitis</para>
						<para>
							<bbw>Cardiac disease, autoimmune disease, infection, depression</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7688">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7696">
					<label>•</label>
					<sec_title>Adult<route> SUBCUT monotherapy</route></sec_title>
					<para>
						<list id="lidelem4x7696">
							<item>
								<label>•</label>
								<para> 9 mcg as single inj 3×/wk × 24 wk; leave ≥48 hr between injections; for patients who did not respond or relapsed after discontinuation, give 15 mcg 3×/wk × 48 wk;  15 mcg daily with ribavirin 1000 mg/day PO (&lt;75 kg), 1200 mg/day PO (≥75 kg); give in 2 divided doses for up to 48 wks, use stepwise dose reduction of the interferon dose from 15 mcg to 9 mcg to 6 mcg for serious adverse reactions</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7703">
					<section type="none" id="sidelem4x7704">
						<sec_title>Available forms:</sec_title>
						<para> Inj 9 mcg/0.3 ml, 15 mcg/0.5 ml</para>
					</section>
					<section type="none" id="sidelem4x7709">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7713">
								<item>
									<label>•</label>
									<para>Premedicate with acetaminophen or ibuprofen</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not shake vial; use 1 dose per vial; discard unused portion; use proper inj sites; rotate sites, discard unused product</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not miss doses, give at bedtime for better tolerance</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7730">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7733">
					<section type="none" id="sidelem4x7734">
						<sec_title>CNS:</sec_title>
						<para> Depression, headache, fatigue, fever, rigors, insomnia, dizziness, agitation, nervousness, anxiety, lability, abnormal thinking</para>
					</section>
					<section type="none" id="sidelem4x7739">
						<sec_title>CV:</sec_title>
						<para> Hypertension, palpitation, tachycardia</para>
					</section>
					<section type="none" id="sidelem4x7744">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, earache, conjunctivitis, eye pain</para>
					</section>
					<section type="none" id="sidelem4x7749">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, nausea, diarrhea, anorexia, dyspepsia, vomiting, constipation, flatulence, hemorrhoids, decreased salivation</para>
					</section>
					<section type="none" id="sidelem4x7754">
						<sec_title>GU:</sec_title>
						<para> Dysmenorrhea, vaginitis, menstrual disorders</para>
					</section>
					<section type="none" id="sidelem4x7759">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Granulocytopenia, thrombocytopenia, leukopenia,</emphasis> ecchymosis, <emphasis style="bold">aplastic anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7769">
						<sec_title>INTEG:</sec_title>
						<para> Alopecia, pruritus, rash, erythema, dry skin</para>
					</section>
					<section type="none" id="sidelem4x7774">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, angioedema,</emphasis> flulike illness</para>
					</section>
					<section type="none" id="sidelem4x7782">
						<sec_title>MS:</sec_title>
						<para> Back, limb, neck skeletal pain; rigors</para>
					</section>
					<section type="none" id="sidelem4x7787">
						<sec_title>RESP:</sec_title>
						<para> Pharyngitis, upper respiratory infection, cough, sinusitis, rhinitis, respiratory tract congestion, epistaxis, dyspnea, bronchitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7792">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1-4 hr, peak biologic response 24-36 hr</para>
			</section>
			<section type="interactions" id="sidelem4x7797">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hearing loss—eflornithine (systemic), consider serial audiograms</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> NRTI, use together cautiously</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myelosuppression—myelosuppressives</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—aldesleukin, IL-2 eflornithine, theophylline</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of—antiretrovirals (NNRTs, NRTIs, protease inhibitors)</para>
			</section>
			<section type="considerations" id="sidelem4x7820">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7823">
					<section type="none" id="sidelem4x7824">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Past or present history of depression, seizures; use with caution with these disorders</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Hemolytic anemia:</emphasis> ribavirin may be used with this product and cause hemolytic anemia, cardiac symptoms•Ophthalmologic status; report periodically•<emphasis alert="lifethreat">Pregnancy: determine if patient is pregnant before use with ribavirin, pregnancy (X), when used with ribavirin</emphasis>•CBC, LFTs, ECG, platelet counts, heme concentration, ANC, serum creatinine, albumin, bilirubin, TSH, T4, triglycerides at baseline and periodically•Myelosuppression: hold dose if neutrophil count is &lt;500 × 106/L or if platelets are &lt;50 × 109/L, monitor for infection•For hypersensitivity: discontinue immediately if hypersensitivity occurs</bbw>
						</para>
					</section>
					<section type="none" id="sidelem4x7884">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7888">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased chronic hepatitis C signs/symptoms</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7894">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7899">
								<item>
									<label>•</label>
									<para>With detailed written information about product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7904">
								<item>
									<label>•</label>
									<para>To report signs, symptoms of infection, thyroid/liver dysfunction, changes in behavior</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7912">
							<label>•</label>
							<sec_title>
								<route>To report if pregnancy is planned or suspected (C), when combined with ribavirin pregnancy (X)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x7915">
								<item>
									<label>•</label>
									<para>To use OTC analgesics to decrease flulike symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7920">
								<item>
									<label>•</label>
									<para>If patient will be self-administering injection, teach all aspects of product use, administration, disposal, provide medication guide</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="4.1" status="active">
			<mono_name>interferon beta-1a (Rx)</mono_name>
			<info>
				<pronunciation>(in-ter-feer′on)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x79311">Avonex</tradename>
					<tradename id="tnidelem4x79310">Rebif</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="5.1" status="active">
			<mono_name>interferon beta-1b (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x79361">Betaseron</tradename>
					<tradename id="tnidelem4x79360">Extavia</tradename>
				</tradenames>
				<class type="func"> Multiple sclerosis agent, immune modifier</class>
				<class type="chem"> Interferon,  derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x7949">
				<sec_title>Action:</sec_title>
				<para>Antiviral, immunoregulatory; action not clearly understood; biologic response-modifying properties mediated through specific receptors on cells, inducing expression of interferon-induced gene products</para>
			</section>
			<section type="uses" id="sidelem4x7954">
				<sec_title>Uses:</sec_title>
				<para>Ambulatory patients with relapsing or remitting MS</para>
			</section>
			<section type="contra" id="sidelem4x7959">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to natural or recombinant interferon-β or human albumin, hamster protein, rotovirus vaccine</para>
				<section type="none" id="sidelem4x7964">
					<section type="none" id="sidelem4x7965">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;18 yr, chronic progressive MS, depression, mental disorders, seizure disorder, latex allergy, autoimmune disorders, bone marrow suppression, hepatotoxicity, cardiac disease, alcoholism, chickenpox, herpes zoster</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7970">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7973">
					<sec_title><tradename id="">Interferon beta-1a</tradename></sec_title>
					<section type="none" id="sidelem4x7976">
						<sec_title>Remitting or relapsing multiple sclerosis</sec_title>
						<section type="none" id="sidelem4x7984">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x7984">
									<item>
										<label>•</label>
										<para> (Avonex) 30 mcg/wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7991">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x7991">
									<item>
										<label>•</label>
										<para> (Rebif) 22 or 44 mcg 3×/wk with each dose 48 hr apart, titrate to full dose over 4-wk period</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x7995">
					<sec_title><tradename id="">Interferon beta-1b</tradename></sec_title>
					<section type="none" id="sidelem4x7998">
						<sec_title>Relapsing or remitting multiple sclerosis</sec_title>
						<section type="none" id="sidelem4x8006">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x8006">
									<item>
										<label>•</label>
										<para> 0.0625 mg every other day for wk 1 and 2, then 0.125 mg every other day for wk 3 and 4, then 0.1875 mg every other day for wk 5 and 6, then 0.25 mg every other day thereafter; higher doses should not be used</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8010">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="italic">beta-1a:</emphasis> (Avonex) 30 mcg (6.6 million international units/vial) (autoinjector pen); (Rebif) 22 mcg, 44 mcg/0.5 ml; <emphasis style="italic">beta-1b:</emphasis> powder for inj 0.3 mg (9.6 m international units) kit</para>
					</section>
					<section type="none" id="sidelem4x8021">
						<sec_title>Administer:</sec_title>
						<para/>
					</section>
				</section>
				<section type="none" id="sidelem4x8025">
					<sec_title><tradename id="">Interferon beta-1a</tradename></sec_title>
					<para>
						<list id="lidelem4x8029">
							<item>
								<label>•</label>
								<para>Visually inspect parenteral products for particulate matter and discoloration before use</para>
							</item>
							<item>
								<label>•</label>
								<para>Store in refrigerator; do not freeze</para>
							</item>
						</list>
					</para>
					<section type="none" id="sidelem4x8040">
						<section type="none" id="sidelem4x8041">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x8045">
									<item>
										<label>•</label>
										<para>Premedicate with acetaminophen or ibuprofen and give at bedtime to lessen flulike symptoms</para>
									</item>
									<item>
										<label>•</label>
										<para>Interferon-β1a (Avonex) 30 mcg = 6 million IU</para>
									</item>
									<item>
										<label>•</label>
										<para>If a dose is missed, give it as soon as possible; continue regular schedule but do not give 2 injections within 2 days; all products are single-use only; do not reuse needles, syringes, prefilled syringes, or autoinjectors</para>
									</item>
									<item>
										<label>•</label>
										<para>Rotate injection sites to minimize injection-site reactions</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not inject into an area where skin is irritated, reddened, bruised, infected, or scarred</para>
									</item>
									<item>
										<label>•</label>
										<para>Check site after 2 hr for redness, edema, or tenderness</para>
									</item>
									<item>
										<label>•</label>
										<para>The manufacturer of Avonex offers free training on IM use for patients and health care partners; contact MS ActiveSource for more information (800-456-2255)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8081">
						<section type="none" id="sidelem4x8082">
							<sec_title>Reconstitution and administration of Avonex lyophilized powder for IM route</sec_title>
							<para>
								<list id="lidelem4x8087">
									<item>
										<label>•</label>
										<para>Use aseptic technique for preparation of solution</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8092">
									<item>
										<label>•</label>
										<para>Sites include the thigh or upper arm</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8097">
									<item>
										<label>•</label>
										<para>Slowly add 1.1 ml sterile water for injection, preservative-free (supplied by manufacturer) to the vial; rapid addition of the diluent can cause foaming</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8102">
									<item>
										<label>•</label>
										<para>Gently swirl; do not shake; final concentration should be 30 mcg/ml (6 million IU/ml)</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8107">
									<item>
										<label>•</label>
										<para>The solution should be clear to slightly yellow without particles; discard if the reconstituted product contains particulate or is discolored</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8114">
									<item>
										<label>•</label>
										<para>Withdraw 1 ml of reconstituted solution into a syringe; attach the sterile needle and inject IM</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8119">
									<item>
										<label>•</label>
										<para>A 25-G 1-inch needle for IM may be substituted for the 23-G 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">4</emphasis>-inch needle provided</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x8133">
								<label>•</label>
								<sec_title>Storage</sec_title>
								<para>
									<list id="lidelem4x8133">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Storage:</emphasis> Use within 6 hr of reconstitution; store reconstituted solution in refrigerator; <emphasis style="italic">do not freeze;</emphasis> discard any unused solution; both drug and diluent vials are single-use only</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x8140">
							<sec_title>Administration of Avonex prefilled syringe</sec_title>
							<para>
								<list id="lidelem4x8145">
									<item>
										<label>•</label>
										<para>Patients may self-inject only if provider determines that it is appropriate, and with medical follow-up, and after proper training in IM injection technique</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8150">
									<item>
										<label>•</label>
										<para>The first injection should be performed under the supervision of an appropriately qualified person</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8155">
									<item>
										<label>•</label>
										<para>If self-injecting, rotate injection site between thighs; with help from another person, may rotate injection site between thighs and upper arms</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8160">
									<item>
										<label>•</label>
										<para>Wash hands before handling the Dose Pack</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8165">
									<item>
										<label>•</label>
										<para>Remove prefilled syringe from the refrigerator to warm to room temperature (usually 30 min before use); do not use external heat sources such as hot water to warm the syringe</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8170">
									<item>
										<label>•</label>
										<para>Hold the syringe so the cap is facing down and the 0.5 ml mark is at eye level; be sure the amount of liquid in the syringe is the same or very close to the 0.5 ml mark; if the syringe does not contain the correct amount of liquid, do not use it and call the pharmacist</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8175">
									<item>
										<label>•</label>
										<para>Hold syringe upright so that the rubber cap faces up; remove the cap by bending it at a 90-degree angle until it snaps free</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8180">
									<item>
										<label>•</label>
										<para>Attach the needle by pressing it onto the syringe and turning it clockwise until it locks in place; be careful not to push the plunger while attaching the needle</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8185">
									<item>
										<label>•</label>
										<para>Use the alcohol wipe to clean the skin at the injection site you choose; then, pull the protective cover straight off the needle; do not twist the cover off</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8190">
									<item>
										<label>•</label>
										<para>Inject intramuscularly at a 90-degree angle into the thigh or upper arm as directed by the provider</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8195">
									<item>
										<label>•</label>
										<para>Use gauze pad to apply pressure for a few seconds after the injection</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8200">
									<item>
										<label>•</label>
										<para>Dispose of used needles and syringes in a puncture-resistant container and discard appropriately</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8205">
									<item>
										<label>•</label>
										<para>Instruct patients to contact the health care provider if a skin reaction occurs that does not resolve in a few days</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8210">
									<item>
										<label>•</label>
										<para>A 25-G 1-inch needle for intramuscular injection may be substituted for the 23-G 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">4</emphasis>-inch needle provided by the manufacturer, if deemed appropriate by the physician</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8221">
									<item>
										<label>•</label>
										<para>Refer to the Patient Medication Guide for detailed instructions for preparing and giving a dose</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x8229">
								<label>•</label>
								<sec_title>Storage</sec_title>
								<para>
									<list id="lidelem4x8229">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Storage:</emphasis> Store refrigerated; if refrigeration is unavailable, may store at 77° F or less for up to 7 days; after removing from refrigerator, do not store product above 25° C; if the product has been exposed to conditions other than recommended, discard the product; do not expose to high temperatures; do not freeze; protect from light</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x8233">
							<sec_title>Administration of Avonex prefilled autoinjector</sec_title>
							<para>
								<list id="lidelem4x8238">
									<item>
										<label>•</label>
										<para>Patients may self-inject only if their provider determines that it is appropriate, and with medical follow-up, and after proper training in IM technique</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8243">
									<item>
										<label>•</label>
										<para>The first injection should be performed under the supervision of provider</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8248">
									<item>
										<label>•</label>
										<para>Remove one Administration Dose Pack from the refrigerator to warm to room temperature (about 30 min before use); do not use external heat sources such as hot water to warm the syringe Dose Pack</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8253">
									<item>
										<label>•</label>
										<para>Wash hands before handling Dose Pack contents</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8258">
									<item>
										<label>•</label>
										<para>Ensure tamper-evident cap has not been removed or is loose; then grasp the cap and bend it at a 90-degree angle until it snaps off; pull off the sterile foil from the needle cover</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8263">
									<item>
										<label>•</label>
										<para>Hold the Avonex Pen with the glass syringe tip pointing up; press the needle onto the glass syringe tip; gently turn the needle clockwise until firmly attached; do not remove plastic cover from the needle</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8270">
									<item>
										<label>•</label>
										<para>Hold Pen with one hand and, using other hand, hold on to the injector shield (grooved area) tightly and quickly pull up on the injector shield until the injector shield covers the needle all the way; the plastic needle cover will pop off after the injector shield has been fully extended</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8275">
									<item>
										<label>•</label>
										<para>When the injector shield is extended the right way, there will be a small blue rectangular area next to the oval medication display window; check the display window and make sure the Avonex is clear and colorless</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8280">
									<item>
										<label>•</label>
										<para>Do not use the injection if the liquid is colored, cloudy, or has lumps or particles; air bubbles will not affect the dose</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8285">
									<item>
										<label>•</label>
										<para>Do not push down on the injector shield and the blue activation button at the same time until you are ready to give injection</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8290">
									<item>
										<label>•</label>
										<para>Avonex Pen should be injected into the upper outer thigh</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8295">
									<item>
										<label>•</label>
										<para>Use the alcohol wipe to clean the skin at the injection site and allow it to dry before injection</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8300">
									<item>
										<label>•</label>
										<para>Hold Pen at 90-degree angle to the injection site; firmly push the body of the pen down against the thigh to release the safety lock; safety lock is released when blue rectangle area above the oval medication display window is gone, push down on blue activation button with thumb and count to 10, you will hear a click if the injection is given the right way</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8305">
									<item>
										<label>•</label>
										<para>After counting to 10, pull the Pen straight out of the skin, use gauze pad to apply pressure for a few seconds</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8310">
									<item>
										<label>•</label>
										<para>The circular display window on the Pen is yellow if the full dose is received</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8315">
									<item>
										<label>•</label>
										<para>Cover exposed needle with Pen cover; do not hold the Pen cover with your hands while inserting the needle</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8320">
									<item>
										<label>•</label>
										<para>Dispose of used needles and syringes in a puncture-resistant container and discard appropriately</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8325">
									<item>
										<label>•</label>
										<para>Instruct patients to contact the health care provider if a skin reaction occurs that does not resolve in a few days</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8330">
									<item>
										<label>•</label>
										<para>Refer to the Patient Medication Guide for detailed instructions for preparing and giving a dose</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x8338">
								<label>•</label>
								<sec_title>Storage</sec_title>
								<para>
									<list id="lidelem4x8338">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Storage:</emphasis> Store at 36°-46° F (2°-8° C); if refrigeration is unavailable, may store at 77° F or less for up to 7 days; after removing from refrigerator, do not store product above 25° C; if the product has been exposed to conditions other than recommended, discard the product and do not use; do not expose to high temperatures; do not freeze; protect from light</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x8342">
							<sec_title>Subcutaneous administration</sec_title>
							<para>
								<list id="lidelem4x8346">
									<item>
										<label>•</label>
										<para>Give at the same time (preferably late in the afternoon or evening) on the same days of the week at least 48 hours apart</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not give on two consecutive days; if a dose is missed, administer the dose as soon as possible, then skip the following day; return to the regular schedule the following week</para>
									</item>
									<item>
										<label>•</label>
										<para>Premedication with acetaminophen or ibuprofen can lessen the severity of flulike symptoms</para>
									</item>
									<item>
										<label>•</label>
										<para>Interferon-β1a (Rebif) 44 mcg is equivalent to 12 million IU</para>
									</item>
									<item>
										<label>•</label>
										<para>Rotate injection sites; appropriate injection sites include thigh, outer surface of upper arm, stomach, or buttocks; do not inject into an area where the skin is irritated, reddened, bruised, or infected</para>
									</item>
									<item>
										<label>•</label>
										<para>A Starter Pack containing a lower dose of Rebif syringes is available for the initial titration period; patients and/or their caregivers should be trained and understand appropriate preparation and administration</para>
									</item>
									<item>
										<label>•</label>
										<para>The manufacturer offers complimentary services including injection training and reimbursement support; contact MS LifeLines at 877-44-REBIF</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8382">
							<sec_title>Injection (Rebif)</sec_title>
							<para>
								<list id="lidelem4x8386">
									<item>
										<label>•</label>
										<para>Interferon-β1a (Rebif) is available in a prefilled syringe with a 29-G needle</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject subcutaneously into the outer surface of the upper arm, abdomen, thigh, or buttock, do not inject the area near the navel or waistline; take care not to inject intradermally</para>
									</item>
									<item>
										<label>•</label>
										<para>Discard any unused solution; prefilled syringes do not contain preservatives and are single-use only</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x8403">
					<sec_title><tradename id="">Interferon beta-1b</tradename></sec_title>
					<section type="none" id="sidelem4x8406">
						<section type="none" id="sidelem4x8407">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x8411">
									<item>
										<label>•</label>
										<para>The manufacturers of Betaseron and of Extavia offer materials to assist with training on subcut use, call 1-800-788-1467 (Betaseron), 1-888-669-6682 (Extavia)</para>
									</item>
									<item>
										<label>•</label>
										<para>Premedication with acetaminophen or ibuprofen and use of product at bedtime can lessen the severity of flulike symptoms</para>
									</item>
									<item>
										<label>•</label>
										<para>Visually inspect parenteral products for particulate matter and discoloration before use; do not use if particulate matter is present</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8427">
							<sec_title>Reconstitution</sec_title>
							<para>
								<list id="lidelem4x8431">
									<item>
										<label>•</label>
										<para>Add 1.2 ml of 0.54% sodium chloride injection (supplied by the manufacturer) to the vial by using the vial adapter to attach the prefilled syringe that contains the diluent; keep the plunger depressed, and gently swirl, do not shake; if you take your thumb off the plunger, the solution can come back into the syringe before the product is fully reconstituted; if foaming occurs, allow the vial to sit until the foam settles; final concentration (250 mcg interferon-β1b/ml, which corresponds to 8 million IU/ml)</para>
									</item>
									<item>
										<label>•</label>
										<para>If not used immediately, store in the refrigerator for up to 3 hr; do not freeze; discard any unused portion after 3 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8442">
							<sec_title>Injection</sec_title>
							<para>
								<list id="lidelem4x8446">
									<item>
										<label>•</label>
										<para>Withdraw the desired amount of the reconstituted solution into the syringe by turning the vial and syringe to get the vial on top; pull the plunger back to get the desired amount of product; turn the syringe to point the needle upward, and tap the syringe and release any air bubbles; twist the vial adapter to remove it and the vial</para>
									</item>
									<item>
										<label>•</label>
										<para>Choose an injection site on the upper back arm; abdomen; buttock; or front thigh; do not inject within 2 inches of the navel or in a site where the skin is red, bruised, infected, broken, painful, uneven, or scabbed; rotate injection sites to minimize injection-site reactions such as necrosis or localized infection</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject subcutaneously; take care not to inject intradermally</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8462">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8465">
					<section type="none" id="sidelem4x8466">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, fever, pain, chills, mental changes, depression,</emphasis> hypertonia, <emphasis style="bold">suicide attempts, seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8476">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Migraine, palpitations, hypertension,</emphasis> tachycardia, peripheral vascular disorders</para>
					</section>
					<section type="none" id="sidelem4x8484">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Conjunctivitis,</emphasis> blurred vision</para>
					</section>
					<section type="none" id="sidelem4x8492">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, constipation, vomiting, abdominal pain</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8499">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Dysmenorrhea, irregular menses, metrorrhagia,</emphasis> cystitis, breast pain</para>
					</section>
					<section type="none" id="sidelem4x8507">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Decreased lymphocytes, ANC, WBC;</emphasis><emphasis style="italic">lymphadenopathy,</emphasis> anemia</para>
					</section>
					<section type="none" id="sidelem4x8517">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Sweating, inj-site reaction</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8524">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Myalgia,</emphasis><emphasis style="bold">myasthenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8533">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Sinusitis,</emphasis> dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8541">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x8544">
					<section type="none" id="sidelem4x8545">
						<sec_title>β-1a:</sec_title>
						<para> Onset ≤12 hr, peak 16 hr, duration 4 days, half-life 8.6 hr</para>
					</section>
					<section type="none" id="sidelem4x8550">
						<sec_title>β-1b:</sec_title>
						<para> Onset rapid, peak 2-8 hr, duration unknown, half-life 8 min-4.3 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x8555">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hepatic damage—antiretrovirals (NNRTIs, NRTIs, protease inhibitors)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myelosuppression—antineoplastics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> clearance of zidovudine</para>
				<section type="none" id="sidelem4x8570">
					<section type="none" id="sidelem4x8571">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x8575">
								<item>
									<label>•</label>
									<para>Change in immunomodulation: astragalus, echinacea, melatonin</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8581">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Interference:</emphasis> vaccines, toxoids; avoid concurrent use</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8592">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8595">
					<section type="none" id="sidelem4x8596">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x8601">
								<item>
									<label>•</label>
									<para>Blood, hepatic studies: CBC, differential, platelet counts, BUN, creatinine ALT, urinalysis; if absolute neutrophil count &lt;750/mm<emphasis style="sup">3</emphasis> or if AST/ALT is 10× normal, discontinue product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8609">
								<item>
									<label>•</label>
									<para>CNS symptoms: headache, fatigue, depression</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8614">
								<item>
									<label>•</label>
									<para>GI status: diarrhea or constipation, vomiting, abdominal pain</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8619">
								<item>
									<label>•</label>
									<para>Cardiac status: increased B/P, tachycardia</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8628">
							<label>•</label>
							<sec_title>
								<route>suicidal thoughts,</route>
							</sec_title>
							<para>
								<list id="lidelem4x8628">
									<item>
										<label>•</label>
										<para>Mental status: depression, depersonalization,  insomnia</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x8633">
								<item>
									<label>•</label>
									<para>Multiple sclerosis symptoms</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8638">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8642">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of multiple sclerosis</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8648">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8653">
								<item>
									<label>•</label>
									<para>With written, detailed information about product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8658">
								<item>
									<label>•</label>
									<para>That blurred vision, hearing loss, sweating may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8663">
								<item>
									<label>•</label>
									<para>That female patients may experience irregular menses, dysmenorrhea or metrorrhagia, breast pain</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8668">
								<item>
									<label>•</label>
									<para>To use sunscreen to prevent photosensitivity</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8673">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is suspected</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8678">
								<item>
									<label>•</label>
									<para>About injection technique, care of equipment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8686">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of increased temperature, chills, muscle soreness, fatigue, depression, symptoms of hepatotoxicity</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="6.1" status="active">
			<mono_name>interferon gamma-1b (Rx)</mono_name>
			<info>
				<pronunciation>(in-ter-feer′on)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x86940">Actimmune</tradename>
				</tradenames>
				<class type="func"> Biologic response modifier</class>
				<class type="chem"> Lymphokine, interleukin type</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x8704">
				<sec_title>Action:</sec_title>
				<para>Species-specific protein synthesized in response to viruses, effects; can mediate killing of <emphasis style="italic">Staphylococcus aureus, Toxoplasma gondii, Leishmania donovani, Listeria monocytogenes, Mycobacterium avium intracellulare;</emphasis> enhances oxidative metabolism of macrophages, enhances antibody-dependent cellular cytotoxicity</para>
			</section>
			<section type="uses" id="sidelem4x8712">
				<sec_title>Uses:</sec_title>
				<para>Serious infections associated with chronic granulomatous disease, osteopetrosis</para>
				<section type="none" id="sidelem4x8717">
					<section type="none" id="sidelem4x8718">
						<sec_title>Unlabeled uses:</sec_title>
						<para> <emphasis style="italic">Mycobacterium avium</emphasis> complex (MAC)</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x8726">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to interferon-γ, <emphasis style="italic">Escherichia coli</emphasis>–derived products</para>
				<section type="none" id="sidelem4x8734">
					<section type="none" id="sidelem4x8735">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;1 yr, cardiac disease, seizure disorders, CNS disorders, myelosuppression</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8740">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8748">
					<label>•</label>
					<sec_title>Adult<route> SUBCUT</route></sec_title>
					<para>
						<list id="lidelem4x8748">
							<item>
								<label>•</label>
								<para> 50 mcg/m<emphasis style="sup">2</emphasis> (1.5 million units/m<emphasis style="sup">2</emphasis>) for patients with surface area &gt;0.5 m<emphasis style="sup">2</emphasis>; 1.5 mcg/kg/dose for patients with surface area &lt;0.5 m<emphasis style="sup">2</emphasis>; give Monday, Wednesday, Friday for 3×/wk dosing</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8764">
					<section type="none" id="sidelem4x8765">
						<sec_title>Available forms:</sec_title>
						<para> Inj 100 mcg (2 million units)/single-dose vial</para>
					</section>
					<section type="none" id="sidelem4x8770">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8774">
								<item>
									<label>•</label>
									<para>At bedtime to minimize adverse reactions; give acetaminophen for fever, headache</para>
								</item>
								<item>
									<label>•</label>
									<para>50% of dose if severe reactions occur or discontinue treatment until reactions subside</para>
								</item>
								<item>
									<label>•</label>
									<para>In right and left deltoid and anterior thigh</para>
								</item>
								<item>
									<label>•</label>
									<para>Warm to room temperature before use; do not leave at room temperature &gt;12 hr (unopened vial)</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in refrigerator upon receipt; do not freeze; do not shake</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8800">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8803">
					<section type="none" id="sidelem4x8804">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, fatigue,</emphasis> depression, fever, chills</para>
					</section>
					<section type="none" id="sidelem4x8812">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, anorexia,</emphasis> abdominal pain, weight loss, diarrhea, vomiting, colitis</para>
					</section>
					<section type="none" id="sidelem4x8820">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, thrombocytopenia, neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8827">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pain at inj site, <emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8834">
						<sec_title>MS:</sec_title>
						<para> Myalgia, arthralgia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8839">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x8842">
					<section type="none" id="sidelem4x8843">
						<sec_title>SUBCUT:</sec_title>
						<para> Dose absorbed 89%, elimination half-life 5.9 hr, peak 7 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x8848">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> myelosuppression—other myelosuppressive agents</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> level of theophylline, aminophylline</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> liver toxicity—protease inhibitors, nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs)</para>
			</section>
			<section type="considerations" id="sidelem4x8864">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8867">
					<section type="none" id="sidelem4x8868">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x8872">
								<item>
									<label>•</label>
									<para>Blood, renal, hepatic studies: CBC, differential, platelet counts, BUN, creatinine, ALT, urinalysis</para>
								</item>
								<item>
									<label>•</label>
									<para>CNS symptoms: headache, fatigue, depression</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8883">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8887">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased serious infections; improvement in existing infections and inflammatory conditions</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8893">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8897">
								<item>
									<label>•</label>
									<para>About the method of administration if family members will be giving medication</para>
								</item>
								<item>
									<label>•</label>
									<para>With written, detailed information about product</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="7.1" status="active" ha="yes">
			<mono_name> ipilimumab</mono_name>
			<info>
				<pronunciation>(ip-i-lim′ue-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x89150">Yervoy</tradename>
				</tradenames>
				<class type="func"> Antineoplastic; biologic response modifier</class>
			</info>
			<section type="actions" id="sidelem4x8921">
				<sec_title>Action:</sec_title>
				<para>A recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4); action is indirect, possibly through T-cell–mediated antitumor immune responses</para>
			</section>
			<section type="uses" id="sidelem4x8926">
				<sec_title>Uses:</sec_title>
				<para>Treatment of unresectable or metastatic malignant melanoma</para>
			</section>
			<section type="contra" id="sidelem4x8931">
				<sec_title>Contraindications</sec_title>
				<para>Hyper-sensitivity</para>
				<section type="none" id="sidelem4x8936">
					<section type="none" id="sidelem4x8937">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy, breastfeeding, Crohn’s disease, hepatitis, immunosuppression, inflammatory bowel disease, iritis, ocular disease, organ transplant, pancreatitis, renal disease, rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus, thyroid disease, ulcerative colitis, uveitis</para>
						<para>
							<bbw>Adrenal insufficiency, diarrhea, Guillain-Barré syndrome, hepatic disease, myasthenia gravis, hypo/hyperthyroidism, hypopituitarism, peripheral neuropathy, serious rash</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8952">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8960">
					<label>•</label>
					<sec_title>Adult/geriatric<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x8960">
							<item>
								<label>•</label>
								<para> 3 mg/kg over 90 min q3wk × 4 doses; permanently discontinue if the full treatment course is not completed within 16 wk from 1st dose or for severe or life-threatening adverse reactions; withhold a dose for any moderate endocrine or immune-mediated adverse reactions; if the moderate adverse reaction completely or partially resolves (Grade 0-1) and if the patient is receiving &lt;7.5 mg predniSONE or equivalent/day, resume at a dose of 3 mg/kg IV q3wk until all 4 planned doses or 16 wk from 1st dose, whichever occurs earlier; if moderate adverse reactions are persistent or if the corticosteroid dose cannot be reduced to 7.5 mg predniSONE or equivalent/day, permanently discontinue</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8964">
					<section type="none" id="sidelem4x8965">
						<sec_title>Available forms:</sec_title>
						<para> Sol for inj 50 mg/10 ml, 200 mg/40 ml</para>
					</section>
					<section type="none" id="sidelem4x8970">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x8973">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x8977">
									<item>
										<label>•</label>
										<para>Visually inspect parenteral products for particulate matter and discoloration before using whenever sol and container permit; sol may have a pale yellow color and have translucent to white, amorphous particles; discard the vial if sol is cloudy, if there is pronounced discoloration, or if particulate matter is present</para>
									</item>
									<item>
										<label>•</label>
										<para>Allow vials to stand at room temperature for 5 min before infusion preparation; withdraw the required volume and transfer into an IV bag; discard partially used vials or empty vials; dilute with 0.9% sodium chloride injection or 5% dextrose injection to a final concentration (1-2 mg/ml); mix diluted sol by gentle inversion; do not admix</para>
									</item>
									<item>
										<label>•</label>
										<para>Give infusion over 90 min through an IV line with a low-protein binding in-line filter, do not give with other products; after each infusion, flush the line with 0.9% sodium chloride injection or 0.5% dextrose injection</para>
									</item>
									<item>
										<label>•</label>
										<para>Store once diluted for no more than 24 hr refrigerated or at room temperature</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9000">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9003">
					<section type="none" id="sidelem4x9004">
						<sec_title>CNS:</sec_title>
						<para> Severe and fatal immune-mediated neuropathies, fatigue, headache, fever</para>
					</section>
					<section type="none" id="sidelem4x9009">
						<sec_title>EENT:</sec_title>
						<para> Uveitis, iritis, episcleritis</para>
					</section>
					<section type="none" id="sidelem4x9014">
						<sec_title>ENDO:</sec_title>
						<para> Severe and fatal immune-mediated endocrinopathies</para>
					</section>
					<section type="none" id="sidelem4x9019">
						<sec_title>GI:</sec_title>
						<para> Severe and fatal immune-mediated enterocolitis, hepatitis, pancreatitis, abdominal pain, nausea, diarrhea, appetite decreased, vomiting, constipation, colitis</para>
					</section>
					<section type="none" id="sidelem4x9024">
						<sec_title>INTEG:</sec_title>
						<para> Severe and fatal immune-mediated dermatitis pruritus, rash, urticaria</para>
					</section>
					<section type="none" id="sidelem4x9029">
						<sec_title>MISC:</sec_title>
						<para> Cough, dyspnea, anemia, eosinophilia, nephritis</para>
					</section>
					<section type="none" id="sidelem4x9034">
						<sec_title>SYST:</sec_title>
						<para> Antibody formation, Stevens-Johnson syndrome, toxic epidermal necrolysis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9039">
				<sec_title>Pharmacokinetics:</sec_title>
				<para>Steady-state by 3rd dose; terminal half-life 15.4 days</para>
			</section>
			<section type="considerations" id="sidelem4x9044">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9052">
					<label>•</label>
					<sec_title>Serious skin disorders<route> Stevens-Johnson syndrome, toxic epidermal necrolysis</route></sec_title>
				</section>
				<section type="none" id="sidelem4x9058">
					<label>•</label>
					<sec_title>Hepatotoxicity<route> LFTs baseline and before each dose to rule out infectious or malignant causes, increase the frequency of liver function test monitoring until resolution, permanently discontinue in patients with Grade 3-5 toxicity, give systemic corticosteroids at a dose of 1-2 mg/kg/day of predniSONE or equivalent</route></sec_title>
				</section>
				<section type="none" id="sidelem4x9064">
					<label>•</label>
					<sec_title>Neuropathy</sec_title>
					<para>
						<list id="lidelem4x9064">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Neuropathy:</emphasis> monitor for motor or sensory neuropathy (unilateral or bilateral weakness, sensory alterations, or paresthesias) before each dose; permanently discontinue if severe neuropathy (interfering with daily activities), such as Guillain-Barré–like syndromes, occur</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9071">
					<label>•</label>
					<sec_title>Endocrinopathy</sec_title>
					<para>
						<list id="lidelem4x9071">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Endocrinopathy:</emphasis> monitor thyroid function tests at baseline and before each dose; monitor hypophysitis, adrenal insufficiency, adrenal crisis, hypo/hyperthyroidism (fatigue, headache, mental status changes, abdominal pain, unusual bowel habits, hypotension, or nonspecific symptoms that may resemble other causes)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9075">
					<section type="none" id="sidelem4x9076">
						<sec_title>Evaluate:</sec_title>
						<para>Decreasing spread of malignant melanoma</para>
					</section>
					<section type="none" id="sidelem4x9081">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x9089">
							<label>•</label>
							<sec_title>
								<route>To immediately report allergic reactions, skin rash, severe abdominal pain, yellowing of skin or eyes, tingling of extremities, change in bowel habits</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x9092">
								<item>
									<label>•</label>
									<para>About the reason for treatment and expected results</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="8.1" status="active">
			<mono_name>ipratropium (Rx)</mono_name>
			<info>
				<pronunciation>(i-pra-troe′pee-um)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x91020">Atrovent HFA</tradename>
				</tradenames>
				<class type="func"> Anticholinergic, bronchodilator</class>
				<class type="chem"> Synthetic quaternary ammonium compound</class>
			</info>
			<section type="confusion" id="sidelem4x9112">
				<para>
					<confusion>
						<tradename id="tnidelem4x91120">Atrovent</tradename>
						<drug type="generic" refid="idelem4x91120">Alupent</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x9116">
				<sec_title>Action:</sec_title>
				<para>Inhibits interaction of acetylcholine at receptor sites on the bronchial smooth muscle, thereby resulting in decreased cGMP and bronchodilation</para>
			</section>
			<section type="uses" id="sidelem4x9122">
				<sec_title>Uses:</sec_title>
				<para>Bronchospasm, COPD; rhinorrhea (nasal spray)</para>
			</section>
			<section type="contra" id="sidelem4x9127">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, atropine, bromide, soybean or peanut products</para>
				<section type="none" id="sidelem4x9132">
					<section type="none" id="sidelem4x9133">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children &lt;12 yr, angioedema, heart failure, surgery, acute bronchospasm, bladder obstruction, closed-angle glaucoma, prostatic hypertrophy, urinary retention, pregnancy (B)</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9138">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9141">
					<section type="none" id="sidelem4x9142">
						<sec_title>Bronchospasm in chronic bronchitis/emphysema</sec_title>
						<section type="none" id="sidelem4x9150">
							<label>•</label>
							<sec_title>Adult<route> INH</route></sec_title>
							<para>
								<list id="lidelem4x9150">
									<item>
										<label>•</label>
										<para> 2 sprays (17 mcg/spray) 3-4×/day, max 12 /24 hr;  500 mcg (1 unit dose) given 3-4×/day by nebulizer; nasal spray: 2 sprays (42 mcg/spray) 3-4×/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9163">
							<label>•</label>
							<sec_title>Child 5-11 yr<route> INH</route></sec_title>
							<para>
								<list id="lidelem4x9163">
									<item>
										<label>•</label>
										<para> 4-8 inhalations q20min as needed for ≤3 hr (asthma, unlabeled);  250-500 mcg q20min as needed for ≤3 hr (asthma, unlabeled)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9170">
						<sec_title>Rhinorrhea perennial rhinitis</sec_title>
						<section type="none" id="sidelem4x9178">
							<label>•</label>
							<sec_title>Adult/child ≥6 yr<route> INTRANASAL</route></sec_title>
							<para>
								<list id="lidelem4x9178">
									<item>
										<label>•</label>
										<para> 2 sprays (43 mcg)/nostril bid or tid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9185">
							<label>•</label>
							<sec_title>Child 5-12 yr<route> INTRANASAL</route></sec_title>
							<para>
								<list id="lidelem4x9185">
									<item>
										<label>•</label>
										<para> 2 sprays (0.03%) in each nostril 3×/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9189">
						<sec_title>Available forms:</sec_title>
						<para> Aerosol 17 mcg/actuation; nasal spray 0.03%, 0.06%; sol for inh 0.0125% <country code="CAN">FIX_STRUCTURE Aerosol 17 mcg/actuation; nasal spray 0.03%, 0.06%; sol for inh 0.0125% </country>, 0.02%</para>
					</section>
					<section type="none" id="sidelem4x9197">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x9201">
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9207">
							<sec_title>Nebulizer route</sec_title>
							<para>
								<list id="lidelem4x9211">
									<item>
										<label>•</label>
										<para>Use sol in nebulizer with a mouthpiece rather than a face mask</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9217">
							<sec_title>Intranasal route</sec_title>
							<para>
								<list id="lidelem4x9221">
									<item>
										<label>•</label>
										<para>Priming pump initially requires 7 actuations of pump; priming again is not necessary if used regularly, tilt head backward after dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9227">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9230">
					<section type="none" id="sidelem4x9231">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Anxiety, dizziness, headache,</emphasis> nervousness</para>
					</section>
					<section type="none" id="sidelem4x9239">
						<sec_title>CV:</sec_title>
						<para> Palpitation</para>
					</section>
					<section type="none" id="sidelem4x9244">
						<sec_title>EENT:</sec_title>
						<para> Dry mouth, blurred vision, nasal congestion</para>
					</section>
					<section type="none" id="sidelem4x9249">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, cramps</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9256">
						<sec_title>INTEG:</sec_title>
						<para> Rash</para>
					</section>
					<section type="none" id="sidelem4x9261">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough, worsening of symptoms,</emphasis><emphasis style="bold">bronchospasms</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9270">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 2 hr, does not cross blood-brain barrier</para>
			</section>
			<section type="interactions" id="sidelem4x9275">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—other bronchodilators (INH)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticholinergic action—phenothiazines, antihistamines, disopyramide</para>
				<section type="none" id="sidelem4x9286">
					<section type="none" id="sidelem4x9287">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> anticholinergic effect—belladonna</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> bronchodilator effect—green tea (large amts), guarana</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9298">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9301">
					<section type="none" id="sidelem4x9302">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x9310">
							<label>•</label>
							<sec_title>
								<route>Palpitations;</route>
							</sec_title>
							<para>
								<list id="lidelem4x9310">
									<item>
										<label>•</label>
										<para> if severe, product may have to be changed</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9314">
								<item>
									<label>•</label>
									<para>Tolerance over long-term therapy; dose may have to be increased or changed</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9322">
							<label>•</label>
							<sec_title>
								<route>Atropine sensitivity;</route>
							</sec_title>
							<para>
								<list id="lidelem4x9322">
									<item>
										<label>•</label>
										<para> patient may also be sensitive to this product</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9329">
							<label>•</label>
							<sec_title>Respiratory status</sec_title>
							<para>
								<list id="lidelem4x9329">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Respiratory status:</emphasis> rate, rhythm, auscultate breath sounds before and after administration</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9333">
								<item>
									<label>•</label>
									<para>Hard candy, frequent drinks, sugarless gum to relieve dry mouth</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9338">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9342">
								<item>
									<label>•</label>
									<para>Therapeutic response: ability to breathe adequately</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9348">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9352">
								<item>
									<label>•</label>
									<para>That compliance is necessary with number of inhalations/24 hr or overdose may occur; about spacer device for geriatric patients; that max therapeutic effects may take 2-3 mo</para>
								</item>
								<item>
									<label>•</label>
									<para>To shake before using</para>
								</item>
								<item>
									<label>•</label>
									<para>About the correct method of inhalation; how to clean equipment daily</para>
								</item>
								<item>
									<label>•</label>
									<para>Patients should prime the inhaler before using for the first time by releasing 2 test sprays into the air, away from the face, rinse after use</para>
								</item>
								<item>
									<label>•</label>
									<para>Each inhaler has 200 actuations or sprays</para>
								</item>
								<item>
									<label>•</label>
									<para>Use spacer to improve drug use if required</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="9.1" status="active">
			<mono_name>irbesartan (Rx)</mono_name>
			<info>
				<pronunciation>(er-be-sar′tan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x93900">Avapro</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Angiotensin II receptor blocker (Type AT)</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg> <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x9403">
				<para>
					<confusion>
						<tradename id="tnidelem4x94030">Avapro</tradename>
						<drug type="generic" refid="idelem4x94030">Anaprox</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x9407">
				<sec_title>Action:</sec_title>
				<para>Blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II; selectively blocks the binding of angiotensin II to the AT<emphasis style="inf">1</emphasis> receptor found in tissues</para>
			</section>
			<section type="uses" id="sidelem4x9415">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, alone or in combination; nephropathy in type 2 diabetic patients; proteinuria</para>
				<section type="none" id="sidelem4x9420">
					<section type="none" id="sidelem4x9421">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Heart failure</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x9426">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<para>
					<bbw>Pregnancy (D) 2nd/3rd trimester</bbw>
				</para>
				<section type="none" id="sidelem4x9441">
					<section type="none" id="sidelem4x9442">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>) 1st trimester, breastfeeding, children &lt;6 yr, geriatric patients, hypersensitivity to ACE inhibitors; hepatic/renal disease; renal artery stenosis, African descent, angioedema</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9447">
				<sec_title>Dosages and routes</sec_title>
				<section type="none" id="sidelem4x9450">
					<section type="none" id="sidelem4x9451">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x9459">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9459">
									<item>
										<label>•</label>
										<para> 150 mg/day; may be increased to 300 mg/day, volume-depleted patients: start with 75 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9463">
						<sec_title>Nephropathy in type 2 diabetic patients</sec_title>
						<section type="none" id="sidelem4x9471">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9471">
									<item>
										<label>•</label>
										<para> maintenance dose 300 mg/day, start 75 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9475">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 75, 150, 300 mg</para>
					</section>
					<section type="none" id="sidelem4x9480">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x9484">
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>May be used with other antihypertensives, diuretic</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9495">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9498">
					<section type="none" id="sidelem4x9499">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness,</emphasis> anxiety, <emphasis style="italic">headache, fatigue,</emphasis> syncope</para>
					</section>
					<section type="none" id="sidelem4x9510">
						<sec_title>CV:</sec_title>
						<para> Hypotension</para>
					</section>
					<section type="none" id="sidelem4x9515">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, dyspepsia,</emphasis> hepatitis, cholestasis</para>
					</section>
					<section type="none" id="sidelem4x9523">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9530">
						<sec_title>MISC:</sec_title>
						<para> Edema, chest pain, rash, tachycardia, UTI, <emphasis style="bold">angioedema,</emphasis> hyperkalemia</para>
					</section>
					<section type="none" id="sidelem4x9538">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough, upper respiratory tract infection,</emphasis> sinus disorder, pharyngitis, rhinitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9546">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1.5-2 hr, extensively metabolized by CYP2C9, half-life 11-15 hr, highly bound to plasma proteins, excreted in urine and feces, protein binding 90%</para>
			</section>
			<section type="interactions" id="sidelem4x9551">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia: potassium-sparing diuretics, potassium salt substitutes, ACE inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> irbesartan level—CYP2C9 inhibitors (amiodarone, delavirdine, fluconazole, FLUoxetine, fluvastatin, fluvoxaMINE, imatinib, sulfonamides, sulfinpyrazone, voriconazole, zafirlukast)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—NSAIDs</para>
				<section type="none" id="sidelem4x9566">
					<section type="none" id="sidelem4x9567">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—black cohosh, goldenseal, hawthorn, kelp</para>
						<para>
							<emphasis style="bold">Increase or decrease:</emphasis> antihypertensive effect—astragalus, cola tree</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—guarana, khat, licorice, yohimbe</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9583">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9586">
					<section type="none" id="sidelem4x9587">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x9595">
							<label>•</label>
							<sec_title>Hypotension</sec_title>
							<para>
								<list id="lidelem4x9595">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypotension:</emphasis> for severe hypotension, place in supine position and give IV infusion of NS, drug may be continued after B/P is restored</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9599">
								<item>
									<label>•</label>
									<para>B/P, pulse q4hr; note rate, rhythm, quality</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9604">
								<item>
									<label>•</label>
									<para>Baselines of renal/hepatic studies before therapy begins; periodically monitor LFTs, total/direct bilirubin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9609">
								<item>
									<label>•</label>
									<para>Skin turgor, dryness of mucous membranes for hydration status; edema in feet, legs daily</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9614">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9618">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9624">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9628">
								<item>
									<label>•</label>
									<para>To comply with dosage schedule, even if feeling better; that max therapeutic effects may take 2-3 mo, to take without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>That product may cause dizziness, fainting, light-headedness</para>
								</item>
								<item>
									<label>•</label>
									<para>To rise slowly to sitting or standing position to minimize orthostatic hypotension</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not stop product abruptly
<bbw>To notify prescriber if pregnancy is suspected; discontinue if pregnant; pregnancy (D) 2nd/3rd trimester, (C) 1st trimester</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="10.1" status="active" ha="yes">
			<mono_name> irinotecan (Rx)</mono_name>
			<info>
				<pronunciation>(ear-een-oh-tee′kan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x96650">Camptosar</tradename>
				</tradenames>
				<class type="func"> Antineoplastic</class>
				<class type="chem"> Camptothecin analog</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x9675">
				<sec_title>Action:</sec_title>
				<para>Cytotoxic by producing damage to single-strand DNA during DNA synthesis; binds to topoisomerase I</para>
			</section>
			<section type="uses" id="sidelem4x9680">
				<sec_title>Uses:</sec_title>
				<para>Metastatic carcinoma of the colon or rectum or 1st-line treatment in combination with 5-FU and leucovorin for metastatic colon or rectal carcinomas</para>
				<section type="none" id="sidelem4x9685">
					<section type="none" id="sidelem4x9686">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Cervical, gastric, lung, ovarian, pancreatic cancer, malignant glioma, rhabdomyosarcoma</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x9691">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity</para>
				<section type="none" id="sidelem4x9696">
					<section type="none" id="sidelem4x9697">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, geriatric patients, irradiation, hepatic disease</para>
						<para>
							<bbw>Myelosuppression, diarrhea</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9712">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9715">
					<section type="none" id="sidelem4x9716">
						<sec_title>First-line treatment of colorectal cancer in combination with 5-fluorouracil (5-FU):</sec_title>
						<section type="none" id="sidelem4x9719">
							<sec_title>Intravenous dosage (with bolus 5-FU/leucovorin)</sec_title>
							<section type="none" id="sidelem4x9727">
								<label>•</label>
								<sec_title>Adult<route> IV</route></sec_title>
								<para>
									<list id="lidelem4x9727">
										<item>
											<label>•</label>
											<para> 125 mg/m<emphasis style="sup">2</emphasis> over 90 min followed by leucovorin 20 mg/m<emphasis style="sup">2</emphasis> IV bolus and then 5-FU 500 mg/m<emphasis style="sup">2</emphasis> IV bolus on days 1, 8, 15, and 22; the next course begins on day 43 or when toxicity has recovered to NCI grade 1 or less</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x9740">
							<sec_title>Intravenous dosage (with infusional 5-FU/leucovorin)</sec_title>
							<section type="none" id="sidelem4x9748">
								<label>•</label>
								<sec_title>Adult<route> IV</route></sec_title>
								<para>
									<list id="lidelem4x9748">
										<item>
											<label>•</label>
											<para> 180 mg/m<emphasis style="sup">2</emphasis> over 90 min followed by leucovorin 200 mg/m<emphasis style="sup">2</emphasis> IV over 2 hr, then 5-FU bolus and continuous infusion 400 mg/m<emphasis style="sup">2</emphasis> IV bolus, then 600 mg/m<emphasis style="sup">2</emphasis> IV infusion over 22 hr on days 1, 15, and leucovorin and 5-FU are given on days 1, 2, 15, 16, 29, and 30; the next course begins on day 43 or when toxicity has recovered to NCI grade 1 or less</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
					<section type="none" id="sidelem4x9764">
						<sec_title>Available forms:</sec_title>
						<para> Inj 20 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x9769">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x9773">
								<item>
									<label>•</label>
									<para>Use cytotoxic handling precautions</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9779">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x9784">
									<item>
										<label>•</label>
										<para>Premedicate with antiemetic dexamethasone plus another antiemetic agent, such as a 5-HT<emphasis style="inf">3</emphasis> blocker, given at least 30 min before use</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x9796">
								<label>•</label>
								<sec_title>
									<route>Before beginning a course of therapy, the granulocyte count should be ≥1500, the platelet count should be ≥100,000, and treatment-related diarrhea should be fully resolved</route>
								</sec_title>
							</section>
						</section>
						<section type="none" id="sidelem4x9799">
							<sec_title>Dilution</sec_title>
							<para>
								<list id="lidelem4x9803">
									<item>
										<label>•</label>
										<para>Dilute appropriate dose in D<emphasis style="inf">5</emphasis>W (preferred) or NS injection to a final concentration of 0.12-2.8 mg/ml</para>
									</item>
									<item>
										<label>•</label>
										<para>Store up to 24 hr at room temperature and room lighting; however, because of possible microbial contamination during preparation, an admixture prepared with D<emphasis style="inf">5</emphasis>W or NS should be used within 6 hr, solutions prepared with D<emphasis style="inf">5</emphasis>W, refrigerated, protected from light must be used within 48 hr; avoid refrigeration if prepared with NS</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9823">
							<sec_title>Intravenous infusion</sec_title>
							<para>
								<list id="lidelem4x9827">
									<item>
										<label>•</label>
										<para>Infuse intravenously over 90 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9833">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9836">
					<section type="none" id="sidelem4x9837">
						<sec_title>CNS:</sec_title>
						<para> Fever, headache, chills, dizziness</para>
					</section>
					<section type="none" id="sidelem4x9842">
						<sec_title>CV:</sec_title>
						<para> Vasodilation, edema, <emphasis style="bold">thromboembolism</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9849">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="bold">Severe diarrhea,</emphasis><emphasis style="italic">nausea, vomiting,</emphasis> anorexia, constipation, cramps, flatus, stomatitis, dyspepsia, <emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9861">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, anemia, neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9868">
						<sec_title>INTEG:</sec_title>
						<para> Irritation at site, rash, sweating, alopecia</para>
					</section>
					<section type="none" id="sidelem4x9873">
						<sec_title>MISC:</sec_title>
						<para> Edema, asthenia, weight loss, back pain</para>
					</section>
					<section type="none" id="sidelem4x9878">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, increased cough, rhinitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9883">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly and completely absorbed, excreted in urine and bile as metabolites, half-life 6-12 hr, bound to plasma proteins 30%-68%, increased risk for toxicity in patients homozygous for UGT1A1 28</para>
			</section>
			<section type="interactions" id="sidelem4x9888">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—fluorouracil</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—NSAIDs, anticoagulants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> irinotecan levels—some CYP3A4 inhibitors (ketoconazole)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myelosuppression, diarrhea—other antineoplastics, radiation</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> lymphocytopenia, hyperglycemia—dexamethasone</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> akathisia—prochlorperazine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> dehydration—diuretics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> irinotecan levels—CYP3A4 inducers (phenytoin, carBAMazepine, PHENobarbital)</para>
				<section type="none" id="sidelem4x9922">
					<section type="none" id="sidelem4x9923">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis alert="lifethreat">Decrease: product level—St. John’s wort; avoid concurrent use</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x9929">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> alk phos, LFTs, bilirubin</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> platelets, WBC, neutrophils, Hgb/HcT</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9940">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9943">
					<section type="none" id="sidelem4x9944">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x9948">
								<item>
									<label>•</label>
									<para>CNS symptoms: fever, headache, chills, dizziness
<bbw>CBC, differential, platelet count weekly; use colony-stimulating factor if WBC &lt;2000/mm3 or platelet count &lt;100,000/mm3, Hgb ≤9 g/dl, neutrophil ≤1000/mm3; notify prescriber of results; product should be discontinued</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>Buccal cavity for dryness, sores or ulceration, white patches, oral pain, bleeding, dysphagia
<bbw>GI symptoms: frequency of stools; cramping; severe, life-threatening diarrhea may occur with fluid and electrolyte imbalances, treat diarrhea within 24 hr of use with 0.25-1 mg atropine IV; treat diarrhea &gt;24 hr of use with loperamide, diarrhea &gt;24 hr (late diarrhea) can be fatal</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>Signs of dehydration: rapid respirations, poor skin turgor, decreased urine output, dry skin, restlessness, weakness</para>
								</item>
								<item>
									<label>•</label>
									<para>Bone marrow depression: bruising, bleeding, blood in stools, urine, sputum, emesis</para>
								</item>
								<item>
									<label>•</label>
									<para>Increased fluid intake to 2-3 L/day to prevent dehydration unless contraindicated</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10001">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10005">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in tumor size, spread of cancer</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10012">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10017">
								<item>
									<label>•</label>
									<para>To avoid foods with citric acid or hot or rough texture if stomatitis is present; to drink adequate fluids</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10022">
								<item>
									<label>•</label>
									<para>To report stomatitis; any bleeding, white spots, ulcerations in mouth; to examine mouth daily, report symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10027">
								<item>
									<label>•</label>
									<para>To report signs of anemia: fatigue, headache, faintness, SOB, irritability, infection, rash</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10032">
								<item>
									<label>•</label>
									<para>To use contraception during therapy</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10040">
							<label>•</label>
							<sec_title>
								<route>To report if pregnancy is planned or suspected pregnancy (D)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x10043">
								<item>
									<label>•</label>
									<para>To avoid salicylates, NSAIDs, alcohol because bleeding may occur; to avoid all products unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10048">
								<item>
									<label>•</label>
									<para>About alopecia; that, when hair grows back, it will be different texture, thickness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10053">
								<item>
									<label>•</label>
									<para>To avoid vaccinations while taking this product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10059">
								<item>
									<para>
										<emphasis alert="nurse">To report diarrhea that occurs 24 hr after administration; severe dehydration can occur rapidly</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="11.1" status="active">
			<mono_name>iron dextran (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x100672">DexFerrum</tradename>
					<tradename id="tnidelem4x100671">INFeD</tradename>
					<tradename id="tnidelem4x100670">Velphoro</tradename>
				</tradenames>
				<class type="func"> Hematinic</class>
				<class type="chem"> Ferric hydroxide complex with dextran</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x10077">
				<sec_title>Action:</sec_title>
				<para>Iron is carried by transferrin to the bone marrow, where it is incorporated into hemoglobin</para>
			</section>
			<section type="uses" id="sidelem4x10082">
				<sec_title>Uses:</sec_title>
				<para>Iron-deficiency anemia</para>
			</section>
			<section type="contra" id="sidelem4x10087">
				<sec_title>Contraindications:</sec_title>
				<para>
					<bbw>Hypersensitivity</bbw>
				</para>
				<section type="none" id="sidelem4x10100">
					<section type="none" id="sidelem4x10101">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, neonates, infants &lt;4 mo, children, acute renal disease, asthma, rheumatoid arthritis (IV), ankylosing spondylitis, lupus, hypotension, all anemias excluding iron-deficiency anemia, hepatic/cardiac/renal disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10106">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10114">
					<label>•</label>
					<sec_title>Adult and child<route> IM 0.5 ml as a test dose by Z-track, then no more than the following total dose including test dose per day</route></sec_title>
				</section>
				<section type="none" id="sidelem4x10122">
					<label>•</label>
					<sec_title>Adult/adolescent/child (&gt;15 kg)</sec_title>
					<para>
						<list id="lidelem4x10122">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Adult/adolescent/child (&gt;15 kg):</emphasis> Total iron dextran dose in ml = [0.0442 × (Desired Hb − observed Hb) × LBW] + (0.26 × LBW), max of undiluted is 100 mg (2 ml)/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10129">
					<label>•</label>
					<sec_title>Child (10-15 kg)</sec_title>
					<para>
						<list id="lidelem4x10129">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Child (10-15 kg):</emphasis> Total iron dextran dose in ml = [0.0442 × (Desired Hb − observed Hb) × LBW] + (0.26 × ABW), max of undiluted iron dextran is 100 mg (2 ml)/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10136">
					<label>•</label>
					<sec_title>Child/Infant &gt;4 mo (5-9.9 kg)</sec_title>
					<para>
						<list id="lidelem4x10136">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Child/Infant &gt;4 mo (5-9.9 kg):</emphasis> Total iron dextran dose in ml = [0.0442 × (Desired Hb − observed Hb) × LBW] + (0.26 × ABW)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10143">
					<label>•</label>
					<sec_title>Infants &gt;4 mo (&lt;5 kg)</sec_title>
					<para>
						<list id="lidelem4x10143">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Infants &gt;4 mo (&lt;5 kg):</emphasis> Total iron dextran dose in ml = [0.0442 × (Desired Hb − observed Hb) × LBW] + (0.26 × ABW)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10147">
					<section type="none" id="sidelem4x10148">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x10152">
								<item>
									<label>•</label>
									<para>D/C oral iron before parenteral; give only after test dose of 25 mg by preferred route; wait at least 1 hr before giving remaining portion</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature in cool environment</para>
								</item>
								<item>
									<label>•</label>
									<para>Recumbent position 30 min after IV inj to prevent orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10168">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x10173">
									<item>
										<label>•</label>
										<para>IM deeply in large muscle mass; use <emphasis style="sans-serif">Z</emphasis>-track method, 19- to 20-G 2- to 3-in needle; ensure needle long enough to place product deep in muscle; change needles after withdrawing product and before injecting to prevent skin, tissue staining</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x10182">
									<item>
										<para>
											<emphasis alert="nurse">Only with EPINEPHrine available in case of anaphylactic reaction during dose</emphasis>
										</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10187">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x10191">
									<item>
										<label>•</label>
										<para>IV after flushing with 10 ml 0.9% NaCl; give undiluted; may be diluted in 50-250 ml NS for infusion; give ≤1 ml (50 mg) over ≥1 min; flush line after use with 10 ml 0.9% NaCl; patient should remain recumbent for <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr</para>
									</item>
									<item>
										<label>•</label>
										<para>IV inj requires single-dose vial without preservative; verify on label that IV use approved</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10209">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10212">
					<section type="none" id="sidelem4x10213">
						<sec_title>CNS:</sec_title>
						<para> Headache, paresthesia, dizziness, shivering, weakness, <emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10220">
						<sec_title>CV:</sec_title>
						<para> Chest pain, <emphasis style="bold">shock,</emphasis> hypotension, tachycardia</para>
					</section>
					<section type="none" id="sidelem4x10228">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, metallic taste, abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x10236">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukocytosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10243">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, urticaria, fever, sweating, chills, brown skin discoloration, pain at inj site, necrosis, sterile abscesses, phlebitis</para>
					</section>
					<section type="none" id="sidelem4x10248">
						<sec_title>OTHER:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10255">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10260">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x10263">
					<section type="none" id="sidelem4x10264">
						<sec_title>IM:</sec_title>
						<para> Excreted in feces, urine, bile, breast milk; crosses placenta; most absorbed through lymphatics; can be gradually absorbed over weeks/months from fixed locations</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x10269">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—oral iron; do not use</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> reticulocyte response—chloramphenicol</para>
				<section type="none" id="sidelem4x10280">
					<section type="none" id="sidelem4x10281">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False increase:</emphasis> serum bilirubin</para>
						<para>
							<emphasis style="bold">False decrease:</emphasis> serum calcium</para>
						<para>
							<emphasis style="bold">False positive:</emphasis>
							<emphasis style="sup">99m</emphasis>Tc diphosphate bone scan, iron test (large doses &gt;2 ml)</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10298">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10301">
					<section type="none" id="sidelem4x10302">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x10307">
								<item>
									<label>•</label>
									<para>Observe for 1 hr after test dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10312">
								<item>
									<label>•</label>
									<para>Blood studies: Hct, Hgb, reticulocytes, transferrin, plasma iron concentrations, ferritin, total iron binding, bilirubin before treatment, at least monthly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10317">
								<item>
									<para>
<bbw>Allergy: anaphylaxis, rash, pruritus, fever, chills, wheezing; notify prescriber immediately, keep emergency equipment available</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10328">
								<item>
									<label>•</label>
									<para>Cardiac status: anginal pain, hypotension, tachycardia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10333">
								<item>
									<label>•</label>
									<para>Nutrition: amount of iron in diet (meat, dark green leafy vegetables, dried beans, dried fruits, eggs)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10338">
								<item>
									<label>•</label>
									<para>Cause of iron loss or anemia, including use of salicylates, sulfonamides</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10346">
							<label>•</label>
							<sec_title>Toxicity<route> nausea, vomiting, diarrhea, fever, abdominal pain (early symptoms), cyanotic-looking lips, nailbeds, seizures, CV collapse (late symptoms)</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x10349">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased serum iron levels, Hct, Hgb</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10354">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10358">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased serum iron level, increased Hgb, Hct</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10364">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x10372">
							<label>•</label>
							<sec_title>
								<route>That iron poisoning may occur if increased beyond recommended level; not to take oral iron preparation or vitamins containing iron</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x10378">
							<label>•</label>
							<sec_title>
								<route>That delayed reaction may occur 1-2 days after administration and last 3-4 days (IV), 3-7 days (IM); to report fever, chills, malaise, muscle, joint aches, nausea, vomiting, backache</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x10384">
							<label>•</label>
							<sec_title>
								<route>To avoid breastfeeding</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x10387">
								<item>
									<label>•</label>
									<para>That stools may become dark</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x10392">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Discontinue product, treat allergic reaction, give diphenhydrAMINE or EPINEPHrine as needed, give iron-chelating product for acute poisoning</para>
			</section>
		</monograph>
<monograph id="12.1" status="active">
			<mono_name>iron sucrose (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x104000">Venofer</tradename>
				</tradenames>
				<class type="func"> Hematinic</class>
				<class type="chem"> Ferric hydroxide complex with dextran</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x10410">
				<sec_title>Action:</sec_title>
				<para>Iron is carried by transferrin to the bone marrow, where it is incorporated into hemoglobin</para>
			</section>
			<section type="uses" id="sidelem4x10415">
				<sec_title>Uses:</sec_title>
				<para>Iron-deficiency anemia, hyperphosphatemia in chronic kidney disease on dialysis</para>
				<section type="none" id="sidelem4x10420">
					<section type="none" id="sidelem4x10421">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Dystrophic epidermolysis bullosa (DEB)</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x10426">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, all anemias excluding iron-deficiency anemia, iron overload</para>
				<section type="none" id="sidelem4x10432">
					<section type="none" id="sidelem4x10433">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, abdominal pain, anaphylactic shock, arthralgia, chest pain, cough, diarrhea, dizziness, dyspnea, edema, increased LFTs, fever, headache, heart failure, hypo/hypertension, infection, MS pain nausea/vomiting, seizures, weakness</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10438">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10446">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x10446">
							<item>
								<label>•</label>
								<para> 5 ml (100 mg of elemental iron) given during dialysis; most will need 1000 mg of elemental iron over 10 sequential dialysis sessions</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10453">
					<label>•</label>
					<sec_title>Child ≥2 yr/adolescents<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x10453">
							<item>
								<label>•</label>
								<para> 0.5 mg/kg by slow IV inj over 5 min (undiluted) or diluted in 25 ml of 0.9% NaCl, give over 5-60 min, max 100 mg every 2 wk × 12 wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10457">
					<section type="none" id="sidelem4x10458">
						<sec_title>Hyperphosphatemia in chronic kidney disease</sec_title>
						<para>
							<list id="lidelem4x10462">
								<item>
									<label>•</label>
									<para>Adult: PO 500 mg tid</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10468">
						<sec_title>Available forms:</sec_title>
						<para> Inj 20 mg/ml; chew tab 500 mg</para>
					</section>
					<section type="none" id="sidelem4x10473">
						<sec_title>Administer:</sec_title>
						<para>
							<emphasis alert="nurse">Only with EPINEPHrine, Solu-MEDROL available in case of anaphylactic reaction during dose</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x10481">
						<sec_title>IV route</sec_title>
						<para>
							<list id="lidelem4x10485">
								<item>
									<label>•</label>
									<para>Do not use if particulate is present or if discolored</para>
								</item>
								<item>
									<label>•</label>
									<para>Give directly in dialysis line by slow inj or infusion; give by slow inj at 1 ml/min (5 min/vial); infusion dilute each vial exclusively in ≤100 ml 0.9% NaCl, give at 100 mg of iron/15 min; discard unused portions</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not use with IV products</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature in cool environment; do not freeze</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10506">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10509">
					<section type="none" id="sidelem4x10510">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness</para>
					</section>
					<section type="none" id="sidelem4x10515">
						<sec_title>CV:</sec_title>
						<para> Chest pain, hypo/hypertension, hypervolemia, <emphasis style="bold">heart failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10522">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, abdominal pain</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10529">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, urticaria, fever, sweating, chills</para>
					</section>
					<section type="none" id="sidelem4x10534">
						<sec_title>OTHER:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis,</emphasis> hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x10542">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, pneumonia, cough</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10547">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Excreted in urine, half-life 6 hr</para>
			</section>
			<section type="interactions" id="sidelem4x10552">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—oral iron, dimercaprol, do not use</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> iron sucrose effect—chloramphenicol</para>
				<section type="none" id="sidelem4x10563">
					<section type="none" id="sidelem4x10564">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> glucose</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10571">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10574">
					<section type="none" id="sidelem4x10575">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x10580">
								<item>
									<label>•</label>
									<para>Blood studies: Hct, Hgb, reticulocytes, transferrin, plasma iron concentrations, ferritin, total iron binding; bilirubin before treatment, at least monthly</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10588">
							<label>•</label>
							<sec_title>Allergy, anaphylaxis<route> rash, pruritus, fever, chills, wheezing; notify prescriber immediately, keep emergency equipment available</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x10591">
								<item>
									<label>•</label>
									<para>Cardiac status: hypo/hypertension, hypervolemia</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10599">
							<label>•</label>
							<sec_title>Toxicity<route> nausea, vomiting, diarrhea, fever, abdominal pain (early symptoms), cyanotic-looking lips, nailbeds, seizures, CV collapse (late symptoms)</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x10602">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10606">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased serum iron levels, Hct, Hgb</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10612">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x10620">
							<label>•</label>
							<sec_title>
								<route>To report itching, rash, chest pain, headache, vertigo, nausea, vomiting, abdominal pain, joint/muscle pain, numbness, tingling</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x10626">
							<label>•</label>
							<sec_title>
								<route>That iron poisoning may occur if dosage increased beyond recommended level; not to take oral iron preparation</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x10629">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Discontinue product, treat allergic reaction, give diphenhydrAMINE or EPINEPHrine as needed, give iron-chelating product for acute poisoning</para>
			</section>
		</monograph>
<monograph id="13.1" status="active">
			<mono_name>isoniazid (Rx)</mono_name>
			<info>
				<pronunciation>(eye-soe-nye′a-zid)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x106390">
						<country code="CAN">Isotamine </country>
					</tradename>
				</tradenames>
				<class type="func"> Antitubercular</class>
				<class type="chem"> Isonicotinic acid hydrazide</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x10651">
				<sec_title>Action:</sec_title>
				<para>Bactericidal interference with lipid, nucleic acid biosynthesis</para>
			</section>
			<section type="uses" id="sidelem4x10657">
				<sec_title>Uses:</sec_title>
				<para>Treatment, prevention of TB</para>
			</section>
			<section type="contra" id="sidelem4x10662">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<para>
					<bbw>Acute hepatic disease</bbw>
				</para>
				<section type="none" id="sidelem4x10677">
					<section type="none" id="sidelem4x10678">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), renal disease, diabetic retinopathy, cataracts, ocular defects, IV drug users, &gt;35 yr, postpartum, HIV, neuropathy</para>
						<para>
							<bbw>Alcoholism, females (African descent/Hispanic patients)</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10693">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10701">
					<label>•</label>
					<sec_title>Adult/adolescent with/without HIV<route> PO/IM</route></sec_title>
					<para>
						<list id="lidelem4x10701">
							<item>
								<label>•</label>
								<para> 5 mg/kg/day ≤300 mg/day or 15 mg/kg 2-3×/wk, max 900 mg 2-3×/wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10708">
					<label>•</label>
					<sec_title>Child/infant with HIV<route> PO/IM</route></sec_title>
					<para>
						<list id="lidelem4x10708">
							<item>
								<label>•</label>
								<para> 10-15 mg/kg/day, max 300 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10712">
					<section type="none" id="sidelem4x10713">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 100, 300 mg; inj 100 mg/ml; oral sol 10 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x10718">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x10721">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x10725">
									<item>
										<label>•</label>
										<para>PO with meals to decrease GI symptoms; better to take on empty stomach 1 hr before or 2 hr after meals</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10731">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x10735">
									<item>
										<label>•</label>
										<para>IM deep in large muscle mass; massage; rotate injection site; warm inj to room temperature to dissolve crystals</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10741">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10744">
					<section type="none" id="sidelem4x10745">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Peripheral neuropathy, dizziness,</emphasis> memory impairment, <emphasis style="bold">toxic encephalopathy, seizures,</emphasis> psychosis, slurred speech</para>
					</section>
					<section type="none" id="sidelem4x10756">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, optic neuritis</para>
					</section>
					<section type="none" id="sidelem4x10761">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> epigastric distress, <emphasis style="bold">jaundice, fatal hepatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10771">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, hemolytic, aplastic anemia, thrombocytopenia, eosinophilia, methemoglobinemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10778">
						<sec_title>Hypersensitivity:</sec_title>
						<para> Fever, skin eruptions, lymphadenopathy, vasculitis</para>
					</section>
					<section type="none" id="sidelem4x10783">
						<sec_title>MISC:</sec_title>
						<para> Dyspnea, B<emphasis style="inf">6</emphasis> deficiency, pellagra, hyperglycemia, metabolic acidosis, gynecomastia, rheumatic syndrome, SLE-like syndrome</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10791">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver, excreted in urine (metabolites), crosses placenta, excreted in breast milk, half life 1-4 hr</para>
				<section type="none" id="sidelem4x10796">
					<section type="none" id="sidelem4x10797">
						<sec_title>PO:</sec_title>
						<para> Peak 1-2 hr</para>
					</section>
					<section type="none" id="sidelem4x10802">
						<sec_title>IM:</sec_title>
						<para> Peak 45-60 min</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x10807">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—tyramine foods, alcohol, cycloSERINE, ethionamide, rifampin, carBAMazepine, phenytoin, benzodiazepines, meperidine</para>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome—SSRIs, SNRIs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption—aluminum antacids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effectiveness of BCG vaccine, ketoconazole</para>
				<section type="none" id="sidelem4x10825">
					<section type="none" id="sidelem4x10826">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x10830">
								<item>
									<label>•</label>
									<para>Do not give with high-tyramine foods, alcohol</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10836">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, bilirubin, glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> platelets granulocytes</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10847">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10850">
					<section type="none" id="sidelem4x10851">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Hepatic studies weekly: baseline in all patients, those &gt;35 yr and all women should be monitored periodically; ALT, AST, bilirubin; increased test results may indicate hepatitis; hepatic status: decreased appetite, jaundice, dark urine, fatigue, those with fast acetylation (genetic) may metabolize product more than 5 times faster (black, Asian patients are at greater risk) some Caucasian patients; fatal hepatitis is at greater risk in black/Hispanic patients after birth•Mental status often: affect, mood, behavioral changes; psychosis may occur•Paresthesia in hands, feet</bbw>
						</para>
					</section>
					<section type="none" id="sidelem4x10875">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10879">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of TB</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10886">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10891">
								<item>
									<label>•</label>
									<para>That compliance with dosage schedule, duration is necessary; not to skip or double dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10896">
								<item>
									<label>•</label>
									<para>That scheduled appointments must be kept or relapse may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10902">
								<item>
									<para>
										<emphasis alert="nurse">To avoid alcohol while taking product; may increase risk for hepatic injury</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10907">
								<item>
									<label>•</label>
									<para>That, if diabetic, to use blood glucose monitor to obtain correct result</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10913">
								<item>
									<para>
										<emphasis alert="nurse">To report weakness, fatigue, loss of appetite, nausea, vomiting, jaundice of skin or eyes, tingling/numbness of hands/feet</emphasis>
<bbw>
											<emphasis alert="lifethreat">Fatal hepatitis:</emphasis> to notify prescriber immediately of yellow skin/eyes, dark urine, loss of appetite</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="14.1" status="active">
			<mono_name>isosorbide dinitrate (Rx)</mono_name>
			<info>
				<pronunciation>(eye-soe-sor′bide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x109344">
						<country code="CAN">Apo-ISDN </country>
					</tradename>
					<tradename id="tnidelem4x109343">Dilatrate-SR</tradename>
					<tradename id="tnidelem4x109342">Isochron</tradename>
					<tradename id="tnidelem4x109341">IsoDitrate</tradename>
					<tradename id="tnidelem4x109340">Isordil</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="15.1" status="active">
			<mono_name>isosorbide mononitrate (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x109421">
						<country code="CAN">Apo-ISMN </country>
					</tradename>
					<tradename id="tnidelem4x109420">Imdur</tradename>
				</tradenames>
				<class type="func"> Antianginal, vasodilator</class>
				<class type="chem"> Nitrate</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x10955">
				<para>
					<confusion>
						<tradename id="tnidelem4x109550">Imdur</tradename>
						<drug type="generic" refid="idelem4x109550">Imuran/Inderal/K-Dur</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x10959">
				<sec_title>Action:</sec_title>
				<para>Relaxation of vascular smooth muscle, which leads to decreased preload, afterload, which is responsible for decreasing left ventricular end-diastolic pressure, systemic vascular resistance, and reducing cardiac oxygen demand</para>
			</section>
			<section type="uses" id="sidelem4x10964">
				<sec_title>Uses:</sec_title>
				<para>Treatment, prevention of chronic stable angina pectoris</para>
				<section type="none" id="sidelem4x10969">
					<section type="none" id="sidelem4x10970">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Diffuse esophageal spasm, heart failure (dinitrate)</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x10975">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or nitrates; severe anemia, closed-angle glaucoma</para>
				<section type="none" id="sidelem4x10980">
					<section type="none" id="sidelem4x10981">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, orthostatic hypotension, MI, CHF, severe renal/hepatic disease, increased intracranial pressure, cerebral hemorrhage, acute MI, geriatric patients, GI disease, syncope</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10986">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10989">
					<sec_title>Dinitrate</sec_title>
					<section type="none" id="sidelem4x10997">
						<label>•</label>
						<sec_title>Adult<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x10997">
								<item>
									<label>•</label>
									<para> 5-20 mg bid-tid initially, maintenance 10-40 mg bid-tid;  buccal 2.5-5 mg, may repeat q5-10min × 3 doses;  40-80 mg q8-12hr, max 160 mg/day</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x11007">
					<sec_title>Mononitrate</sec_title>
					<section type="none" id="sidelem4x11015">
						<label>•</label>
						<sec_title>Adult<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x11015">
								<item>
									<label>•</label>
									<para> (Monoket) 10-20 mg bid, 7 hr apart; (Imdur) initiate at 30-60 mg/day as a single dose, increase q3days as needed, may increase to 120 mg/day, max 240 mg/day</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11019">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="italic">Dinitrate:</emphasis> sus rel caps (SR) 40 mg, SR tabs 40 mg; tabs 5, 10, 20, 30, 40 mg; SL tabs 2.5, 5 mg; <emphasis style="italic">mononitrate:</emphasis> tabs (Monoket) 10, 20 mg; ext rel (Imdur) 30, 60, 120 mg</para>
					</section>
					<section type="none" id="sidelem4x11030">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x11035">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew sus rel caps, SL tabs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11040">
								<item>
									<label>•</label>
									<para>After checking expiration date</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11045">
								<item>
									<label>•</label>
									<para>PO with 8 oz water on empty stomach</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11050">
								<item>
									<label>•</label>
									<para>SL tabs should be placed under the tongue until dissolved; avoid smoking, eating, drinking until dissolved</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11058">
							<label>•</label>
							<sec_title>SUS REL cap/tab</sec_title>
							<para>
								<list id="lidelem4x11058">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">SUS REL cap/tab:</emphasis> allow dosing interval &gt;18 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11062">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11065">
					<section type="none" id="sidelem4x11066">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Vascular headache, flushing, dizziness,</emphasis> weakness</para>
					</section>
					<section type="none" id="sidelem4x11074">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension,</emphasis> tachycardia, <emphasis style="bold">collapse,</emphasis> syncope</para>
					</section>
					<section type="none" id="sidelem4x11085">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x11090">
						<sec_title>INTEG:</sec_title>
						<para> Pallor, sweating, rash</para>
					</section>
					<section type="none" id="sidelem4x11095">
						<sec_title>MISC:</sec_title>
						<para> Twitching, <emphasis style="bold">hemolytic anemia, methemoglobinemia,</emphasis> tolerance, xerostomia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11103">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x11106">
					<section type="none" id="sidelem4x11107">
						<sec_title>Dinitrate</sec_title>
						<para>Metabolized by liver, excreted in urine as metabolites (80%-100%)</para>
						<para>
							<emphasis style="bold">PO:</emphasis> Onset 15-30 min, duration 4-6 hr, half-life 5-6 hr</para>
						<para>
							<emphasis style="bold">SUS REL:</emphasis> Onset ≤4 hr, duration 6-8 hr</para>
						<para>
							<emphasis style="bold">SL:</emphasis> Onset 2-5 min, duration 1-4 hr, half-life 2 hr</para>
					</section>
					<section type="none" id="sidelem4x11125">
						<sec_title>Mononitrate</sec_title>
						<para>
							<emphasis style="bold">SUS REL:</emphasis> Onset 30-60 min, peak 1-4 hr, duration 6-8 hr, half-life 5 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x11132">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Fatal hypotension: sildenafil, tadalafil, vardenafil, do not use together</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—β-blockers, diuretics, antihypertensives, alcohol, calcium channel blockers, phenothiazines</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> heart rate, B/P—sympathomimetics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myocardial ischemia—rosiglitazone; avoid concurrent use</para>
			</section>
			<section type="considerations" id="sidelem4x11152">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11155">
					<section type="none" id="sidelem4x11156">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x11164">
							<label>•</label>
							<sec_title>Anginal pain</sec_title>
							<para>
								<list id="lidelem4x11164">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Anginal pain:</emphasis> duration, time started, activity being performed, character</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11171">
							<label>•</label>
							<sec_title>Methemoglobinemia (rare)<route> Cyanosis of lips, nausea/vomiting, coma, shock, usually caused by high dose of product but may occur with normal dosing</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x11174">
								<item>
									<label>•</label>
									<para>B/P, pulse, respirations during beginning therapy and periodically thereafter</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11179">
								<item>
									<label>•</label>
									<para>Tolerance if taken over long period, to prevent, allow intervals of 12-14 hr/day without product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11184">
								<item>
									<label>•</label>
									<para>Headache, light-headedness, decreased B/P; may indicate a need for decreased dosage, treat headache with OTC analgesics</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11189">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11193">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease or prevention of anginal pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11199">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11204">
								<item>
									<label>•</label>
									<para>To leave tabs in original container</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11209">
								<item>
									<label>•</label>
									<para>To avoid alcohol, OTC products unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11214">
								<item>
									<label>•</label>
									<para>That product may cause headache; that taking with meals may reduce or eliminate headache; to take no later than 7 <emphasis style="smallcaps">pm</emphasis> (last dose)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11222">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if dizziness occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11227">
								<item>
									<label>•</label>
									<para>About the importance of complying with complete medical regimen</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11232">
								<item>
									<label>•</label>
									<para>To make position changes slowly to prevent orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11240">
							<label>•</label>
							<sec_title>
								<route>Not to use with sildenafil, tadalafil, vardenafil with nitrates, may cause serious drop in B/P</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x11246">
							<label>•</label>
							<sec_title>
								<route>Not to discontinue abruptly, may cause heart attack</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x11252">
							<label>•</label>
							<sec_title>
								<route>To use at beginning of angina symptoms, may repeat every 15 min; if no relief, seek medical attention immediately</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="16.1" status="active" ru="yes">
			<mono_name> ISOtretinoin (Rx)</mono_name>
			<info>
				<pronunciation>(eye-soe-tret′i-noyn)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x112625">Absorica</tradename>
					<tradename id="tnidelem4x112624">Amnesteem</tradename>
					<tradename id="tnidelem4x112623">Claravis</tradename>
					<tradename id="tnidelem4x112622">Myorisan</tradename>
					<tradename id="tnidelem4x112621">Sotret</tradename>
					<tradename id="tnidelem4x112620">Zenatane</tradename>
				</tradenames>
				<class type="func"> Antiacne agent, retinoid</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="uses" id="sidelem4x11268">
				<sec_title>Uses:</sec_title>
				<para>Severe recalcitrant nodulocystic acne</para>
			</section>
			<section type="contra" id="sidelem4x11273">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, parabens, retinoids, inflamed skin, blood donation</para>
				<para>
					<bbw>Pregnancy (X)</bbw>
				</para>
			</section>
			<section type="doses" id="sidelem4x11288">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11296">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x11296">
							<item>
								<label>•</label>
								<para> 0.5-2 mg/kg/day in 2 divided doses × 15-20 wk; if relapse occurs, repeat after 2 mo off product</para>
							</item>
						</list>
					</para>
				</section>
			</section>
		</monograph>
<monograph id="17.1" status="active">
			<mono_name>itraconazole (Rx)</mono_name>
			<info>
				<pronunciation>(it-ra-con′a-zol)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x113051">Onmel</tradename>
					<tradename id="tnidelem4x113050">Sporanox</tradename>
				</tradenames>
				<class type="func"> Antifungal, systemic</class>
				<class type="chem"> Triazole derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x11315">
				<sec_title>Action:</sec_title>
				<para>Alters cell membranes; inhibits several fungal enzymes</para>
			</section>
			<section type="uses" id="sidelem4x11320">
				<sec_title>Uses:</sec_title>
				<para>Histoplasmosis, blastomycosis (pulmonary and extrapulmonary), aspergillosis, onychomycosis of toenail/fingernail</para>
				<section type="none" id="sidelem4x11326">
					<section type="none" id="sidelem4x11327">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Dermatomycosis, histoplasmosis, chromoblastomycosis, coccidioidomycosis, pityriasis versicolor, sebopsoriasis, vaginal candidiasis, cryptococcus, subcutaneous mycoses, dimorphic infections, fungal keratitis, zygomycosis, superficial mycoses (dermatophytoses), chronic mucocutaneous candidiasis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x11332">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, fungal meningitis; onychomycosis or dermatomycosis with cardiac dysfunction, in pregnant women</para>
				<para>
					<bbw>Heart failure, ventricular dysfunction, coadministration with other products</bbw>
				</para>
				<section type="none" id="sidelem4x11347">
					<section type="none" id="sidelem4x11348">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, cardiac/renal/hepatic disease, achlorhydria or hypochlorhydria (product-induced), dialysis, hearing loss, cystic fibrosis neuropathy</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11353">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11362">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x11362">
							<item>
								<label>•</label>
								<para> 200 mg/day with food; may increase to 200 mg bid if needed; life-threatening infections may require a loading dose of 200 mg tid × 3 days</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x11366">
					<section type="none" id="sidelem4x11367">
						<sec_title>Available forms:</sec_title>
						<para> Caps 100 mg; oral sol 10 mg/ml; tab 200 mg</para>
					</section>
					<section type="none" id="sidelem4x11372">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x11376">
								<item>
									<label>•</label>
									<para>In the presence of acid products only; do not use alkaline products, antacids within 2 hr of product; may give coffee, tea, acidic fruit juices</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11382">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x11386">
									<item>
										<label>•</label>
										<para>Swallow caps whole; do not break, crush, or chew caps</para>
									</item>
									<item>
										<label>•</label>
										<para>Give caps after full meal to ensure absorption</para>
									</item>
									<item>
										<label>•</label>
										<para>Oral sol: patient should swish in mouth vigorously, use on empty stomach</para>
									</item>
									<item>
										<label>•</label>
										<para>Oral sol and caps are not interchangeable on mg/mg basis</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in tight container at room temperature, do not freeze</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11412">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11415">
					<section type="none" id="sidelem4x11416">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness,</emphasis> insomnia, somnolence, depression</para>
					</section>
					<section type="none" id="sidelem4x11424">
						<sec_title>CV:</sec_title>
						<para> Hypertension, CHF</para>
					</section>
					<section type="none" id="sidelem4x11429">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, diarrhea,</emphasis> cramps, <emphasis style="italic">abdominal pain,</emphasis> flatulence, <emphasis style="bold">GI bleeding, hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11442">
						<sec_title>GU:</sec_title>
						<para> Gynecomastia, impotence, decreased libido</para>
					</section>
					<section type="none" id="sidelem4x11447">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Pruritus,</emphasis> fever, <emphasis style="italic">rash,</emphasis><emphasis style="bold">toxic epidermal necrolysis, Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11459">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Edema, fatigue,</emphasis> malaise, hypokalemia, tinnitus, <emphasis style="bold">rhabdomyolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11469">
						<sec_title>RESP:</sec_title>
						<para> Rhinitis, sinusitis, upper respiratory infection, pulmonary edema</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11474">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x11477">
					<section type="none" id="sidelem4x11478">
						<sec_title>PO:</sec_title>
						<para> Peak 3-4 hr; half-life 21 hr, IV 35.4 hr; metabolized in liver; excreted in bile, feces, urine 40%; requires acid pH for absorption; distributed poorly to CSF; 99.8% protein bound; inhibits CYP4503A4</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x11483">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Life-threatening CV reactions: pimozide, quiNIDine, dofetilide, levomethadyl, dronedarone</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> tinnitus, hearing loss—quiNIDine</para>
				<para>
					<emphasis alert="lifethreat">Increase: hepatotoxicity—other hepatotoxic products</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> edema—calcium channel blockers</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> severe hypoglycemia—oral hypoglycemics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> sedation—ALPRAZolam, clorazepate, diazepam, estazolam, flurazepam, triazolam, oral midazolam</para>
				<para>
					<emphasis alert="lifethreat">Increase: levels, toxicity—busPIRone, busulfan, clarithromycin, cycloSPORINE, diazepam, digoxin, felodipine, fentaNYL, atorvastatin, carBAMazepine, disopyramide, indinavir, isradipine, niCARdipine, NiFEdipine, niMODipine, phenytoin, quiNIDine, QUEtiapine, ritonavir, saquinavir, tacrolimus, warfarin</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> itraconazole action—antacids, H<emphasis style="inf">2</emphasis>-receptor antagonists, rifamycins, didanosine, carBAMazepine, isoniazid, proton pump inhibitors</para>
				<section type="none" id="sidelem4x11520">
					<section type="none" id="sidelem4x11521">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x11525">
								<item>
									<label>•</label>
									<para>Food increases absorption</para>
								</item>
								<item>
									<label>•</label>
									<para>Grapefruit juice decreases itraconazole level</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11537">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, alk phos, bilirubin, triglyceride, GGT</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x11544">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11547">
					<section type="none" id="sidelem4x11548">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x11556">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x11556">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF:</emphasis> if present, discontinue product</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11560">
								<item>
									<label>•</label>
									<para>Type of infection; may begin treatment before obtaining results</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11568">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x11568">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> temperature, WBC, sputum at baseline and periodically</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11572">
								<item>
									<label>•</label>
									<para>I&amp;O ratio, potassium levels</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11577">
								<item>
									<label>•</label>
									<para>Hepatic studies (ALT, AST, bilirubin) if patient receiving long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11582">
								<item>
									<label>•</label>
									<para>Allergic reaction: rash, photosensitivity, urticaria, dermatitis</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11588">
								<item>
									<para>
										<emphasis alert="nurse">Hepatotoxicity: nausea, vomiting, jaundice, clay-colored stools, fatigue</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11593">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11597">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased fever, malaise, rash, negative C&amp;S for infecting organism</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11603">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11608">
								<item>
									<label>•</label>
									<para>That long-term therapy may be needed to clear infection (1 wk-6 mo, depending on infection)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11613">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if dizziness occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11618">
								<item>
									<label>•</label>
									<para>To take 2 hr before administration of other products that increase gastric pH (antacids, H<emphasis style="inf">2</emphasis>-blockers, omeprazole, sucralfate, anticholinergics); to avoid grapefruit juice; to notify health care provider of all medications taken; to take after a full meal (caps) or on empty stomach (oral sol)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11626">
								<item>
									<label>•</label>
									<para>About the importance of compliance with product regimen; to use alternative methods of contraception</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11634">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of GI symptoms; signs of hepatic dysfunction (fatigue, jaundice, nausea, anorexia, vomiting, dark urine, pale stools); heart failure (trouble breathing, unusual weight gain, fatigue, swelling); hearing changes</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="18.1" status="active" ru="yes">
			<mono_name> ivacaftor</mono_name>
			<info>
				<pronunciation>(eye′va-kaf′tor)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x116440">Kalydeco</tradename>
				</tradenames>
				<class type="func"> Respiratory agent</class>
			</info>
			<section type="uses" id="sidelem4x11650">
				<sec_title>Uses:</sec_title>
				<para>Cystic fibrosis in those with G551D, G1244E, G1349D, G178R, G5515S, S1255P, S549N, S549R mutation in the CFTR gene</para>
			</section>
			<section type="doses" id="sidelem4x11655">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11663">
					<label>•</label>
					<sec_title>Adult/adolescent/child ≥6 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x11663">
							<item>
								<label>•</label>
								<para> 150 mg every 12 hr with fat-containing food</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x11670">
					<label>•</label>
					<sec_title>Child 2-5 yr, ≥14 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x11670">
							<item>
								<label>•</label>
								<para> 75 mg q12hr with fat-containing food</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x11677">
					<label>•</label>
					<sec_title>Child 2-5 yr, &lt;14 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x11677">
							<item>
								<label>•</label>
								<para> 50 mg q12hr with fat-containing food</para>
							</item>
						</list>
					</para>
				</section>
			</section>
		</monograph>
<monograph id="19.1" status="active" ha="yes">
			<mono_name> ixabepilone (Rx)</mono_name>
			<info>
				<pronunciation>(ix-ab-ep′i-lone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x116880">Ixempra</tradename>
				</tradenames>
				<class type="func"> Antineoplastic—miscellaneous</class>
				<class type="chem"> Epothilone</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x11698">
				<sec_title>Action:</sec_title>
				<para>Microtubule stabilizing agent; microtubules are needed for cell division</para>
			</section>
			<section type="uses" id="sidelem4x11703">
				<sec_title>Uses:</sec_title>
				<para>Breast cancer</para>
			</section>
			<section type="contra" id="sidelem4x11708">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity to products with polyoxyethylated castor oil, neutropenia of &lt;1500/mm<emphasis style="sup">3</emphasis>, thrombocytopenia</para>
				<para>
					<bbw>Hepatic disease</bbw>
				</para>
				<section type="none" id="sidelem4x11726">
					<section type="none" id="sidelem4x11727">
						<sec_title>Precautions:</sec_title>
						<para> Children, geriatric patients, alcoholism, bone marrow suppression, cardiac dysrhythmias, cardiac/renal disease, diabetes mellitus, peripheral neuropathy, ventricular dysfunction</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11734">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11737">
					<section type="none" id="sidelem4x11738">
						<sec_title>Breast cancer, metastatic or locally advanced given with capecitabine and resistant to anthracycline, taxane</sec_title>
						<section type="none" id="sidelem4x11746">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x11746">
									<item>
										<label>•</label>
										<para> 40 mg/m<emphasis style="sup">2</emphasis> over 3 hr q3wk plus capecitabine  2000 mg/m<emphasis style="sup">2</emphasis>/day in 2 divided doses on days 1-14 q21days; in those with BSA &gt;2.2 m<emphasis style="sup">2</emphasis>, dose should be calculated for a BSA of 2.2 m<emphasis style="sup">2</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11764">
						<sec_title>Breast cancer, metastatic or locally advanced resistant/refractory to anthracycline, taxane, capecitabine</sec_title>
						<section type="none" id="sidelem4x11772">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x11772">
									<item>
										<label>•</label>
										<para> 40 mg/m<emphasis style="sup">2</emphasis> over 3 hr q3wk; in those with BSA &gt;2.2 m<emphasis style="sup">2</emphasis>, dose should be calculated for a BSA of 2.2 m<emphasis style="sup">2</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11784">
						<sec_title>Dosage reduction in those taking a strong CYP3A4 inhibitor</sec_title>
						<section type="none" id="sidelem4x11792">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x11792">
									<item>
										<label>•</label>
										<para> 20 mg/m<emphasis style="sup">2</emphasis> over 3 hr q3wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11799">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 15, 45 mg</para>
					</section>
					<section type="none" id="sidelem4x11804">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x11808">
								<item>
									<label>•</label>
									<para>Premedicate with histamine antagonists 1 hr before use, prevents hypersensitivity</para>
								</item>
								<item>
									<label>•</label>
									<para>Antiemetic 30-60 min before product and prn</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11819">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x11823">
									<item>
										<label>•</label>
										<para>Let kit stand at room temperature for 30 min; to reconstitute, withdraw supplied diluent (8 ml for 15-mg vials, 23.5 ml for 45-mg vials); slowly inject sol into vial; gently swirl and invert to mix, final concentration 2 mg/ml; further dilute in LR in DEHP-free bags, final concentration should be between 0.2 and 0.6 mg/ml; after added, mix by manual rotation</para>
									</item>
									<item>
										<label>•</label>
										<para>Diluted sol stable for 6 hr at room temperature; infusion must be completed within 6 hr</para>
									</item>
									<item>
										<label>•</label>
										<para>Use in-line filter, 0.2-1.2 micron</para>
									</item>
									<item>
										<label>•</label>
										<para>Give over 3 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11844">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11847">
					<section type="none" id="sidelem4x11848">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Peripheral neuropathy,</emphasis> impaired cognition, chills, fatigue, fever, flushing, headache, insomnia, <emphasis style="italic">asthenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11858">
						<sec_title>CV:</sec_title>
						<para> Bradycardia, <emphasis style="italic">hypotension,</emphasis><emphasis style="bold">abnormal ECG,</emphasis> angina, <emphasis style="bold">atrial flutter, cardiomyopathy,</emphasis> chest pain, edema, <emphasis style="bold">MI,</emphasis> vasculitis</para>
					</section>
					<section type="none" id="sidelem4x11874">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea,</emphasis> abdominal pain, anorexia, colitis, constipation, gastritis, jaundice, GERD, hepatic failure, trismus</para>
					</section>
					<section type="none" id="sidelem4x11882">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11889">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, thrombocytopenia, anemia,</emphasis> infections, coagulopathy</para>
					</section>
					<section type="none" id="sidelem4x11897">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Alopecia,</emphasis> rash, hot flashes</para>
					</section>
					<section type="none" id="sidelem4x11905">
						<sec_title>META:</sec_title>
						<para> Hypokalemia, metabolic acidosis</para>
					</section>
					<section type="none" id="sidelem4x11910">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Arthralgia, myalgia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11917">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Bronchospasm,</emphasis> cough, dyspnea</para>
					</section>
					<section type="none" id="sidelem4x11925">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="italic">Hypersensitivity reactions,</emphasis><emphasis style="bold">anaphylaxis,</emphasis> dehydration, <emphasis style="bold">radiation recall reaction</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11937">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver by P45CYP3A4; excreted in feces (65%) and urine (21%); terminal half-life 52 hr</para>
			</section>
			<section type="interactions" id="sidelem4x11942">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> ixabepilone level—CYP3A4 inhibitors (amiodarone, amprenavir, aprepitant, atazanavir, chloramphenicol, clarithromycin, conivaptan, cycloSPORINE, danazol, darunavir, dalforpistin, delavirdine, diltiazem, erythromycin, estradiol, fluconazole, fluvoxaMINE, fosamprenavir, imatinib, indinavir, isoniazid, itraconazole, ketoconazole, lopinavir, miconazole, nefazodone, nelfinavir, propoxyphene, ritonavir, RU-486, saquinavir, tamoxifen, telithromycin, troleandomycin, verapamil, voriconazole, zafirlukast)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> ixabepilone levels—CYP3A4 inducers (aminoglutethimide, barbiturates, bexarotene, bosentan, carBAMazepine, dexamethasone, efavirenz, griseofulvin, modafinil, nafcillin, nevirapine, OXcarbazepine, phenytoin, rifamycin, topiramate)</para>
				<section type="none" id="sidelem4x11953">
					<section type="none" id="sidelem4x11954">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x11958">
								<item>
									<label>•</label>
									<para>Avoid use with St. John’s wort</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11965">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x11969">
								<item>
									<label>•</label>
									<para>Avoid use with grapefruit products</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x11975">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11978">
					<section type="none" id="sidelem4x11979">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x11984">
								<item>
									<label>•</label>
									<para>CBC, differential, platelet count before treatment and weekly; withhold product if WBC is &lt;1500/mm<emphasis style="sup">3</emphasis> or platelet count is &lt;100,000/mm<emphasis style="sup">3</emphasis>, notify prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11995">
								<item>
									<label>•</label>
									<para>Monitor temperature q4hr (may indicate beginning infection)
<bbw>Liver function tests before, during therapy (bilirubin, AST, ALT, LDH) prn or monthly; check for jaundiced skin and sclera, dark urine, clay-colored stools, itchy skin, abdominal pain, fever, diarrhea</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12009">
								<item>
									<label>•</label>
									<para>VS during 1st hr of infusion; check IV site for signs of infiltration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12015">
								<item>
									<para>
										<emphasis alert="nurse">Hypersensitivity reactions, anaphylaxis including hypotension, dyspnea, angioedema, generalized urticaria; discontinue infusion immediately; keep emergency equipment available</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12020">
								<item>
									<label>•</label>
									<para>Effects of alopecia on body image; discuss feelings about body changes</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12025">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12029">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12035">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x12039">
								<item>
									<label>•</label>
									<para>To report signs of infection: fever, sore throat, flulike symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>To report signs of anemia: fatigue, headache, faintness, SOB</para>
								</item>
								<item>
									<label>•</label>
									<para>To report any complaints or side effects to nurse or prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>That hair may be lost during treatment; that a wig or hairpiece may make patient feel better; that new hair may be different in color, texture</para>
								</item>
								<item>
									<label>•</label>
									<para>That pain in muscles and joints 2-5 days after infusion is common</para>
								</item>
								<item>
									<label>•</label>
									<para>To use nonhormonal type of contraception</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid receiving vaccinations while receiving product</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>

</alpha>
</drug_guide>